0000950170-23-053873 | 20-F | XBRL Viewer

Print Document View Excel Document

Commitments For Expenditure (Additional Information) (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Commitments For Expenditure [Abstract]
Operating lease term	3 years	4 years

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Current
Other receivables	$ 886	$ 42,483
Loss allowance	0	0
Trade and other receivable, Before tax	886	42,483
GST Receivables	13,832	21,877
Trade and other receivable, Net	$ 14,718	$ 64,360

Remuneration of Auditors - Schedule of Auditors Remuneration Explanatory (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
Auditor's remuneration	$ 500,500	$ 969,726	$ 86,500
Group
Disclosure of attribution of expenses by nature to their function [line items]
Audit or Review of Financial Reports	$ 357,500	$ 969,726	$ 86,500
Shares issued under the F-1
Disclosure of attribution of expenses by nature to their function [line items]
Agreed -upon-procedures	118,000
Shelf (F-3) & ATM SEC filing
Disclosure of attribution of expenses by nature to their function [line items]
Agreed -upon-procedures	25,000

Other Assets (Tables)

12 Months Ended

Jun. 30, 2023

Miscellaneous current assets [abstract]

Summary of Detailed Information About Other Current Assets


	2023 A$		2022 A$
Current
Prepayments		1,202,826		1,461,078
Accrued income		388		190
		1,203,214		1,461,268

Other Intangible Assets (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about intangible assets [abstract]

Summary of Carrying Amounts of Each Class of Other Intangible Assets


	KV1.3 compound			VDA compound			MultiCore technology			Cancer stem cell technology			Total
	A$			A$			A$			A$			A$
Gross carrying amount at July 1, 2021		1,546,542			2,282,527			1,265,590			17,681,361			22,776,020
Additions		-			-			-			-			-
Foreign currency exchange differences		-			-			-			1,515,296			1,515,296
Gross carrying amount at June 30, 2022		1,546,542			2,282,527			1,265,590			19,196,657			24,291,316
Additions		-			-			-			-			-
Foreign currency exchange differences		-			-			-			700,873			700,873.00
Gross carrying amount at June 30, 2023		1,546,542			2,282,527			1,265,590			19,897,530			24,992,189

Accumulated amortisation amount at July 1, 2021		(1,546,542	)		(2,282,527	)		(1,265,590	)		(7,735,606	)		(12,830,265	)
Amortisation (Note 6)		-			-			-			(913,373	)		(913,373	)
Foreign currency exchange differences		-			-			-			(709,404	)		(709,404	)
Accumulated amortisation amount at June 30, 2022		(1,546,542	)		(2,282,527	)		(1,265,590	)		(9,358,383	)		(14,453,042	)
Amortisation (Note 6)		-			-			-			(984,724	)		(984,724	)
Foreign currency exchange differences		-			-			-			(351,829	)		(351,829	)
Accumulated amortisation amount at June 30, 2023		(1,546,542	)		(2,282,527	)		(1,265,590	)		(10,694,936	)		(15,789,595	)

Net carrying amount June 30, 2022		-			-			-			9,838,274			9,838,274
Net carrying amount June 30, 2023		-			-			-			9,202,594			9,202,594

Cash Flow Information (Tables)

12 Months Ended

Jun. 30, 2023

Statement of cash flows [abstract]

Summary of Cash Flow Information

For the purposes of the consolidated statement of cash flows, cash and cash equivalents include cash on hand and in banks, net of outstanding bank overdrafts. Cash and cash equivalents at the end of the reporting period as shown in the consolidated statement of cash flows can be reconciled to the related items in the consolidated statement of financial position as follows:


	2023 A$		2022 A$		2021 A$
Cash and cash equivalents		18,250,255		33,564,857		28,499,449

(b)

Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities


	2023 A$			2022 A$			2021 A$
(Loss) for the year		(31,846,957	)		(21,759,358	)		(8,697,037	)
Items in loss
Depreciation and amortisation		1,156,992			1,109,412			1,700,878
Share-based payments		1,904,553			2,829,689			1,308,349
Loss on asset disposals		-			1,827			21,010
Contingent consideration – change in fair value		988,179			936,354			(3,212,503	)
Amortisation of transaction costs		-			-			252,019
Accrual of final borrowing payment								528,819
Net foreign exchange differences		(33,555	)		738,423			(1,067,746	)
Interest received		(479,726	)		(9,869	)		(5,756	)

Changes in Operating Assets and Liabilities
Decrease/(Increase) in receivables		49,642			(39,148	)		34,078
Decrease/(Increase)in research and development incentive receivable		6,092,202			(5,791,688	)		1,991,468
Decrease/(Increase) in other assets		258,252			(600,285	)		(85,648	)
Increase/(Decrease) in payables		714,207			979,902			(63,305	)
Increase/(Decrease) in provisions		59,635			41,062			(55,923	)
(Decrease) in deferred tax liability		(206,792	)		(191,808	)		(187,427	)
Net cash outflows from operating activities		(21,343,368	)		(21,755,487	)		(7,538,724	)

Issued Capital - Summary of Inputs Used (Details) - $ / shares	Feb. 21, 2023	Jul. 08, 2022	Dec. 02, 2021	Nov. 20, 2020
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk free interest rate				0.30%
Share Options \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at date of issue	$ 0.028	$ 0.058	$ 0.125
Exercise price	$ 0.0321	$ 0.0543	$ 0.2014
Bionomics share volatility	74.18%	80.13%	85.53%
Risk free interest rate	3.627%	3.196%	0.413%
Share Options \| Monte Carlo Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at date of issue	$ 0.028
Exercise price	$ 0.052
Bionomics share volatility	7418.00%
Risk free interest rate	3.627%
Share Options 1 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price at date of issue			$ 0.125
Exercise price			$ 0.0965
Bionomics share volatility			85.53%
Risk free interest rate			0.413%

Provisions

12 Months Ended

Jun. 30, 2023

Disclosure Of Provision Abstract

Provisions

NOTE 19: PROVISIONS


	2023 A$		2022 A$
Current
Employee benefits		457,017		409,320
Non-Current
Employee benefits		22,398		10,460

Loss Per Share - Summary of Number Of Potential Anti Dilutive Ordinary Shares Excluded From Computation Of Loss Per S (Details) - shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Employee Options
Earnings per share [line items]
Potential ordinary shares which are anti-dilutive and excluded from weighted average number of ordinary shares	(46,690,480)	(31,065,272)	(20,056,450)
Warrants
Earnings per share [line items]
Potential ordinary shares which are anti-dilutive and excluded from weighted average number of ordinary shares	(142,000,000)	(142,000,000)	(166,082,988)

Key Management Personnel Compensation - Disclosure of Key Management Personnel Compensation (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Key management personnel compensation [abstract]
Short-term employee compensation	$ 3,717,144	$ 2,535,550	$ 2,269,030
Post-employment benefits	71,876	69,039	51,982
Other long-term benefits	33,133	22,241	9,480
Share-based payments	1,899,827	2,819,133	1,298,208
Total key management personnel compensation	$ 5,721,980	$ 5,445,963	$ 3,628,700

Issued Capital - Additional Information (Details)								12 Months Ended
Issued Capital - Additional Information (Details)	Feb. 21, 2023 shares $ / shares	Jul. 15, 2022 $ / shares shares	Nov. 11, 2021 shares $ / shares	Sep. 02, 2021 shares $ / shares	Nov. 20, 2020 $ / shares shares	Aug. 28, 2020 $ / shares shares	Aug. 26, 2020 AUD ($) $ / shares shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2023 shares $ / shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 AUD ($) shares	Dec. 31, 2022 $ / shares shares	Dec. 02, 2021 $ / shares shares	Dec. 02, 2021 $ / shares shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of conversion of option exercised										When exercised, each option is convertible into one ordinary share.
Vested and exercisable								46,690,480	46,690,480	31,065,275
Weighted average remaining contractual life of unlisted share options outstanding								4 years 10 months 6 days	4 years 10 months 6 days	4 years 11 months 4 days
Vesting period								five years	five years
Number of share options exercised in share-based payment arrangement				2,000,000				0	0	2,000,000
Shares issued on exercise of options, exercise price \| $ / shares				$ 0.0136						$ 0.0136
Share price \| $ / shares				$ 0.19
Warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vested and exercisable								142,000	142,000		142,000,000
Weighted average remaining contractual life of unlisted share options outstanding								1 month 28 days	1 month 28 days	7 months 6 days
Shares issued price per share \| $ / shares								$ 0.01	$ 0.01
Share price \| $ / shares			$ 0.125
Number of shares vested or exercised			2,000,000					0	0	8,000,000
Weighted average exercise price Exercised during the financial year \| $ / shares			$ 0.06							$ 0.06
Warrants \| Apeiron
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued							150,000,000
Share price \| $ / shares							$ 0.06
Share issuance price \| $							$ 15,000,000
Warrants expiry date							Aug. 26, 2023
Placement of shares amount \| $											$ 15,991,634
Percentage of risk adjusted estimated fee											9.00%
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price \| (per share)					$ 0.13				$ 0.14
Monte Carlo Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price \| $ / shares								$ 0.24
Dr Errol De Souza \| Vest when Sales of ADSs recorded on NASDAQ exceeds $12.35 per ADS
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	5,000,000
Vesting period	to vest when the volume weighted average price of ADSs on NASDAQ over the prior 20 days on which sales of ADSs were recorded on NASDAQ exceeds $12.35 per ADS, and provided the relevant calculation period ends on or before 30 June 2024.
Dr Errol De Souza \| Vests if Company Appoints a Chief Executive Officer on or before 31 December 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	1,666,666
Vesting period	to vest if the Company appoints a Chief Executive Officer on or before 31 December 2022.
Dr Errol De Souza \| Vest on Achievement of Successful Data Readout for Phase 2 Trial for BNC210 in PTSD
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	1,666,666
Vesting period	to vest on achievement of successful data readout for Phase 2 trial for BNC210 in PTSD as reasonably determined by the Board in its sole discretion.
Dr Errol De Souza \| Vest on Achievement of Successful Data Readout for Phase 2 Trial for BNC210 in SAD.
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	1,666,666
Vesting period	to vest on achievement of successful data readout for Phase 2 trial for BNC210 in SAD as reasonably determined by the Board in its sole discretion.
Dr Jane Ryan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued					500,000
Share options subscribed					500,000
Shares issued price per share \| $ / shares					$ 0.1687
Share Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued						15,000,000
Share options subscribed						15,000,000
Exercise price \| $ / shares						$ 0.04
Share Options \| Data Readout for Phase2 Trial for BNC210 in SAD had been Announced and was Deemed not Successful
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares not issued	1,666,666
Share Options \| Vested on Date of Issue if Share Options, as CEO was Already Appointed
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares vested or exercised	1,666,666
Share Options \| Dr Errol De Souza
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	10,000,000												47,786,607	47,786,607
Share options subscribed												10,000,000	47,786,607	47,786,607
Shares issued price per share \| (per share)												$ 0.052		$ 0.2014
Share Options \| Dr Errol De Souza \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued													13,430,160	13,430,160
Share options subscribed													13,430,160	13,430,160
Shares issued price per share \| $ / shares													$ 0.09645
Share Options \| Dr Papapetropoulos
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued	27,067,015
Share options subscribed	27,067,015
Shares issued price per share \| $ / shares	$ 0.052
Percentage of share options granted on first anniversary of the grant date	25.00%
Description of share options granted	balance vesting on a quarterly basis over a 3-year period commencing from that date.
Employee Equity Plan \| Share Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued		7,700,000
Share options subscribed		7,700,000
Exercise price \| $ / shares		$ 0.0543
Vesting period		25% of the Options vest at the end of 12 months following the Offer Date (8 July 2022), and 75% vest in 12 substantially equal instalments (6.25%) on the last day of each calendar quarter over the 4-year period following the end of the initial 12 months following the Offer Date. The share options expire on the date that is 5 years following each vesting date.
Share options expiry date		5 years
Employee Equity Plan \| Share Options \| Vest at End of 12 Months Following Offer Date 8 July 2022 Member
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage		25.00%
Employee Equity Plan \| Share Options \| Vest in 12 Substantially Equal Instalments Member
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage		75.00%
Employee Equity Plan \| Share Options \| Last Day of Each Calendar Quarter Over 4 Year Period Following End of Initial 12 Months Following Offer Date Member
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage		(6.25%)
Employee Equity Plan \| Share Options \| Key Management Personnel
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share options issued		7,500,000

Expenses Related to Continuing Operations - Schedule of Expenses Related to Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Expenses by nature [abstract]
Interest expense on lease liabilities	$ 21,278	$ 26,872	$ 26,934
Bank fees	7,952	17,293	17,527
Amortisation of transaction costs			252,019
Accrual of final payment			528,819
Interest expense on bank and other loans			618,586
Finance expenses, Total	29,230	44,165	1,443,885
Wages and salaries	3,785,547	2,901,689	2,577,954
Superannuation	176,710	266,127	148,662
Share-based payments	1,904,553	2,829,689	1,308,349
Employment benefit expenses, Total	5,866,810	5,997,505	4,034,965
Plant and equipment	1,368	2,681	45,553
Right-of-use assets (rental property)	170,900	193,358	762,813
Intellectual property	984,724	913,373	892,512
Depreciation and Amortisation, Total	1,156,992	1,109,412	1,700,878
Minimum lease payments	$ 5,729	$ 5,260	$ 7,277

Key Management Personnel Compensation (Tables)

12 Months Ended

Jun. 30, 2023

Key management personnel compensation [abstract]

Disclosure of Key Management Personnel Compensation

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:


	2023 A$		2022 A$		2021 A$
Short-term employee compensation		3,717,144		2,535,550		2,269,030
Post-employment benefits		71,876		69,039		51,982
Other long-term benefits		33,133		22,241		9,480
Share-based payments		1,899,827		2,819,133		1,298,208
Total key management personnel compensation		5,721,980		5,445,963		3,628,700

Consolidated Statement of Cash Flows - AUD ($)	12 Months Ended
Consolidated Statement of Cash Flows - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities
Research and development incentives received	$ 6,719,760		$ 2,919,541
Receipts from customers	22,047	$ 270,975	394,815
Payments to suppliers and employees	(28,055,945)	(21,982,297)	(10,126,660)
Interest and bank fees paid	(29,230)	(44,165)	(726,420)
Net cash (used) by Operating Activities	(21,343,368)	(21,755,487)	(7,538,724)
Cash Flows from Investing Activities
Interest received	479,528	12,516	4,094
Payments for other financial assets			(118,466)
Proceeds from disposal of other financial assets		435,640
Payments for purchases of property, plant and equipment		(1,544)	(1,468)
Proceeds from disposals of property, plant and equipment		175,091	35,634
Net cash provided/(used) by Investing Activities	479,528	621,703	(80,206)
Cash Flows from Financing Activities
Repayment of borrowings			(11,087,139)
Principal elements of lease payments	(160,040)	(174,218)	(779,807)
Proceeds from share issues	7,419,235	32,890,463	43,836,131
Payments for share issue costs	(1,702,332)	(5,720,623)	(415,479)
Net cash provided by Financing Activities	5,556,863	26,995,622	31,553,706
Net (decrease)/increase in Cash and Cash Equivalents	(15,306,977)	5,861,838	23,934,776
Cash and cash equivalents at the beginning of the financial year	33,564,857	28,499,449	4,577,747
Effects of exchange rate changes on the balance of cash held in foreign currencies	(7,625)	(796,430)	(13,074)
Cash and Cash Equivalents at the End of the Year	$ 18,250,255	$ 33,564,857	$ 28,499,449

Right-of-Use Assets (Tables)

12 Months Ended

Jun. 30, 2023

Right-of-use assets [member]

Disclosure of quantitative information about right-of-use assets [line items]

Summary of Right-of-Use Assets


	2023 A$			2022 A$
Cost		854,500			854,500
Accumulated depreciation		(356,042	)		(185,142	)
		498,458			669,358

Opening balance July 1		669,358			862,716
Addition of new property being rented		-			-
Depreciation (Note 6)		(170,900	)		(193,358	)
Closing balance June 30		498,458			669,358

Events Occurring After Reporting Date

12 Months Ended

Jun. 30, 2023

Disclosure of non-adjusting events after reporting period [abstract]

Events Occurring After Reporting Date

NOTE 31: EVENTS OCCURRING AFTER REPORTING DATE

As from the close of trading on 28 August 2023, Bionomics delisted from the ASX and now is only listed on the NASDAQ.

On 8 May 2023, Bionomics announced the establishment of an ATM Program with Cantor, who will act as sales agent. During the month of September 2023 and up to the date of this report, Cantor sold under the ATM Program, 2,100,866 ADSs (378,155,880 ordinary shares) raising gross proceeds of US$6,715,878. Net proceeds after deducting Cantor’s commission and the ADS issuance fee were US$6,409,359.

There are no other matters or circumstances that have arisen since the end of the financial year which significantly affect or may significantly affect the results of the operations of the Group

General Information

12 Months Ended

Jun. 30, 2023

General information [abstract]

General Information

NOTE 1: GENERAL INFORMATION

Bionomics Limited (“the Company”) is a unlisted public company incorporated in Australia. The address of its registered office and principal place of business is as follows:

200 Greenhill Road

Eastwood, South Australia, 5063

Tel: +61 8 8150 7400

Principal Activities

The principal activities of the Company and its controlled entities (“the Group”) during the period include the development of novel drug candidates focused on the treatment of serious central nervous system disorders.

Contingent Consideration - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Contingent consideration [abstract]
Contingent consideration liability increase (decrease)	$ 988,179	$ 936,354

Issued Capital - Summary of Options Issued (Details)					12 Months Ended
Issued Capital - Summary of Options Issued (Details)	Feb. 21, 2023 shares $ / shares	Jul. 08, 2022 shares $ / shares	Dec. 22, 2021 shares $ / shares	Nov. 20, 2020 shares $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting date					five years
Number \| shares	8,333,333	7,700,000	47,786,607		117,211,315	79,056,617	20,985,450	6,364,550
Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price				$ 0.1687
Number \| shares	27,067,015		13,430,160
Tranche 1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	30-Jun-24	8-Jul-23	30-Sep-21	20-Oct-21
Expiry date	30-Jun-29	8-Jul-28	30-Sep-26
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	5,000,000	1,925,000	2,986,663	100,000
Fair value at date of issue	$ 0.0053	$ 0.041	$ 0.074	$ 0.089
Tranche 1 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Dec-23		31-Mar-22
Expiry date	16-Dec-28		31-Mar-27
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	6,766,754		839,385
Fair value at date of issue	$ 0.017		$ 0.09
Tranche 2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	23-Feb-23	31-Oct-23	31-Dec-21	20-Oct-22
Expiry date	23-Feb-28	31-Oct-28	31-Dec-26
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	1,666,666	481,251	2,986,663	100,000
Fair value at date of issue	$ 0.014	$ 0.042	$ 0.076	$ 0.095
Tranche 2 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Mar-24		30-Jun-22
Expiry date	16-Mar-29		30-Jun-27
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.017		$ 0.091
Tranche 3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	30-Sep-23	31-Jan-24	31-Mar-22	20-Oct-23
Expiry date	30-Sep-28	31-Jan-29	31-Mar-27
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	1,666,667	481,251	2,986,663	100,000
Fair value at date of issue	$ 0.015	$ 0.043	$ 0.078	$ 0.099
Tranche 3 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Jun-24		30-Sep-22
Expiry date	16-Jun-29		30-Sep-27
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,689		839,385
Fair value at date of issue	$ 0.018		$ 0.092
Tranche 4
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21	20-Nov-20
Vesting date		30-Apr-24	30-Jun-22	20-Oct-24
Expiry date		30-Apr-29	30-Jun-27
Exercise price		$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares		481,251	2,986,663	100,000
Fair value at date of issue		$ 0.043	$ 0.079	$ 0.103
Tranche 4 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Sep-24		31-Dec-22
Expiry date	16-Sep-29		31-Dec-27
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.018		$ 0.094
Tranche 5
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21	20-Nov-20
Vesting date		31-Jul-24	30-Sep-22	20-Oct-25
Expiry date		31-Jul-29	30-Sep-27
Exercise price		$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares		481,251	2,986,663	100,000
Fair value at date of issue		$ 0.044	$ 0.081	$ 0.107
Tranche 5 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Dec-24		31-Mar-23
Expiry date	16-Dec-29		31-Mar-28
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,689		839,385
Fair value at date of issue	$ 0.018		$ 0.095
Tranche 6
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Oct-24	31-Dec-22
Expiry date		31-Oct-29	31-Dec-27
Exercise price		$ 0.0543	$ 0.2014		$ 0.3481
Number \| shares		481,251	2,986,663		10,000
Fair value at date of issue		$ 0.044	$ 0.082		$ 0.2513
Tranche 6 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Mar-25		30-Jun-23
Expiry date	16-Mar-30		30-Jun-28
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.019		$ 0.096
Tranche 7
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Jan-25	31-Mar-23
Expiry date		31-Jan-30	31-Mar-28
Exercise price		$ 0.0543	$ 0.2014		$ 0.3481
Number \| shares		481,251	2,986,663		5,000
Fair value at date of issue		$ 0.045	$ 0.084		$ 0.2513
Tranche 7 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Jun-25		30-Sep-23
Expiry date	16-Jun-30		30-Sep-28
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,689		839,385
Fair value at date of issue	$ 0.019		$ 0.097
Tranche 8
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		30-Apr-25	30-Jun-23
Expiry date		30-Apr-30	30-Jun-28
Exercise price		$ 0.0543	$ 0.2014		$ 0.4136
Number \| shares		481,251	2,986,663		10,000
Fair value at date of issue		$ 0.045	$ 0.085		$ 0.3062
Tranche 8 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Sep-25		31-Dec-23
Expiry date	16-Sep-30		31-Dec-28
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.019		$ 0.098
Tranche 9
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Jul-25	30-Sep-23
Expiry date		31-Jul-30	30-Sep-28
Exercise price		$ 0.0543	$ 0.2014		$ 0.4311
Number \| shares		481,251	2,986,663		5,000
Fair value at date of issue		$ 0.046	$ 0.086		$ 0.3376
Tranche 9 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Dec-25		31-Mar-24
Expiry date	16-Dec-30		31-Mar-29
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,689		839,385
Fair value at date of issue	$ 0.019		$ 0.098
Tranche 10
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Oct-25	31-Dec-23
Expiry date		31-Oct-30	31-Dec-28
Exercise price		$ 0.0543	$ 0.2014		$ 0.575
Number \| shares		481,251	2,986,663		15,000
Fair value at date of issue		$ 0.046	$ 0.088		$ 0.5415
Tranche 10 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Mar-26		30-Jun-24
Expiry date	16-Mar-31		30-Jun-29
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.02		$ 0.099
Tranche 11
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Jan-26	31-Mar-24
Expiry date		31-Jan-31	31-Mar-24
Exercise price		$ 0.0543	$ 0.2014		$ 0.2327
Number \| shares		481,251	2,986,663		4,000
Fair value at date of issue		$ 0.046	$ 0.089		$ 0.2448
Tranche 11 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Jun-26		30-Sep-24
Expiry date	16-Jun-31		30-Sep-29
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,689		839,385
Fair value at date of issue	$ 0.02		$ 0.1
Tranche 12
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		30-Apr-26	30-Jun-24
Expiry date		30-Apr-31	30-Jun-24
Exercise price		$ 0.0543	$ 0.2014		$ 0.2349
Number \| shares		481,251	2,986,663		200,000
Fair value at date of issue		$ 0.047	$ 0.09		$ 0.2621
Tranche 12 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Sep-26		31-Dec-24
Expiry date	16-Sep-31		31-Dec-29
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.02		$ 0.101
Tranche 13
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21
Vesting date		31-Jul-26	30-Sep-24
Expiry date		31-Jul-31	30-Jun-24
Exercise price		$ 0.0543	$ 0.2014		$ 0.2866
Number \| shares		481,239	2,986,663		200,000
Fair value at date of issue		$ 0.047	$ 0.091		$ 0.2504
Tranche 13 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23		2-Dec-21
Vesting date	16-Dec-26		31-Mar-25
Expiry date	16-Dec-31		31-Mar-30
Exercise price	$ 0.0321		$ 0.09645
Number \| shares	1,691,688		839,385
Fair value at date of issue	$ 0.02		$ 0.102
Tranche 14
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			31-Dec-24
Expiry date			31-Dec-29
Exercise price			$ 0.2014		$ 0.3556
Number \| shares			2,986,663		5,000
Fair value at date of issue			$ 0.092		$ 0.237
Tranche 14 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			30-Jun-25
Expiry date			30-Jun-30
Exercise price			$ 0.09645
Number \| shares			839,385
Fair value at date of issue			$ 0.102
Tranche 15
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			31-Mar-25
Expiry date			31-Mar-30
Exercise price			$ 0.2014		$ 0.6611
Number \| shares			2,986,663		4,000
Fair value at date of issue			$ 0.093		$ 0.4573
Tranche 15 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			30-Sep-25
Expiry date			30-Sep-30
Exercise price			$ 0.09645
Number \| shares			839,385
Fair value at date of issue			$ 0.103
Tranche 16
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			30-Jun-25
Expiry date			30-Jun-30
Exercise price			$ 0.2014		$ 0.5125
Number \| shares			2,986,662		100,000
Fair value at date of issue			$ 0.094		$ 0.1798
Tranche 16 \| Black Scholes Model
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date			2-Dec-21
Vesting date			31-Dec-25
Expiry date			31-Dec-30
Exercise price			$ 0.09645
Number \| shares			839,385
Fair value at date of issue			$ 0.104

Consolidated Statement of Changes in Equity - AUD ($)	Total	Issued Capital	Foreign Currency Translation Reserve	Share-Based Payments Reserve	Accumulated Losses
Equity at beginning of period at Jun. 30, 2020	$ 12,682,007	$ 148,156,005	$ 6,288,371	$ 7,125,413	$ (148,887,782)
(Loss) for the period	(8,697,037)				(8,697,037)
Exchange differences on translation of foreign operations	(1,169,171)		(1,169,171)
Total comprehensive income	(9,866,208)		(1,169,171)		(8,697,037)
Recognition of share-based payments	1,308,349			1,308,349
Transfer of expired options and warrants				(3,544,318)	3,544,318
Issue of ordinary shares as result of share options being exercised	21,229,874	21,229,874
Issue of ordinary shares as result of warrants being exercised	22,606,257	22,606,257
Issue of ordinary shares to employees	60,750	60,750
Share issue costs	(423,492)	(1,862,739)		1,439,247
Equity at end of period at Jun. 30, 2021	47,597,537	190,190,147	5,119,200	6,328,691	(154,040,501)
(Loss) for the period	(21,759,358)				(21,759,358)
Exchange differences on translation of foreign operations	1,067,134		1,067,134
Total comprehensive income	(20,692,224)		1,067,134		(21,759,358)
Recognition of share-based payments	2,829,689			2,829,689
Transfer of expired options and warrants				(2,493,356)	2,493,356
Issue of ordinary shares as result of share options being exercised	27,200	27,200
Issue of ordinary shares as result of warrants being exercised	480,000	480,000
Transfer from share-based payments reserve		327,760		(327,760)
Issue of ordinary shares as result of US IPO	32,383,263	32,383,263
Share issue costs	(5,712,611)	(5,712,611)
Equity at end of period at Jun. 30, 2022	56,912,854	217,695,759	6,186,334	6,337,264	(173,306,503)
(Loss) for the period	(31,846,957)				(31,846,957)
Exchange differences on translation of foreign operations	460,506		460,506
Total comprehensive income	(31,386,451)		460,506		(31,846,957)
Recognition of share-based payments	1,904,553			1,904,553
Transfer of expired options and warrants				(382,911)	382,911
Issue of ordinary shares as result of US F-1	7,419,235	7,419,235
Share issue costs	(1,702,332)	(1,702,332)
Equity at end of period at Jun. 30, 2023	$ 33,147,859	$ 223,412,662	$ 6,646,840	$ 7,858,906	$ (204,770,549)

Contingent Liabilities - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of contingent liabilities [abstract]
Restricted term deposit	$ 119,000	$ 119,000
Rent guarantee	119,000	$ 119,000
Contingent liability payable	787,500
Contingent liability paid	$ 683,701

Summary of Significant Accounting Policies

12 Months Ended

Jun. 30, 2023

Disclosure Of Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This financial report includes the consolidated financial statements and notes of the Group.

(i)

Statement of Compliance

These financial statements comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

For the purposes of preparing the consolidated financial statements, the Company is a for-profit entity.

(ii)

Basis of Preparation

The consolidated financial statements have been prepared on the basis of historical cost, except for contingent consideration liability, that is measured at fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars unless otherwise noted.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2, leasing transactions that are within the scope of IFRS 16, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in IFRS 2 or value in use in International Accounting Standards (“IAS”) 36.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable market inputs and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at measurement date;

•

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for that asset or liability, either directly or indirectly, and

•

Level 3 inputs are unobservable inputs for the asset or liability.

(iii)

Application of New and Revised Accounting Standards

The Group has adopted all the new and revised Standards and Interpretations issued by the IASB that are relevant to its operations and effective for an accounting period that begins on or after July 1, 2022. The adoption of these new and revised Standards and Interpretations has resulted in no significant changes to the consolidated entity’s accounting policies. Standards and Interpretations issued by the IASB that are relevant to its operations from July 1, 2023 are not expected to result in significant changes to the consolidated entity's accounting policies.

(iv)

Accounting Policies

The following significant accounting policies have been adopted in the preparation and presentation of the financial report.

(a)

Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

•

has power over the investee;

•

is exposed, or has rights, to variable returns from its involvement with the investee, and

•

has the ability to use its power to affect its returns.

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

(b)

Borrowings
Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

(c)

Borrowing Costs

All borrowing costs (other than transaction costs) are recognised in profit or loss in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

(d)

Business Combinations

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value which is calculated as the sum of the acquisition-date fair values of assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred.

At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognised at their fair value, except that:

•

Deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements, are recognised and measured in accordance with IAS 12 ‘Income Taxes’ and IAS 19 ‘Employee Benefits’, respectively;

•

Liabilities or equity instruments related to share-based payment arrangements of the acquiree, or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 ‘Share-based Payment’ at the acquisition date, and

•

Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 ‘Non-current Assets Held for Sale and Discontinued Operations’ are measured in accordance with that Standard.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a gain on bargain purchase.

Where the consideration transferred by the Group in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.

The subsequent accounting for changes in the fair value of contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration is recognised at fair value, classified as a liability which is remeasured at subsequent reporting dates in accordance with IFRS 9 and IAS 137 ‘Provisions, Contingent Liabilities and Contingent Assets’ respectively, as appropriate, with the corresponding gain or loss being recognised in profit or loss.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see above), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date.

(e)

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the consolidated statement of financial position.

(f)

Earnings/(Loss) per Share

•

Basic Earnings/(Loss) per Share

Basic earnings/(loss) per share is calculated by dividing the profit/(loss) after income tax attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the year, adjusted for bonus elements in ordinary shares issued during the year.

•

Diluted Earnings/(Loss) per Share

Diluted earnings/(loss) per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to options.

(g)

Employee Benefits

•

Short-term and Long-term Employee Benefits

A liability is recognised for benefits accruing to employees in respect of wages and salaries, annual leave and long service leave when it is probable that settlement will be required, and they are capable of being measured reliably. Liabilities recognised in respect of short-term employee benefits, are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Liabilities recognised in respect of long-term employee benefits are measured as the present value of the estimated

future cash outflows to be made by the Group in respect of services provided by employees up to reporting date, discounted using rates applicable to high quality corporate bonds.

•

Superannuation

Retirement benefits are contributions made to employee superannuation funds and are charged as expenses when incurred. These contributions are made to external superannuation funds and are not defined benefits programs.

•

Share-based Payments

•

Share-based compensation benefits have been provided to employees via the Bionomics Employee Equity Plan (“EEP”) that was approved by shareholders at the Annual General Meeting held on 2 December 2021, with the exception of share options issued to the Executive Chairman (Dr De Souza) and Chief Executive Officer (Dr Papapetropoulos) which were approved by shareholders at the General Meeting held on 21 February 2023.

The fair value of shares issued to employees for no cash consideration under the EEP and share options issued to the Executive Chairman are recognized as an employee benefits expense with a corresponding increase in equity. The fair value is measured at grant date and recognized on a straight-line basis over the vesting period based on the Group’s estimate of equity instruments that will eventually vest or over the period of the Consultancy Agreement, as applicable.

The disclosure in Note 20 relates to the EEP and the former Employee Share Option Plan (“ESOP”). The Bionomics EEP was approved by the Board and shareholders in 2017. Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Group for a period of not less than six months or a Director of the Group. Options are granted under the plan for no consideration and vest equally over five years, or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date. See Note 20 for details on how the fair value of options and warrants issued during the year are calculated.

(h)

Financial Assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

All recognized financial assets are measured subsequently in their entirety at either amortized cost or fair value, depending on the classification of the financial assets.

Classification of Financial Assets at amortized costs

•

The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flow, and

•

The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payment of principal and interest on the principal amount outstanding.

Debt instruments that meet the following conditions are measured subsequently at fair value through other comprehensive income (“FVTOCI”):

•

The financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets, and

•

The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

By default, all other financial assets are measured subsequently at fair value through profit or loss (“FVTPL”).

Despite the foregoing, the Group may make the following irrevocable election/designation at initial recognition of a financial asset:

•

The Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income if certain criteria are met (see (ii) below); and

•

The Group may irrevocably designate a debt investment that meets the amortised cost or FVTOCI criteria as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch (see (ii) below).

(i)

Amortised Cost and Effective Interest Method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocation interest income over the relevant period.

For financial assets other than purchased or originated credit-impaired financial assets (i.e. assets that are credit-impaired on initial recognition), the effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) excluding expected credit losses, through the expected life of the debt instrument, or, where appropriate, a shorter period, to the gross carrying amount of the debt instrument on initial recognition. For purchased or originated credit-impaired financial assets, a credit-adjusted effective interest rate is calculated by discounting the estimated future cash flows, including expected credit losses, to the amortised cost of the debt instrument on initial recognition.

The amortised cost of a financial asset is the amount at which the financial asset is measured at initial recognition minus the principal repayments, plus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, adjusted for any loss allowance.

Interest income is recognised using the effective interest method for debt instruments measured subsequently at amortised cost and at FVTOCI. For financial assets other than purchased or originated credit-impaired financial assets, interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired, (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset. If, in subsequent reporting periods, the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset.

For purchased or originated credit-impaired financial assets, the Group recognizes interest income by applying the credit-adjusted effective interest rate to the amortised cost of the financial asset from initial recognition. The calculation does not revert to the gross basis even if the credit risk of the financial asset subsequently improves so that the financial asset is no longer credit-impaired.

Interest income is recognised in profit or loss and is included in the “other Scholes model was used to obtain income” line item.

(ii)

Financial Assets at FVTPL

Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI are measured at FVTPL. Specifically:

•

Investments in equity instruments are classified as at FVTPL, unless the Group designates an equity investment that is neither held for trading nor a contingent consideration arising from a business combination as at FVTOCI on initial recognition.

•

Debt instruments that do not meet the amortised cost criteria or the FVTOCI criteria are classified as at FVTPL. In addition, debt instruments that meet either the amortised cost criteria or the FVTOCI criteria may be designated as at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency (so called ‘accounting mismatch’)

that would arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases. The Group has not designated any debt instructions as at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair values gains or losses recognised in profit or loss to the extent they are not part of a designated hedging relationship (see hedge accounting policy). The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset and is included in the ‘other gains and losses’ line item.

(iii)

Impairment of Financial Assets

The Group recognizes a loss allowance for expected credit losses (“ECL”) on investments in debt instruments that are measured at amortised cost or a FVTOCI, lease receivables, trade receivables and contract assets, as well as on financial guaranteed contracts. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument.

The Group always recognizes lifetime ECL for trade receivables, contract assets and lease receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate.

For all other financial instruments, the Group recognizes lifetime ECL when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECL.

Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.

(i)

Foreign Currencies

The individual financial statements of each group entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each group entity are expressed in Australian dollars (“$”), which is the functional currency of the Company and the presentation currency for the consolidated financial statements.

In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences on monetary items are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the net investment in the foreign operation), which are recognised initially in other comprehensive income and reclassified from equity to profit or loss on repayment of the monetary items.

For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into Australian dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity.

Goodwill and fair value adjustments to identifiable assets acquired and liabilities assumed through acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the rate of exchange prevailing at the end of each reporting period. Exchange differences arising are recognised in other comprehensive income and accumulated in equity.

(j)

Goods and Services Tax (“GST”)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement of financial position.

Cash flows are presented on a gross basis. The GST component of cash flow arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow.

(k)

Government Research and Development Incentives

Government grants, including Research and Development incentives, are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met.

Grants relating to cost reimbursements are recognised as other income in profit or loss in the period when the costs were incurred or when the incentive meets the recognition requirements (if later).

(l)

Impairment of Tangible and Intangible Assets Other than Goodwill and Indefinite Lived Intangibles

At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified.

A CGU is the smallest identifiable group of assets that generates cash flow that is largely independent of cash flows from other assets or group of assets. The Company's CGU (drug development) is defined as a research program that has the potential to be commercialized at some point in the future. Achievement of certain milestones within the current central nervous system research program will determine when a new CGU comes into existence.

Intangible assets with indefinite useful lives are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or CGU) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

(m)

Income Tax

Income tax expense represents the sum of the tax currently payable and deferred tax.

Current Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the consolidated statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred Tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax liabilities and assets are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis.

Current and Deferred Tax for the Year

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

Tax Consolidation Legislation

Bionomics and its wholly owned Australian controlled entities have implemented the tax consolidation legislation effective 31 December 2005.

The head entity, Bionomics Limited, and the controlled entities in the tax consolidated group account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a stand-alone taxpayer in its own right.

In addition to its own current and deferred tax amounts, Bionomics Limited also recognizes the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group.

Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group.

Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated entities.

(n)

Intangible Assets

(i)

Intellectual Property

Acquired intellectual property is recognised as an asset at cost and amortised over its useful life. There is currently no internally generated intellectual property that has been capitalised. Intellectual property with a finite life is amortised on a straight-line basis over that life. Intellectual property with an indefinite useful life is subjected to an annual impairment review. There is currently no intellectual property with an indefinite life.

Current useful life of all existing intellectual property is in the range of 15 to 20 years.

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance date.

(ii)

Goodwill

Goodwill arising on an acquisition of a business is carried at cost as established at the date of the acquisition of the business (see Note 2(d) above) less accumulated impairment losses, if any.

For the purposes of impairment testing, goodwill is allocated to the Group's CGU that is expected to benefit from the synergies of the combination.

A CGU to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the CGU may be impaired. If the recoverable amount of the CGU is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the CGU and then to the other assets of the CGU pro rata based on the carrying amount of each asset in the CGU. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

On disposal of the relevant CGU, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

(iii)

Intangible Assets Acquired in a Business Combination

Intangible assets acquired in a business combination and recognised separately from goodwill are initially recognised at their fair value at the acquisition date (which is regarded as their cost).

Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

(o)

Issued Capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options, or for the acquisition of a business, are deducted directly from equity.

(p)

Leases

The Group assesses whether a contract is or contains a lease, at inception of the contract. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group as Lessee

The Group assesses whether a contract is or contains a lease, at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones).

For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee entity uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise:

•

Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable;

•

Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;

•

The amount expected to be payable by the lessee under residual value guarantees;

•

The exercise price of purchase options, if the lessee is reasonably certain to exercise the options, and

•

Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease.

The lease liability is presented as a separate line in the consolidated statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

•

The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate.

•

The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used).

•

A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

The Group did not make any such adjustments during the periods presented.

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. Current useful life of right-to-use assets is 5 years.

If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Group expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the consolidated statement of financial position.

The Group applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in Note 2(l) above.

Group as Lessor

Leases in which the Group does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Rental income arising is accounted for on a straight-line basis over the lease term and is included in revenue in the statement of profit or loss due to its operating nature. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.

(q)

Property, Plant and Equipment

Plant and equipment are stated at cost less accumulated depreciation or accumulated impairment losses, where applicable.

Depreciation is recognized so as to write off the cost of assets less their residual values over their useful lives, using the diminishing value or straight-line methods, depending on the type of asset. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period.

The depreciation rates for plant and equipment are 20 – 40%.

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss.

(r)

Research and Development

Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized as an expense when it is incurred. Expenditures on development activities are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. Development costs have a finite life and are amortized on a systematic basis matched to the future economic benefits over the useful life of the project. At year end there are currently no capitalized development costs.

(s)

Revenue Recognition

(i)

License revenues in connection with licensing of the Group's intellectual property (including patents) to collaborators are recognized as a right to use the entity's intellectual property as it exists at the point in time at which the license is granted. This is because the contracts for the license of intellectual property are distinct and do not require, nor does the customer reasonably expect, that the Group will undertake further activities that significantly affect the intellectual property to which the collaborator has rights.

(ii)

Although the Group is entitled to sales-based royalties from any eventual sales of goods and services to third parties using the intellectual property transferred, these royalty arrangements do not of themselves indicate that the collaborator would reasonably expect the Group to undertake such activities, and no such activities are undertaken or contracted in practice. Accordingly, the promise to provide rights to the Group's intellectual property is accounted for as a performance obligation satisfied at a point in time.

The following consideration is received in exchange for licenses of intellectual property:

(a)

Up-front payments - These are fixed amounts and are recognized at the point in time when the Group transfers the intellectual property to the collaborator.

(b)

Milestone payments - These are variable considerations that depends upon the collaborator reaching certain milestones in relation to the intellectual property licensed. Such amounts are only recognized when it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration (that is, the collaborator meeting the conditions to trigger payment) is subsequently resolved.

(c)

Sales-based royalties - These are variable consideration amounts promised in exchange for the license of intellectual property that occur late in the collaborator's development of the intellectual property and are recognized when the sales to third parties occur (as the performance obligation to transfer the intellectual property to the collaborator is already satisfied).

(iii)

Rental income is recognized on a straight-line basis over the term of the lease (refer to note 2(p) “Group as lessor” for further comments).

Revenue, Other Income and Other Gains and Losses - Summary of Revenue from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from Continuing Operations	$ 22,047	$ 263,634
Licenses
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from Continuing Operations	$ 22,047	$ 263,634

Cash and Cash Equivalents (Additional Information) (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash and cash equivalents [abstract]
Weighted average interest rate on deposits	3.20%	1.15%

Contingent Consideration (Tables)

12 Months Ended

Jun. 30, 2023

Contingent consideration [abstract]

Disclosure of Contingent Consideration


	2023 A$		2022 A$
Opening balance		2,699,010		1,762,656
Change in fair value		988,179		936,354
Closing balance		3,687,189		2,699,010

Other Assets

12 Months Ended

Jun. 30, 2023

Miscellaneous current assets [abstract]

Other Assets

NOTE 11: OTHER ASSETS


	2023 A$		2022 A$
Current
Prepayments		1,202,826		1,461,078
Accrued income		388		190
		1,203,214		1,461,268

Lease Liabilities - Schedule of Total Group Cash Outflows for Leases (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of quantitative information about leases for lessee [abstract]
Principal element of lease payments	$ 160,040	$ 174,218	$ 779,807
Interest element of lease payments - continuing operations	21,278	26,872	26,934
Total cash outflows for leases	$ 181,318	$ 201,090	$ 806,741

Property, Plant And Equipment (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Schedule of Detailed Information about Property Plant and Equipment


	2023 A$		2022 A$
Cost at 1 July		72,035		106,753
Additions		-		1,544
Disposals		-		(36,262	)
Cost at 30 June		72,035		72,035


Accumulated depreciation at 1 July	(66,863	)	(98,526	)
Depreciation (Note 6)	(1,368	)	(2,681	)
Disposals	-		34,344
Accumulated depreciation at 30 June	(68,231	)	(66,863	)

Net Carrying Amounts at 30 June	3,804		5,172

Income Taxes Relating to Continuing Operations

12 Months Ended

Jun. 30, 2023

Major components of tax expense (income) [abstract]

Income Taxes Relating to Continuing Operations

NOTE 7: INCOME TAXES RELATING TO CONTINUING OPERATIONS


	2023 A$			2022 A$			2021 A$
(a) Income Tax Recognised in Profit or Loss

Current tax
In respect of the current year		-			-			-
In respect of the prior year		-			-			-
		-			-			-
Deferred tax
Recognised in current year		(206,792	)		(191,808	)		(187,427	)
		(206,792	)		(191,808	)		(187,427	)

Total income tax benefit		(206,792	)		(191,808	)		(187,427	)


(b) Reconciliation to Accounting Loss	2023 A$			2022 A$			2021 A$
Loss from continuing operations		(32,053,749	)		(21,951,166	)		(8,884,464	)
Tax at the Australian tax rate of 25% (2021 25% & 2020: 30%)		(8,013,437	)		(5,487,792	)		(2,665,339	)
Tax effect of non-deductible / non-assessable amounts
Exempt income from government assistance		(156,890	)		(1,447,922	)		(293,422	)
Entertainment expenses		1,448			1,231			727
Net gain arising on changes in fair value of contingent consideration		247,045			234,089			(963,751	)
Share-based payments		476,138			707,422			392,505
Research and development expenditure		360,666			3,328,556			640,050
Amortisation of share issue costs		(285,631	)		(285,631	)		-
Temporary differences not recorded as an asset		(787,392	)		(58,374	)		(632,779	)
Tax losses not recorded		7,872,870			2,779,547			3,253,265
Effect of different tax rates in other jurisdictions		78,391			37,066			81,317
		(206,792	)		(191,808	)		(187,427	)

	2023 A$			2022 A$
(c) Net Deferred Tax Liability Recognised
Net deferred tax liability is attributable to the following deferred tax asset/(liability) items:
Intangibles denominated in USD		(1,932,546	)		(2,066,037	)
Tax losses denominated in USD		277177			267,412
		(1,655,369	)		(1,798,625	)
Movement in Net Deferred Tax Liability
Opening balance		(1,798,625	)		(1,842,303	)
Recognized in income		206,792			191,808
Recognized in equity		(63,536	)		(148,130	)
Closing balance		(1,655,369	)		(1,798,625	)


(d) Net Deferred Tax Asset Not Recognised
Revenue tax losses	33,323,740	25,445,487
Net temporary difference	2,387,515	3,460,513
	35,711,255	28,906,000

Deferred tax assets have not been recognized in respect to these items as it is not probable at this time that future taxable profits will be available against which the Group can utilize the benefit.

(f)

Tax Consolidation

Relevance of Tax Consolidation to the Group

The Company and all its wholly-owned Australian resident entities are part of a tax-consolidated group under Australian taxation law. Bionomics is the head entity in the tax-consolidated group. Tax expense/benefit, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax-consolidated group are recognised in the separate financial statements of the members of the tax-consolidated group using the ‘separate taxpayer within group’ approach by reference to the carrying amounts in the separate financial statements of each entity and the tax values applying under tax consolidation. Current tax liabilities and assets and deferred tax assets arising from unused tax losses and relevant tax credits of the members of the tax-consolidated group are recognised by the Company (as head entity in the tax-consolidated group).

Remuneration of Auditors

12 Months Ended

Jun. 30, 2023

Auditor's remuneration [abstract]

Remuneration of Auditors

NOTE 25: REMUNERATION OF AUDITORS


	2023 A$		2022 A$		2021 A$
Audit or Review of Financial Reports
- Group		357,500		969,726		86,500
Agreed -upon-procedures
- Shares issued under the F-1		118,000		-		-
- Shelf (F-3) & ATM SEC filing		25,000		-		-
		500,500		969,726		86,500

The auditor of Bionomics Limited is Ernst & Young.

Income Taxes Relating to Continuing Operations - Summary of Net Deferred Tax Liability Recognised (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of changes in deferred tax liability (asset) [abstract]
Intangibles denominated in USD	$ (1,932,546)	$ (2,066,037)
Tax losses denominated in USD	277,177	267,412
Net deferred tax liability	(1,655,369)	(1,798,625)
Net Deferred Tax Liability, Begining balance	(1,798,625)	(1,842,303)
Recognized in income	206,792	191,808
Recognized in equity	(63,536)	(148,130)
Net Deferred Tax Liability, Ending balance	$ (1,655,369)	$ (1,798,625)

Trade and Other Payables - Disclosure of Trade and Other Payables (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Current
Trade payables	$ 2,062,549	$ 1,556,881
Accrued expenses	1,437,938	1,229,399
Total trade and other current payables	$ 3,500,487	$ 2,786,280

Issues Capital - Summary of Movements in Ordinary Shares (Parenthetical) (Details)				12 Months Ended
	Sep. 02, 2021 shares $ / shares	Mar. 03, 2021 AUD ($)	Aug. 26, 2020 AUD ($) $ / shares shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 AUD ($) shares $ / shares	Jun. 30, 2021 AUD ($) $ / shares shares
Disclosure of classes of share capital [line items]
Share price \| $ / shares	$ 0.19
Proceeds from issuing shares \| $				$ 7,419,235	$ 32,890,463	$ 43,836,131
Minimum proceeds from warrants \| $			$ 15,000,000
Number of options Exercised during the financial year	2,000,000			0	2,000,000
Shares issued on exercise of options, exercise price \| $ / shares	$ 0.0136				$ 0.0136
Number of shares issued on exercise of warrants					8,000,000
Shares issued on exercise of warrants, exercise price \| $ / shares					$ 0.06
Number of shares issued in US IPO and NASDAQ listing					335,754,000
Number of shares issued in IPO F-1 share placement				115,384,680
Description of ordinary shares voting rights					every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote and upon a poll each share is entitled to one vote
Apeiron
Disclosure of classes of share capital [line items]
Number of shares issued				0	14,574,780
Shares issued price per share \| $ / shares			$ 0.06
Number of warrants issued			150,000,000
Share Placement Tranche One
Disclosure of classes of share capital [line items]
Number of shares issued						54,333,000
Share price \| $ / shares						$ 0.04
Proceeds from issuing shares \| $						$ 2,173,320
Share Placement Tranche Two
Disclosure of classes of share capital [line items]
Number of shares issued						131,424,511
Share price \| $ / shares						$ 0.145
Proceeds from issuing shares \| $						$ 19,056,554
Rights Issues Tranche One
Disclosure of classes of share capital [line items]
Number of shares issued						54,304,446
Proceeds from issuing shares \| $						$ 2,172,178
Shares issued price per share \| $ / shares						$ 0.04
Rights Issues Tranche Two
Disclosure of classes of share capital [line items]
Number of shares issued						140,924,683
Proceeds from issuing shares \| $						$ 20,434,079
Shares issued price per share \| $ / shares						$ 0.145
Share Placement \| Apeiron
Disclosure of classes of share capital [line items]
Proceeds from vesting of warrants \| $		$ 15,991,634

Income Taxes Relating to Continuing Operations - Summary of Income Tax Recognised in Profit or Loss (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Deferred tax
Recognised in current year	$ (206,792)	$ (191,808)	$ (187,427)
Deferred tax	(206,792)	(191,808)	(187,427)
Total income tax benefit	$ (206,792)	$ (191,808)	$ (187,427)

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Financial Instruments - Summary of Foreign Currency Sensitivity Analysis (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
10% increase
Profit or loss	$ (579,305)	$ 1,796,641	$ (222,678)
Equity	91,097	18,815	3,135
10% decrease
Profit or loss	579,305	(1,796,641)	222,678
Equity	$ (91,097)	$ (18,815)	$ (3,135)

Trade and Other Receivables (Tables)

12 Months Ended

Jun. 30, 2023

Trade and other receivables [abstract]

Summary of Trade and Other Receivables


	2023 A$		2022 A$
Current
Other receivables		886		42,483
Loss allowance		-		-
		886		42,483
GST receivables		13,832		21,877
		14,718		64,360

Document and Entity Information	12 Months Ended
Document and Entity Information	Jun. 30, 2023 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	BIONOMICS LIMITED/FI
Entity Central Index Key	0001191070
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	1,486,735,424
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Securities Act File Number	001-41157
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	200 Greenhill Road
Entity Address, City or Town	Eastwood SA
Entity Address, Postal Zip Code	5063
Entity Address, Country	AU
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
ICFR Auditor Attestation Flag	false
Auditor Name	Ernst & Young
Auditor Firm ID	1435
Auditor Location	Adelaide, Australia
Trading Symbol	BNOX
Title of 12(b) Security	American Depository Shares, each representing the right to receive one hundred eighty (180) Ordinary Shares, no par value per share
Security Exchange Name	NASDAQ
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	2710 Gateway Oaks Drive
Entity Address, Address Line Two	Suite 150N
Entity Address, City or Town	Sacramento
Entity Address, Postal Zip Code	95833
Entity Address, Country	CA
City Area Code	+61
Local Phone Number	8 881507400
Contact Personnel Name	Spyridon “Spyros” Papapetropoulos, M.D.
Contact Personnel Email Address	spyros@bionomics.com.au

Financial Instruments - Disclosure of Foreign Currency Risk Management (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Monetary Items [Abstract]
Cash and cash equivalents	$ 18,250,255	$ 33,564,857	$ 28,499,449	$ 4,577,747
Trade and other payables	(3,500,487)	(2,786,280)
Contingent consideration	3,687,189	2,699,010
Non Monetary Items [Abstract]
Goodwill	13,084,300	12,868,122	$ 12,400,743
Deferred tax liabilities	(1,655,369)	(1,798,625)
Currency Risk
Monetary Items [Abstract]
Cash and cash equivalents	2,552,731	17,786,031
Trade and other payables	(2,451,693)	(1,298,425)
Contingent consideration	(3,687,189)	(2,699,010)
Total monetary items	(3,586,151)	13,788,596
Non Monetary Items [Abstract]
Goodwill	6,137,205	5,921,027
Other intangible assets	9,202,594	9,838,274
Deferred tax liabilities	(1,655,369)	(1,798,625)
Total non-monetary items	13,684,430	13,960,676
Total denominated in USD	$ 10,098,279	$ 27,749,272

Cash Flow Information - Summary of Cash Flow Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Statement of cash flows [abstract]
Cash and cash equivalents	$ 18,250,255	$ 33,564,857	$ 28,499,449	$ 4,577,747
Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities
(Loss) for the period	(31,846,957)	(21,759,358)	(8,697,037)
Depreciation and amortisation	1,156,992	1,109,412	1,700,878
Share-based payments	1,904,553	2,829,689	1,308,349
Loss/(Gain) on asset disposals		1,827	21,010
Contingent consideration - change in fair value	988,179	936,354	(3,212,503)
Amortisation of transaction costs			252,019
Accrual of final borrowing payment			528,819
Net foreign exchange differences	(33,555)	738,423	(1,067,746)
Interest received	(479,726)	(9,869)	(5,756)
Changes in Operating Assets and Liabilities
Decrease/(Increase) in receivables	49,642	(39,148)	34,078
Decrease/(Increase)in research and development incentive receivable	(6,092,202)	(5,791,688)	1,991,468
Decrease/(Increase) in other assets	258,252	(600,285)	(85,648)
Increase/(Decrease) in payables	714,207	979,902	(63,305)
Increase/(Decrease) in provisions	59,635	41,062	(55,923)
(Decrease) in deferred tax liability	(206,792)	(191,808)	(187,427)
Net cash outflows from operating activities	$ (21,343,368)	$ (21,755,487)	$ (7,538,724)

Issued Capital - Share Options Issued (Details) - $ / shares		12 Months Ended
	Sep. 02, 2021	Jun. 30, 2023
Disclosure of classes of share capital [line items]
Share price at date of issue	$ 0.19
Dr Errol De Souza Share Options \| Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share price at date of issue		$ 0.11
Exercise price		$ 0.04
Bionomics share volatility		105.00%
Risk free interest rate		0.42%
Mr Jack Moschakis And Ms Liz Doolin Share Options \| Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share price at date of issue		$ 0.15
Exercise price		$ 0.04
Bionomics share volatility		105.00%
Risk free interest rate		0.43%

Revenue, Other Income and Other Gains and Losses - Summary of Other Income from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Rent		$ 6,674	$ 203,014
Government Research And Development Incentives	$ 627,558	5,791,688	928,073
Other Income from Continuing Operations	$ 627,558	$ 5,798,362	1,302,587
Cash Flow Boost Grants
Disclosure of disaggregation of revenue from contracts with customers [line items]
Government assistance COVID-19			50,000
Jobkeeper Grants
Disclosure of disaggregation of revenue from contracts with customers [line items]
Government assistance COVID-19			$ 121,500

Income Taxes Relating to Continuing Operations - Summary of Reconciliation to Accounting Loss (Parenthetical) (Details)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2021	Jun. 30, 2020
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Australian tax rate	25.00%	25.00%	30.00%

Trade and Other Payables (Tables)

12 Months Ended

Jun. 30, 2023

Trade and other payables [abstract]

Disclosure of Trade and Other Payables


	2023 A$		2022 A$
Current
Trade payables		2,062,549		1,556,881
Accrued expenses		1,437,938		1,229,399
		3,500,487		2,786,280

Goodwill (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of reconciliation of changes in goodwill [abstract]

Schedule of Changes in Goodwill


	A$
Carrying amount at July 1, 2021		12,400,743
Additions		-
Foreign currency exchange differences		467,379
Carrying amount at June 30, 2022		12,868,122
Additions		-
Foreign currency exchange differences		216,178
Carrying amount at June 30, 2023		13,084,300

Loss Per Share

12 Months Ended

Jun. 30, 2023

Earnings per share [abstract]

Loss Per Share

NOTE 27: LOSS PER SHARE


	2023	2022	2021

Basic loss per share	(A$0.02) (2 cent)	(A$0.02) (2 cent)	(A$0.01) (1 cent)
Diluted loss per share	(A$0.02 (2 cent)	(A$0.02 (2 cent)	(A$0.01 (1 cent)

The basic and diluted loss per share amounts have been calculated using the ‘Loss after income tax’ figure in the consolidated statement of profit or and other comprehensive income.


	2023 A$			2022 A$			2021 A$
Loss Per Share (Basic and Diluted):
Loss after tax for the year		(31,846,957	)		(21,759,358	)		(8,697,037	)


	2023 number			2022 number			2011 number
Weighted Average Number of Ordinary Shares - Basic
Weighted average number of ordinary shares used in calculating basic loss per share:		1,468,735,424			1,353,350,744			779,941,036

Weighted Average Number of Ordinary Shares – Diluted
Weighted average number of ordinary shares used in calculating basic loss per share:		1,468,735,424			1,353,350,744			779,941,036
Shares deemed to be issued for no consideration in respect of employee options		46,690,480			31,065,272			20,056,450
Potential ordinary shares which are anti-dilutive and excluded		(46,690,480	)		(31,065,272	)		(20,056,450	)
Shares deemed to be issued for no consideration in respect of warrants		142,000,000			142,000,000			166,082,988
Potential ordinary shares which are anti-dilutive and excluded		(142,000,000	)		(142,000,000	)		(166,082,988	)
Weighted average number of ordinary shares used in the calculation of diluted loss per share		1,468,735,424			1,353,350,744			779,941,036

The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share.


	2023 number		2022 number		2021 number
Employee options		46,690,480		31,065,272		20,056,450
Warrants		142,000,000		142,000,000		166,082,988

Income Taxes Relating to Continuing Operations (Tables)

12 Months Ended

Jun. 30, 2023

Major components of tax expense (income) [abstract]

Summary of Income Tax Recognised in Profit or Loss


	2023 A$			2022 A$			2021 A$
(a) Income Tax Recognised in Profit or Loss

Current tax
In respect of the current year		-			-			-
In respect of the prior year		-			-			-
		-			-			-
Deferred tax
Recognised in current year		(206,792	)		(191,808	)		(187,427	)
		(206,792	)		(191,808	)		(187,427	)

Total income tax benefit		(206,792	)		(191,808	)		(187,427	)

Summary of Reconciliation to Accounting Loss and Net Deferred Tax Liability Recognised


(b) Reconciliation to Accounting Loss	2023 A$			2022 A$			2021 A$
Loss from continuing operations		(32,053,749	)		(21,951,166	)		(8,884,464	)
Tax at the Australian tax rate of 25% (2021 25% & 2020: 30%)		(8,013,437	)		(5,487,792	)		(2,665,339	)
Tax effect of non-deductible / non-assessable amounts
Exempt income from government assistance		(156,890	)		(1,447,922	)		(293,422	)
Entertainment expenses		1,448			1,231			727
Net gain arising on changes in fair value of contingent consideration		247,045			234,089			(963,751	)
Share-based payments		476,138			707,422			392,505
Research and development expenditure		360,666			3,328,556			640,050
Amortisation of share issue costs		(285,631	)		(285,631	)		-
Temporary differences not recorded as an asset		(787,392	)		(58,374	)		(632,779	)
Tax losses not recorded		7,872,870			2,779,547			3,253,265
Effect of different tax rates in other jurisdictions		78,391			37,066			81,317
		(206,792	)		(191,808	)		(187,427	)

	2023 A$			2022 A$
(c) Net Deferred Tax Liability Recognised
Net deferred tax liability is attributable to the following deferred tax asset/(liability) items:
Intangibles denominated in USD		(1,932,546	)		(2,066,037	)
Tax losses denominated in USD		277177			267,412
		(1,655,369	)		(1,798,625	)
Movement in Net Deferred Tax Liability
Opening balance		(1,798,625	)		(1,842,303	)
Recognized in income		206,792			191,808
Recognized in equity		(63,536	)		(148,130	)
Closing balance		(1,655,369	)		(1,798,625	)

Summary of Net Deferred Tax Asset Not Recognised


(d) Net Deferred Tax Asset Not Recognised
Revenue tax losses	33,323,740	25,445,487
Net temporary difference	2,387,515	3,460,513
	35,711,255	28,906,000

Revenue, Other Income and Other Gains and Losses (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure Of Revenue Other Income And Other Gains And Losses [Abstract]

Summary of Revenue from Continuing Operations


	2023 A$		2022 A$		2021 A$
Revenue from Continuing Operations
Licenses		22,047		263,634		-
		22,047		263,634		-

Other Income from Continuing Operations
Rent		-		6,674		203,014
Government Research and Development Incentives (i)		627,558		5,791,688		928,073
Government assistance COVID-19 (Cash flow boost)		-		-		50,000
Government assistance COVID-19 (Jobkeeper)		-		-		121,500
		627,558		5,798,362		1,302,587

(i)

The Government Research and Development Incentives include cash refunds provided by the Australian Government for 43.5% (2022: 43.5%, 2021: 43.5%) of eligible research and development expenditures by Australian entities having a tax loss and less than A$20 million in revenue. The grants are calculated at the end of the fiscal year to which they relate, based on the expenses incurred in and included in the fiscal year's Australian income tax return after registration of the research and development activities with the relevant authorities. There are no unfulfilled conditions or other contingencies attaching to the Government Research and Development Incentive.

Summary of Other gains and losses from Continuing Operations


	2023 A$			2022 A$			2021 A$
Other gains and losses from Continuing Operations
Net (loss)/gain arising on changes in fair value of contingent consideration (Note 29)		(988,179	)		(936,354	)		3,212,503
Net realised and unrealised foreign currency gains		458,489			356,166			1,081,438
(Loss) on disposal of plant and equipment		-			(1,827	)		(21,010	)
		(529,690	)		(582,015	)		4,272,931

Income Taxes Relating to Continuing Operations - Summary of Net Deferred Tax Asset Not Recognised (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Changes in deferred tax liability (asset) [abstract]
Revenue tax losses	$ 33,323,740	$ 25,445,487
Net temporary difference	2,387,515	3,460,513
Net deferred tax asset not recognised	$ 35,711,255	$ 28,906,000

Financial Instruments - Summary of Remaining Contractual Maturity for Financial Liabilities (Details) - Liquidity and Interest Rate Risk - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Weighted average effective interest rate	3.56%	3.56%
Trade and other payables	$ 3,500,487	$ 2,786,280
Lease liability - rental property (fixed interest rate)	563,262	744,580
Undiscounted cash flows of financial liabilities	4,063,749	3,530,860
Less Than 1 Month
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade and other payables	3,500,487	2,786,280
Lease liability - rental property (fixed interest rate)	15,564	15,069
Undiscounted cash flows of financial liabilities	3,516,051	2,801,349
1 - 3 Months
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	46,691	45,206
Undiscounted cash flows of financial liabilities	46,691	45,206
3 - 12 Months
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	125,018	121,043
Undiscounted cash flows of financial liabilities	125,018	121,043
1 to 5 Years
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Lease liability - rental property (fixed interest rate)	375,989	563,262
Undiscounted cash flows of financial liabilities	$ 375,989	$ 563,262

Commitments For Expenditure - Summary of Non Cancellable Operating Lease Commitments (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	$ 15,572	$ 18,568
Within one year
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	5,469	5,064
Later than one year but not greater than five
Disclosure of maturity analysis of operating lease payments [line items]
Non-cancellable operating lease commitments	$ 10,103	$ 13,504

Cash and Cash Equivalents - Disclosure of Detailed Information About Cash and Cash Equivalents (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Cash and cash equivalents [abstract]
Cash at bank and on hand	$ 18,250,255	$ 33,564,857
Cash and cash equivalents	$ 18,250,255	$ 33,564,857	$ 28,499,449	$ 4,577,747

Trade and Other Payables

12 Months Ended

Jun. 30, 2023

Trade and other payables [abstract]

Trade and Other Payables

NOTE 17: TRADE AND OTHER PAYABLES


	2023 A$		2022 A$
Current
Trade payables		2,062,549		1,556,881
Accrued expenses		1,437,938		1,229,399
		3,500,487		2,786,280

The average credit period on purchases of goods is 45 days. No interest is paid on the trade payables. The Group has financial risk management policies in place to ensure that all payables are paid within the credit time frame.

Issued Capital

12 Months Ended

Jun. 30, 2023

Disclosure of classes of share capital [abstract]

Issued Capital

NOTE 20: ISSUED CAPITAL

(a)

Issued capital

Movements in Ordinary Shares of the Company during the current period were as follows:


Date	Details	Number of shares		A$
Ordinary Shares
July 1, 2020	Opening balance		626,185,872		148,156,005
	Share issue - share placements (i)		185,757,511		21,229,874
	Share issue – rights (ii)		195,229,129		22,606,257
	Shares issued to employees		424,232		60,750
	Share issue costs		-		(423,492	)
	Warrants issued -underwriting fee (iii)		-		(1,439,247	)
June 30, 2021	Closing balance		1,007,596,744		190,190,147
	Shares issued on exercise of options (iv)		2,000,000		27,200
	Shares issued on exercise of warrants (iv)		8,000,000		480,000
	Transfer from share-based payments reserve as result of options and warrants being exercised		-		327,760
	Share issue in a US IPO and NASDAQ listing (v)		335,754,000		32,383,263
	Share issue costs		-		(5,712,611	)
June 30, 2022	Closing balance		1,353,350,744		217,695,759
	Share issue in a US F-1 (vi)		115,384,680		7,419,235
	Share issue costs		-		(1,702,332	)
June 30, 2023	Closing balance		1,468,735,424		223,412,662

(i)

During the year ended June 30, 2021, the following share placements occurred:

•

Issue of 54,333,000 shares at A$0.04 per share raising A$2,173,320. The share issue was approved by shareholders at a General Meeting held on August 26, 2020; and

•

Issue of 131,424,511 shares at A$0.145 per share raising A$19,056,554

(ii)

During the year ended June 30. 2021, the following rights issues occurred:

•

Issue of 54,304,446 at A$0.04 per share raising A$2,172,178; and

•

Issue of 140,924,683 shares at A$0.145 raising A$20,434,079

(iii)

Shareholders at the General Meeting held on August 26, 2020 approved the issue of 150,000,000 warrants to Apeiron Investment Group Ltd (“Apeiron”) to subscribe for shares at A$0.06 per share as consideration of underwriting a share issue that would raise at least A$15,000,000. The warrants vested on 3 March 2021 when with the assistance of Apeiron a share placement was made that raised A$15,991,634.

(iv)

During the year ended June 30, 2022, the following shares were issued:

•

Issue of2,000,000 as a result of share options being exercised that had an exercise price of A$0.0136 per option; and

•

Issue of 8,000,000 shares as a result of warrants being exercised that had an exercise price of A$0.06 per warrant.

(v)

During the year ended June 30, 2022, 335,754,000 shares were issued in a US IPO and Nasdaq listing. The IPO and Nasdaq listing were approved by shareholders at the Annual General Meeting held on December 2, 2021.

(vi)

During the year ended 30 June 2023, 115,384,680 shares were issued in a US IPO a F-1 share placement.

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote and upon a poll each share is entitled to one vote.

(b)

Share Options

When exercised, each option is convertible into one ordinary share.

The Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan

The terms and conditions of the Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan are summarised in Note 2(g)(iii).

Movement in unlisted share options:


	2023				2022				2021
				Weighted				Weighted				Weighted
	Number			average	Number			average	Number			average
	of options			exercise	of options			exercise	of options			exercise
				price				price				price
Opening balance at beginning of financial year		79,056,617		A$0.16		20,985,450		A$0.12		6,364,550		A$0.40
Granted during the financial year		43,100,348		A$0.04		61,216,767		A$0.18		15,500,000		A$0.04
Forfeited during the financial year		(3,500,000	)	A$0.05		-		-		(5,000	)	A$0.41
Exercised during the financial year		-				(2,000,000	)	A$0.01		-		-
Expired during the financial year		(1,445,650	)	A$0.39		(1,145,600	)	A$0.42		(874,100	)	A$0.45
Closing balance at June 30		117,211,315		A$0.12		79,056,617		A$0.16		20,985,450		A$0.12

The number of unlisted share options vested and exercisable at June 30, 2023 is 46,690,480 (2022: 31,065,275).

The weighted average remaining contractual life of any unlisted share options outstanding at the end of the year is 4.85 years (2022: 4.93 years).

(i) Unlisted share options issued during the year ended June 30, 2023

On 15 July 2022, the Company issued 7,700,000 share options to subscribe for 7,700,000 shares at $0.0543 per share, under the Employee Equity Plan, including 7,500,000 share options that were issued to key management personnel (KMP). 25% of the Options vest at the end of 12 months following the Offer Date (8 July 2022), and 75% vest in 12 substantially equal instalments (6.25%) on the last day of each calendar quarter over the 4-year period following the end of the initial 12 months following the Offer Date. The share options expire on the date that is 5 years following each vesting date.

Details of share options that were issued to the KMPs are set out below:


KMP	Number
Mr Adrian Hinton	2,000,000
Mr Connor Bernstein	3,500,000
Ms Liz Doolin	2,000,000

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

8-Jul-22

8-Jul-23

8-Jul-28

A$0.0543

1,925,000

A$0.041

8-Jul-22

31-Oct-23

31-Oct-28

A$0.0543

481,251

A$0.042

8-Jul-22

31-Jan-24

31-Jan-29

A$0.0543

481,251

A$0.043

8-Jul-22

30-Apr-24

30-Apr-29

A$0.0543

481,251

A$0.043

8-Jul-22

31-Jul-24

31-Jul-29

A$0.0543

481,251

A$0.044

8-Jul-22

31-Oct-24

31-Oct-29

A$0.0543

481,251

A$0.044

8-Jul-22

31-Jan-25

31-Jan-30

A$0.0543

481,251

A$0.045

8-Jul-22

30-Apr-25

30-Apr-30

A$0.0543

481,251

A$0.045

8-Jul-22

31-Jul-25

31-Jul-30

A$0.0543

481,251

A$0.046

8-Jul-22

31-Oct-25

31-Oct-30

A$0.0543

481,251

A$0.046

8-Jul-22

31-Jan-26

31-Jan-31

A$0.0543

481,251

A$0.046

8-Jul-22

30-Apr-26

30-Apr-31

A$0.0543

481,251

A$0.047

8-Jul-22

31-Jul-26

31-Jul-31

A$0.0543

481,239

A$0.047

7,700,000

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.058
Exercise price	A$0.0543
Bionomics share volatility	80.13%
Risk free interest rate	3.196%

Shareholders at the General Meeting held on 21 February 2023 approved the issue of 10,000,000 share options to Dr De Souza (Non-executive Chairman) as part of his remuneration as Executive Chairman to 31 December 2022 to subscribe for 10,000,000 shares at $0.052 per share.

The vesting conditions are:

5,000,000 options – to vest when the volume weighted average price of ADSs on NASDAQ over the prior 20 days on which sales of ADSs were recorded on NASDAQ exceeds $12.35 per ADS, and provided the relevant calculation period ends on or before 30 June 2024.

1,666,666 options – to vest if the Company appoints a Chief Executive Officer on or before 31 December 2022.

1,666,666 options – to vest on achievement of successful data readout for Phase 2 trial for BNC210 in PTSD as reasonably determined by the Board in its sole discretion.

1,666,666 options – to vest on achievement of successful data readout for Phase 2 trial for BNC210 in SAD as reasonably determined by the Board in its sole discretion.

1,666,666 share options were not issued as at the date of issue of the share options, the data readout for Phase2 trial for BNC210 in SAD had been announced and was deemed not successful.

1,666,666 share options vested on the date of issue if the share options, as the CEO was already appointed.

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

21-Feb-23

30-Jun-24

30-Jun-29

A$0.052

5,000,000

A$0.0053

21-Feb-23

23-Feb-23

23-Feb-28

A$0.052

1,666,666

A$0.014

21-Feb-23

30-Sep-23

30-Sep-28

A$0.052

1,666,667

A$0.015

8,333,333

A Monte Carlo model was used to obtain the fair value of the share options that have a vesting condition relating to Bionomics' share price and a Black-Scholes model was used to obtain the fair value of the other share options. Inputs used are summarised below:


Share price at date of issue	A$0.028
Exercise price	A$0.0520
Bionomics share volatility	74,18%
Risk free interest rate	3.627%

Shareholders at the General Meeting held on 21 February 2023 approved the issue of 27,067,015 share options to Dr Papapetropoulos (Chief Executive Officer) as part of his remuneration as Chief Executive Officer to subscribe for 27,067,015 shares at $0.052 per share. 25% on the first anniversary of the grant date for the options, with the balance vesting on a quarterly basis over a 3-year period commencing from that date.

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

21-Feb-23

16-Dec-23

16-Dec-28

A$0.0321

6,766,754

A$0.017

21-Feb-23

16-Mar-24

16-Mar-29

A$0.0321

1,691,688

A$0.017

21-Feb-23

16-Jun-24

16-Jun-29

A$0.0321

1,691,689

A$0.018

21-Feb-23

16-Sep-24

16-Sep-29

A$0.0321

1,691,688

A$0.018

21-Feb-23

16-Dec-24

16-Dec-29

A$0.0321

1,691,689

A$0.018

21-Feb-23

16-Mar-25

16-Mar-30

A$0.0321

1,691,688

A$0.019

21-Feb-23

16-Jun-25

16-Jun-30

A$0.0321

1,691,689

A$0.019

21-Feb-23

16-Sep-25

16-Sep-30

A$0.0321

1,691,688

A$0.019

21-Feb-23

16-Dec-25

16-Dec-30

A$0.0321

1,691,689

A$0.019

21-Feb-23

16-Mar-26

16-Mar-31

A$0.0321

1,691,688

A$0.02

21-Feb-23

16-Jun-26

16-Jun-31

A$0.0321

1,691,689

A$0.02

21-Feb-23

16-Sep-26

16-Sep-31

A$0.0321

1,691,688

A$0.02

21-Feb-23

16-Dec-26

16-Dec-31

A$0.0321

1,691,688

A$0.02

27,067,015

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.028
Exercise price	A$0.0321
Bionomics share volatility	74.18%
Risk free interest rate	3.627%

(ii) Unlisted share options issued during the year ended June 30, 2022

On December 2, 2021, shareholders at the Annual General Meeting approved the issuing of 47,786,607 share options to subscribe for 47,786,607 shares at $0.2014 per share to Dr Errol De Souza, Executive Chairman. The options were issued on December 22, 2021, details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

2-Dec-21

30-Sep-21

30-Sep-26

A$0.2014

2,986,663

A$0.0740

2-Dec-21

31-Dec-21

31-Dec-26

A$0.2014

2,986,663

A$0.0760

2-Dec-21

31-Mar-22

31-Mar-27

A$0.2014

2,986,663

A$0.0780

2-Dec-21

30-Jun-22

30-Jun-27

A$0.2014

2,986,663

A$0.0790

2-Dec-21

30-Sep-22

30-Sep-27

A$0.2014

2,986,663

A$0.0810

2-Dec-21

31-Dec-22

31-Dec-27

A$0.2014

2,986,663

A$0.0820

2-Dec-21

31-Mar-23

31-Mar-28

A$0.2014

2,986,663

A$0.0840

2-Dec-21

30-Jun-23

30-Jun-28

A$0.2014

2,986,663

A$0.0850

2-Dec-21

30-Sep-23

30-Sep-28

A$0.2014

2,986,663

A$0.0860

2-Dec-21

31-Dec-23

31-Dec-28

A$0.2014

2,986,663

A$0.0880

2-Dec-21

31-Mar-24

31-Mar-24

A$0.2014

2,986,663

A$0.0890

2-Dec-21

30-Jun-24

30-Jun-24

A$0.2014

2,986,663

A$0.0900

2-Dec-21

30-Sep-24

30-Jun-24

A$0.2014

2,986,663

A$0.0910

2-Dec-21

31-Dec-24

31-Dec-29

A$0.2014

2,986,663

A$0.0920

2-Dec-21

31-Mar-25

31-Mar-30

A$0.2014

2,986,663

A$0.0930

2-Dec-21

30-Jun-25

30-Jun-30

A$0.2014

2,986,662

A$0.0940

47,786,607

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.125
Exercise price	A$0.2014
Bionomics share volatility		85.53	%
Risk free interest rate		0.413	%

On December 2, 2021, shareholders at the Annual General Meeting approved the issuing of 13,430,160 share options to subscribe for 13,430,160 shares at A$0.09645 per share to Dr Errol De Souza, Executive Chairman. The options were issued on 22 December 2021, details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

2-Dec-21

31-Mar-22

31-Mar-27

A$0.09645

839,385

A$0.0900

2-Dec-21

30-Jun-22

30-Jun-27

A$0.09645

839,385

A$0.0910

2-Dec-21

30-Sep-22

30-Sep-27

A$0.09645

839,385

A$0.0920

2-Dec-21

31-Dec-22

31-Dec-27

A$0.09645

839,385

A$0.0940

2-Dec-21

31-Mar-23

31-Mar-28

A$0.09645

839,385

A$0.0950

2-Dec-21

30-Jun-23

30-Jun-28

A$0.09645

839,385

A$0.0960

2-Dec-21

30-Sep-23

30-Sep-28

A$0.09645

839,385

A$0.0970

2-Dec-21

31-Dec-23

31-Dec-28

A$0.09645

839,385

A$0.0980

2-Dec-21

31-Mar-24

31-Mar-29

A$0.09645

839,385

A$0.0980

2-Dec-21

30-Jun-24

30-Jun-29

A$0.09645

839,385

A$0.0990

2-Dec-21

30-Sep-24

30-Sep-29

A$0.09645

839,385

A$0.1000

2-Dec-21

31-Dec-24

31-Dec-29

A$0.09645

839,385

A$0.1010

2-Dec-21

31-Mar-25

31-Mar-30

A$0.09645

839,385

A$0.1020

2-Dec-21

30-Jun-25

30-Jun-30

A$0.09645

839,385

A$0.1020

2-Dec-21

30-Sep-25

30-Sep-30

A$0.09645

839,385

A$0.1030

2-Dec-21

31-Dec-25

31-Dec-30

A$0.09645

839,385

A$0.1040

13,430,160

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below


Share price at date of issue	A$0.125
Exercise price	A$0.0965
Bionomics share volatility		85.53	%
Risk free interest rate		0.413	%

(iii) Unlisted share options issued during the year ended June 30, 2021

On August 28, 2020, the Company issued 15 million share options to subscribe for 15 million shares at A$0.04 per share expiring on August 28, 2025 to key management personnel, details of the issue are set out below:


KMP	Number	Vesting conditions	Fair value at date of issue
Dr Errol De Souza	6,000,000	Company’s share price reaching $0.14 per share	A$0.075
Dr Errol De Souza	6,000,000	Company’s share price reaching $0.24 per share	A$0.071
Mr Jack Moschakis	1,000,000	Company’s share price reaching $0.14 per share	A$0.133
Mr Jack Moschakis	1,000,000	Company’s share price reaching $0.24 per share	A$0.118
Ms Liz Doolin	500,000	Company’s share price reaching $0.14 per share	A$0.133
Ms Liz Doolin	500,000	Company’s share price reaching $0.24 per share	A$0.118

The share options issued to Dr Errol De Souza were approved by shareholders at the general meeting held on August 26, 2020 and the share options issued to Mr Jack Moschakis and Ms Liz Doolin were approved by Directors on 28 August 2020.

A Monte Carlo model was used to obtain the fair value of the share options that were issued to Dr Errol De Souza and the share options issued to Mr Jack Moschakis and Ms Liz Doolin that vest when the Company’s share price reach A$0.24. A Black-Scholes model was used to obtain the fair value of the share options issued to Mr Jack Moschakis and Ms Liz Doolin that vest when the Company’s share price reach $0.14, as the share price had reached A$0.14 when these shares options were approved to be issued. Inputs used are summarised below:


	Dr Errol De Souza share options	Mr Jack Moschakis and Ms Liz Doolin share options
Share price at date of issue	A$0.11	A$0.15
Exercise price	A$0.04	A$0.04
Bionomics share volatility	105%	105%
Risk free interest rate	0.42%	0.43%

On November 20, 2020, the company issued 500,000 share options to subscribe for 500,000 shares at A$0.1687 per share to Dr Jane Ryan (non-executive director). The issue of these options was approved by shareholders at the Annual General Meeting held on 20 November 2020, details of the share options issue are set out below:


Grant date	Vesting date	Expiry date	Exercise price	Number	Fair value at date of issue
20-Nov-20	20-Oct-21	20-Oct-26	A$0.1687	100,000	A$0.089
20-Nov-20	20-Oct-22	20-Oct-27	A$0.1687	100,000	A$0.095
20-Nov-20	20-Oct-23	20-Oct-28	A$0.1687	100,000	A$0.099
20-Nov-20	20-Oct-24	20-Oct-29	A$0.1687	100,000	A$0.103
20-Nov-20	20-Oct-25	20 Oct-30	A$0.1687	100,000	A$0.107

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.13
Exercise price	A$0.1687
Bionomics share volatility	89%
Risk free interest rate	0.30%

As a result of the rights issues that occurred during the year ended June 30, 2021, the exercise price of the above options was recalculated in accordance with the rules of the option plans, and the ASX listing rule 6.22.2.

Unlisted share options exercised during the year ended June 30, 2023

No share options exercised .

Unlisted share options exercised during the year ended June 30, 2022

On September 2, 2021, 2,000,000 unlisted share options were exercised at A$0.0136 per share. The share price at date of exercise was A$0.19.

The table below lists share options outstanding at June 30, 2023:


Grant date	Expiry date	Exercise price	Number of options		Fair value
20-Jul-15	20-Jul-23	A$0.3481		10,000	A$0.2513
20-Jul-15	20-Jul-23	A$0.3481		5,000	A$0.2513
5-Sep-17	5-Sep-23	A$0.4136		10,000	A$0.3062
9-Oct-15	9-Oct-23	A$0.4311		5,000	A$0.3376
10-Oct-13	10-Oct-23	A$0.5750		15,000	A$0.5415
4-Nov-16	4-Nov-23	A$0.2327		4,000	A$0.2448
28-Nov-16	28-Nov-23	A$0.2349		200,000	A$0.2621
28-Nov-16	28-Nov-23	A$0.2866		200,000	A$0.2504
28-Nov-16	28-Nov-23	A$0.3556		5,000	A$0.2370
17-Dec-13	17-Dec-23	A$0.6611		4,000	A$0.4573
24-Dec-15	24-Dec-23	A$0.5125		100,000	A$0.1798
30-Dec-15	30-Dec-23	A$0.4838		50,000	A$0.1912
2-Dec-21	31-Mar-24	A$0.2014		2,986,663	A$0.0890
27-Apr-15	27-Apr-24	A$0.4765		4,000	A$0.2601
6-May-16	6-May-24	A$0.2936		50,000	A$0.2068
25-May-15	25-May-24	A$0.3982		260,600	A$0.2780
2-Dec-21	30-Jun-24	A$0.2014		2,986,663	A$0.0900
2-Dec-21	30-Jun-24	A$0.2014		2,986,663	A$0.0910
20-Jul-15	20-Jul-24	A$0.4077		15,000	A$0.2640
5-Sep-17	5-Sep-24	A$0.4136		10,000	A$0.3236
9-Oct-15	9-Oct-24	A$0.4311		5,000	A$0.3521
4-Nov-16	4-Nov-24	A$0.2327		4,000	A$0.2546
28-Nov-16	28-Nov-24	A$0.2349		200,000	A$0.2721
28-Nov-16	28-Nov-24	A$0.2866		200,000	A$0.2616
28-Nov-16	28-Nov-24	A$0.3556		5,000	A$0.2495
24-Dec-15	24-Dec-24	A$0.5125		100,000	A$0.1925
30-Dec-15	30-Dec-24	A$0.4838		50,000	A$0.2038
27-Apr-15	27-Apr-25	A$0.4765		4,000	A$0.2722
6-May-16	6-May-25	A$0.2936		50,000	A$0.2164
25-May-15	25-May-25	A$0.3982		255,600	A$0.2893
25-May-15	25-May-25	A$0.3982		5,000	A$0.2893
20-Jul-15	20-Jul-25	A$0.4077		15,000	A$0.2756
28-Aug-20	28-Aug-25	A$0.0136		6,000,000	A$0.0750
28-Aug-20	28-Aug-25	A$0.0136		6,000,000	A$0.0710
28-Aug-20	28-Aug-25	A$0.0136		500,000	A$0.1330
28-Aug-20	28-Aug-25	A$0.0136		500,000	A$0.1180
5-Sep-17	5-Sep-25	A$0.0136		10,000	A$0.3388
9-Oct-15	9-Oct-25	A$0.4311		5,000	A$0.3653
4-Nov-16	4-Nov-25	A$0.2327		4,000	A$0.2633
28-Nov-16	28-Nov-25	A$0.2349		200,000	A$0.2810


Grant date	Expiry date	Exercise price	Number of options		Fair value
28-Nov-16	28-Nov-25	A$0.2866		200,000	A$0.2716
28-Nov-16	28-Nov-25	A$0.3556		5,000	A$0.2605
24-Dec-15	24-Dec-25	A$0.5125		100,000	A$0.2039
30-Dec-15	30-Dec-25	A$0.4838		50,000	A$0.2152
6-May-16	6-May-26	A$0.2936		50,000	A$0.2251
5-Sep-17	5-Sep-26	A$0.4136		10,000	A$0.3520
2-Dec-21	30-Sep-26	A$0.2014		2,986,663	A$0.0740
20-Nov-20	20-Oct-26	A$0.1519		100,000	A$0.0890
4-Nov-16	4-Nov-26	A$0.2327		4,000	A$0.2710
28-Nov-16	28-Nov-26	A$0.2349		200,000	A$0.2890
28-Nov-16	28-Nov-26	A$0.2866		200,000	A$0.2804
28-Nov-16	28-Nov-26	A$0.3556		5,000	A$0.2703
2-Dec-21	31-Dec-26	A$0.2014		2,986,663	A$0.0760
2-Dec-21	31-Mar-27	A$0.2014		2,986,663	A$0.0780
2-Dec-21	31-Mar-27	A$0.0965		839,385	A$0.0900
2-Dec-21	30-Jun-27	A$0.2014		2,986,663	A$0.0790
2-Dec-21	30-Jun-27	A$0.0965		839,385	A$0.0910
5-Sep-17	5-Sep-27	A$0.4136		10,000	A$0.3636
2-Dec-21	30-Sep-27	A$0.2014		2,986,663	A$0.0810
2-Dec-21	30-Sep-27	A$0.0965		839,385	A$0.0920
20-Nov-20	20-Oct-27	A$0.15191		100,000	A$0.0950
2-Dec-21	31-Dec-27	A$0.2014		2,986,663	A$0.0820
2-Dec-21	31-Dec-27	A$0.0965		839,385	A$0.0940
21-Feb-23	23-Feb-28	A$0.0520		1,666,666	A$0.0140
2-Dec-21	31-Mar-28	A$0.2014		2,986,663	A$0.0840
2-Dec-21	31-Mar-28	A$0.0965		839,385	A$0.0950
2-Dec-21	30-Jun-28	A$0.2014		2,986,663	A$0.0850
2-Dec-21	30-Jun-28	A$0.0965		839,385	A$0.0960
8-Jul-22	8-Jul-28	A$0.0543		1,925,000	A$0.0410
2-Dec-21	30-Sep-28	A$0.2014		2,986,663	A$0.0860
2-Dec-21	30-Sep-28	A$0.0965		839,385	A$0.0970
21-Feb-23	30-Sep-28	A$0.0520		1,666,667	A$0.0150
20-Nov-20	20-Oct-28	A$0.1519		100,000	A$0.0990
8-Jul-22	31-Oct-28	A$0.0543		481,251	A$0.0420
21-Feb-23	16-Dec-28	A$0.0321		6,766,754	A$0.0170
2-Dec-21	31-Dec-28	A$0.2014		2,986,663	A$0.0880
2-Dec-21	31-Dec-28	A$0.0965		839,385	A$0.0980
8-Jul-22	31-Jan-29	A$0.0543		481,251	A$0.0430
21-Feb-23	16-Mar-29	A$0.0321		1,691,688	A$0.0170
2-Dec-21	31-Mar-29	A$0.0965		839,385	A$0.0980
8-Jul-22	30-Apr-29	A$0.0543		481,251	A$0.0430
21-Feb-23	16-Jun-29	A$0.0321		1,691,689	A$0.0180
2-Dec-21	30-Jun-29	A$0.0965		839,385	A$0.0990
21-Feb-23	30-Jun-29	A$0.0520		5,000,000	A$0.0144
8-Jul-22	31-Jul-29	A$0.0543		481,251	A$0.0440
21-Feb-23	16-Sep-29	A$0.0321		1,691,688	A$0.0180
2-Dec-21	30-Sep-29	A$0.0965		839,385	A$0.1000
20-Nov-20	20-Oct-29	A$0.1519		100,000	A$0.1030
8-Jul-22	31-Oct-29	A$0.0543		481,251	A$0.0440
21-Feb-23	16-Dec-29	A$0.0321		1,691,689	A$0.0180
2-Dec-21	31-Dec-29	A$0.2014		2,986,663	A$0.0920
2-Dec-21	31-Dec-29	A$0.0965		839,385	A$0.1010
8-Jul-22	31-Jan-30	A$0.0543		481,251	A$0.0450


Grant date	Expiry date	Exercise price	Number of options		Fair value
21-Feb-23	16-Mar-30	A$0.0321		1,691,688	A$0.0190
2-Dec-21	31-Mar-30	A$0.2014		2,986,663	A$0.0930
2-Dec-21	31-Mar-30	A$0.0965		839,385	A$0.1020
8-Jul-22	30-Apr-30	A$0.0543		481,251	A$0.0450
21-Feb-23	16-Jun-30	A$0.0321		1,691,689	A$0.0190
2-Dec-21	30-Jun-30	A$0.2014		2,986,662	A$0.0940
2-Dec-21	30-Jun-30	A$0.0965		839,385	A$0.1020
8-Jul-22	31-Jul-30	A$0.0543		481,251	A$0.0460
21-Feb-23	16-Sep-30	A$0.0321		1,691,688	A$0.0190
2-Dec-21	30-Sep-30	A$0.0965		839,385	A$0.1030
20-Nov-20	20-Oct-30	A$0.1519		100,000	A$0.1070
8-Jul-22	31-Oct-30	A$0.0543		481,251	A$0.0460
21-Feb-23	16-Dec-30	A$0.0321		1,691,689	A$0.0190
2-Dec-21	31-Dec-30	A$0.0965		839,385	A$0.1040
8-Jul-22	31-Jan-31	A$0.054		481,251	A$0.0460
21-Feb-23	16-Mar-31	A$0.0321		1,691,688	A$0.0200
8-Jul-22	30-Apr-31	A$0.0543		481,251	A$0.0470
21-Feb-23	16-Jun-31	A$0.0321		1,691,689	A$0.0200
8-Jul-22	31-Jul-31	A$0.0543		481,239	A$0.0470
21-Feb-23	16-Sep-31	A$0.0321		1,691,688	A$0.0200
21-Feb-23	16-Dec-31	A$0.0321		1,691,688	A$0.0200
				117,211,315

(c)

Warrants

When exercised, each warrant is convertible into one ordinary share.

Movement in unlisted share warrants:


	2023			2022				2021
			Weighted				Weighted				Weighted
	Number		average	Number			average	Number			average
	of warrants		exercise	of warrants			exercise	of warrants			exercise
			price				price				price
Opening balance at beginning of financial year		142,000,000	A$0.06		166,082,988		A$0.11		40,207,472		A$0.59
Granted during the financial year	-		-	-			-		150,000,000		A$0.06
Exercised during the financial year	-		-		(8,000,000	)	A$0.06	-			-
Expired during the financial year	-		-		(16,082,988	)	A$0.57		(24,124,484	)	A$0.59
Closing balance at June 30		142,000,000	A$0.06		142,000,000		A$0.06		166,082,988		A$0.11

The number of unlisted warrants vested and exercisable at June 30, 2023 is 142,000 (2021: 142,000,000).

The weighted average remaining contractual life of any unlisted warrants outstanding at the June 30, 2023 is 0.16 years (2022:1.6 years).

Unlisted warrants issued during the year ended June 30, 2021

On August 26, 2020, shareholders approved, as consideration for Apeiron underwriting a share issue that would raise at least A$15 million, that Apeiron would be issued 150 million warrants to subscribe for shares at A$0.06 per share with an expiry date of August 26, 2023.

With the assistance of Apeiron a share placement was made that raised A$15,991,634 and the warrants vested on March 3, 2021. As per IFRS 2 'Share Based Payment', the warrants have been valued based on the fair value of the services received (underwriting a share issue) which has been calculated using a risk adjusted estimated fee of 9% of the amount that was raised.

Unlisted warrants exercised during the year ended June 30, 2023

No warrants were exercised.

Unlisted warrants exercised during the year ended June 30, 2022

On November 11, 2021, 2,000,000 warrants were exercised at A$0.06 per share. The share price at date of exercise was A$0.125.

The table below lists warrants outstanding at June 30, 2023.


Grant Date	Expiry date	Exercise Price	No of options		Fair Value
26-Aug-20	26-Aug-23	A$0.06		142,000,000	A$0.01

General Information - Additional Information (Details)	12 Months Ended
General Information - Additional Information (Details)	Jun. 30, 2023
General information [abstract]
Address of registered office	200 Greenhill Road
Principal place of business	Eastwood, South Australia, 5063

Other Financial Assets - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of financial assets [line items]
Restricted term deposit	$ 119,000	$ 119,000
Effective interest rate on deposits	4.20%	1.95%
Maturity Date of June 3, 2024
Disclosure of financial assets [line items]
Restricted term deposit	$ 119,000
Restricted term deposit maturity date	Jun. 03, 2024
Maturity Date of June 3, 2022
Disclosure of financial assets [line items]
Restricted term deposit		$ 119,000
Restricted term deposit maturity date		Jun. 03, 2022

Financial Instruments - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about financial instruments [line items]
Derivative financial instruments outstanding	$ 0	$ 0
Foreign currency sensitivity rate	10.00%
Forward foreign currency contracts	$ 0	$ 0

Critical Accounting Estimates and Judgements

12 Months Ended

Jun. 30, 2023

Disclosure of changes in accounting estimates [abstract]

Critical Accounting Estimates and Judgements

NOTE 3: CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of the consolidated financial statements requires the Group to make estimates and judgments that can affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities at the date of the financial statements. The Group analyses the estimates and judgments and base estimates and judgments on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may vary from the estimates. The significant accounting policies are detailed in Note 2. Summarized below are the accounting policies of particular importance to the portrayal of the financial position and results of operations and that require the application of significant judgment or estimates by management.

Impairment of Goodwill and Other Intangible Assets

The Group assesses annually, or whenever there is a change in circumstances, whether goodwill or other intangible assets may be impaired.

Determining whether goodwill and other intangible assets are impaired requires an estimation of the higher of value in use and fair value less cost of disposal of the CGU to which goodwill or other intangible assets have been allocated. The value in use calculation is judgmental in nature and requires the Group to make a number of estimates including the future cash flows expected to arise from the CGU based on actual current market deals for drug compounds within the CGU and over a period covering drug discovery, development, approval and marketing as well as, a suitable discount rate in order to calculate present value. The cash flow projections are further weighted based on the observable market comparables probability of realising projected milestone and royalty payments. When the carrying value of the CGU exceeds its recoverable amount, the CGU is considered impaired and the assets in the CGU are written down to their recoverable amount. Impairment losses are recognised in the consolidated statement of profit or loss and other comprehensive income. A detailed valuation was performed as of June 30, 2023 and each computed recoverable amount (based on a value-in-use model) of the CGU was in excess of the carrying amount, respectively. As a result of this evaluation, it was determined that no impairment of goodwill or other intangible assets existed at June 30, 2023.

Contingent Consideration

As a result of the acquisition of Eclipse Therapeutic, Inc (“Eclipse”) during the year ended June 30, 2013, the Group determines and recognizes at each reporting date the fair value of the additional consideration that may be payable to Eclipse security holders due to potential royalty payments based on achieving late-stage development success or partnering outcomes based on Eclipse assets. Such potential earn-out payments are recorded at fair value and include a number of significant estimates including adjusted revenue projections and expenses, probability of such projections and a suitable discount rate to calculate fair value (see Note 29 for further information).

Lease Liabilities (Tables)

12 Months Ended

Jun. 30, 2023

Lease liabilities [abstract]

Schedule of Lease Liabilities Secured at Amortised Costs


	2023 A$			2022 A$			2021 A$
Secured – at amortised costs

Loan Movement Schedule
Opening Balance – July 1		693,623			867,841			793,148
New lease for new property - being rented		-			-			854,500
Repayments		(160,040	)		(174,218	)		(779,807	)
Closing Balance – June 30		533,583			693,623			867,841

Disclosed in the financial statements as:


Current liabilities	171,841	160,040	174,218
Non-current liabilities	361,742	533,583	693,623
	533,583	693,623	867,841

Schedule of Total Group Cash Outflows for Leases

The total Group cash outflows for leases is set out below:


	2023 A$		2022 A$		2021 A$
Principal element of lease payments		160,040		174,218		779,807
Interest element of lease payments - continuing operations		21,278		26,872		26,934
Total cash outflows for leases		181,318		201,090		806,741

Schedule of Undiscounted Potential Future Rental Payments

Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term:


	Within five years A$		More than five years A$		Total A$
As at June 30, 2023
Extension options expected not to be exercised		-		1,183,105		1,183,105

As at June 30, 2022
Extension options expected not to be exercised		-		1,183,105		1,183,105

Issued Capital - Summary of Share Options Issue (Details)					12 Months Ended
	Feb. 21, 2023 shares $ / shares	Jul. 08, 2022 shares $ / shares	Dec. 22, 2021 shares $ / shares	Nov. 20, 2020 shares $ / shares	Jun. 30, 2023 shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting date					five years
Number \| shares	8,333,333	7,700,000	47,786,607		117,211,315	79,056,617	20,985,450	6,364,550
Tranche 1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	30-Jun-24	8-Jul-23	30-Sep-21	20-Oct-21
Expiry date				Oct. 20, 2026
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	5,000,000	1,925,000	2,986,663	100,000
Fair value at date of issue	$ 0.0053	$ 0.041	$ 0.074	$ 0.089
Tranche 2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	23-Feb-23	31-Oct-23	31-Dec-21	20-Oct-22
Expiry date				Oct. 20, 2027
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	1,666,666	481,251	2,986,663	100,000
Fair value at date of issue	$ 0.014	$ 0.042	$ 0.076	$ 0.095
Tranche 3
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	21-Feb-23	8-Jul-22	2-Dec-21	20-Nov-20
Vesting date	30-Sep-23	31-Jan-24	31-Mar-22	20-Oct-23
Expiry date				Oct. 20, 2028
Exercise price	$ 0.052	$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares	1,666,667	481,251	2,986,663	100,000
Fair value at date of issue	$ 0.015	$ 0.043	$ 0.078	$ 0.099
Tranche 4
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21	20-Nov-20
Vesting date		30-Apr-24	30-Jun-22	20-Oct-24
Expiry date				Oct. 20, 2029
Exercise price		$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares		481,251	2,986,663	100,000
Fair value at date of issue		$ 0.043	$ 0.079	$ 0.103
Tranche 5
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		8-Jul-22	2-Dec-21	20-Nov-20
Vesting date		31-Jul-24	30-Sep-22	20-Oct-25
Expiry date				Oct. 20, 2030
Exercise price		$ 0.0543	$ 0.2014	$ 0.1687
Number \| shares		481,251	2,986,663	100,000
Fair value at date of issue		$ 0.044	$ 0.081	$ 0.107

Right-of-Use Assets - Summary of Right-of-Use Assets (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	$ 669,358
Depreciation (Note 6)	(170,900)	$ (193,358)	$ (762,813)
Closing balance June 30	498,458	669,358
Right-of-use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	669,358	862,716
Addition of new property being rented		0
Depreciation (Note 6)	(170,900)	(193,358)
Closing balance June 30	498,458	669,358	$ 862,716
Right-of-use Assets \| Cost
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	854,500
Closing balance June 30	854,500	854,500
Right-of-use Assets \| Accumulated depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Opening balance July 1	(185,142)
Closing balance June 30	$ (356,042)	$ (185,142)

Related Party Transactions

12 Months Ended

Jun. 30, 2023

Related Party Transactions

NOTE 28: RELATED PARTY TRANSACTIONS

(a)

Parent Entity

The immediate parent and ultimate controlling party of the Group is Bionomics Limited. Interests in subsidiaries are set out in Note 12.

(b)

Loans to Directors and Other Key Management Personnel

There were no loans to any Directors of the Company or other key management personnel of the Group during the financial year ended 30 June 30, 2023 (2022: Nil).

(c)

Appointment of New Chief Executive Officer

On 5 January 2023, Dr Spyros Papapetropoulos commenced employment as President and Chief Executive Officer, details of the employment contract are set out below:

•

Fixed Remuneration of $525,000 per year base salary, plus reimbursement for the cost of procuring health benefits in the United States for an amount equal to $2,500 per month;

•

Signing on bonus of $50,000;

•

A short-term incentive/bonus potential of 50% of base salary, upon meeting the applicable performance criteria established by the Remuneration Committee of the Board, against agreed financial, strategic and operational targets;

•

Severance pay of 1 times base salary plus a 1 time target bonus potential to be paid in equal instalments over the following 12-month period; and

•

any outstanding equity compensation awards will fully and immediately vest.

(d)

Termination Payment to Dr Errol DE Souza

As a result of Dr Spyros Papapetropoulos commencing employment as President and Chief Executive Officer on 5 January 2023 (see above for details), Dr De Souza resumed the role as Non-executive Chairman from 1 January 2023 and was replaced as Chairman by Mr Alan Fisher on 1 July 2023. As per the agreement with Dr De Souza a transitional payment of $351,376 and bonus payment of $332,325 became payable. This was partially offset by no Director fees being paid to the Non-Executive Chairman for the period 1 January 2023 to 30 June 2023.

(e)

Share Options Issued to Directors and Other Key Management Personnel

During the year ended 30 June 2023 share options were issued to Dr Errol De Souza and Dr Spyros Papapetropoulos (directors), and Mr Adrian Hinton, Mr Connor Bernstein and Ms Liz Doolin (other key Management personnel), details about these share options are set out in Note 20(b) (i) to the Financial Statements). (2022: share options were issued to Dr Errol De Souza, details about these share options are set out in Note 20(b) (ii) to the Financial Statement).

(f)

Share Options forfeited by Other Key Management Personnel

As Mr Connors consultancy agreement was not renewed on 30 June 2023 the share options that had been issued to him (3,500,000) during the current year were forfeited (2022: Nil).

(g)

Shares Issued to Apeiron Investment Group Limited (“Apeiron”) and Apeiron Presight Capital Fund II LP (“Presight”), (Director related entities)

No shares were issued during the year ended 30 June 2023 (2022:14,574,780 shares were issued to Apeiron and 109,311,660 shares were issued to Presight at $0.09645 per share as a result of the US IPO).

(h)

Shares Issued to BVF Partners (a Director related entity) ("BVF")

BVF was a Director related entity during the year ended 30 June 2022 and 7,287,480 shares at $0.09645 per share were issued to BVF during December 2022 as a result of the US IPO. After the share issue BVF Partners ceased to be a Director related entity.

Expenses Relating to Continuing Operations (Tables)

12 Months Ended

Jun. 30, 2023

Expenses by nature [abstract]

Schedule of Expenses Related to Continuing Operations


	2023 A$		2022 A$		2021 A$
Loss before income tax benefit includes the following specific expenses:

Finance expenses
- Interest expense on lease liabilities		21,278		26,872		26,934
- Bank fees		7,952		17,293		17,527
- Amortisation of transaction costs (Note18)						252,019
- Accrual of final payment (Note18)						528,819
- Interest expense on bank loan and other loans						618,586
		29,230		44,165		1,443,885

Employment benefit expenses of:
- Wages and salaries		3,785,547		2,901,689		2,577,954
- Superannuation		176,710		266,127		148,662
- Share-based payments		1,904,553		2,829,689		1,308,349
		5,866,810		5,997,505		4,034,965

Depreciation and Amortisation of non-current assets
- Plant and equipment (Note 13)		1,368		2,681		45,553
- Right-of-use assets (rental property) (Note 14)		170,900		193,358		762,813
- Intellectual property (Note 16)		984,724		913,373		892,512
		1,156,992		1,109,412		1,700,878
Rental expense on operating leases (low value assets)
- Minimum lease payments		5,729		5,260		7,277

Cash Flow Information

12 Months Ended

Jun. 30, 2023

Statement of cash flows [abstract]

Cash Flow Information

NOTE 26: CASH FLOW INFORMATION

(a)

Cash and Cash Equivalents


	2023 A$		2022 A$		2021 A$
Cash and cash equivalents		18,250,255		33,564,857		28,499,449

(b)

Reconciliation of Operating Loss to Net Cash Outflow from Operating Activities


	2023 A$			2022 A$			2021 A$
(Loss) for the year		(31,846,957	)		(21,759,358	)		(8,697,037	)
Items in loss
Depreciation and amortisation		1,156,992			1,109,412			1,700,878
Share-based payments		1,904,553			2,829,689			1,308,349
Loss on asset disposals		-			1,827			21,010
Contingent consideration – change in fair value		988,179			936,354			(3,212,503	)
Amortisation of transaction costs		-			-			252,019
Accrual of final borrowing payment								528,819
Net foreign exchange differences		(33,555	)		738,423			(1,067,746	)
Interest received		(479,726	)		(9,869	)		(5,756	)

Changes in Operating Assets and Liabilities
Decrease/(Increase) in receivables		49,642			(39,148	)		34,078
Decrease/(Increase)in research and development incentive receivable		6,092,202			(5,791,688	)		1,991,468
Decrease/(Increase) in other assets		258,252			(600,285	)		(85,648	)
Increase/(Decrease) in payables		714,207			979,902			(63,305	)
Increase/(Decrease) in provisions		59,635			41,062			(55,923	)
(Decrease) in deferred tax liability		(206,792	)		(191,808	)		(187,427	)
Net cash outflows from operating activities		(21,343,368	)		(21,755,487	)		(7,538,724	)

Trade and Other Payables - Additional Information (Details)	12 Months Ended
	Jun. 30, 2023 AUD ($)
Trade and other payables [abstract]
Average credit period on purchases of goods	45 days
Interest paid on trade payables	$ 0

Right-of-Use Assets - Summary of Depreciation Disclosed in Consolidated Statement of Profit or Loss and Other Comprehensive Income (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortisation expense	$ 1,156,992	$ 1,109,412	$ 1,700,878

Provisions (Tables)

12 Months Ended

Jun. 30, 2022

Disclosure Of Provision Abstract

Summary of Detailed Information About Provisions


	2023 A$		2022 A$
Current
Employee benefits		457,017		409,320
Non-Current
Employee benefits		22,398		10,460

Other Intangible Assets - Summary of Carrying Amounts of Each Class of Other Intangible Assets (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	$ 9,838,274
Amortisation	984,724	$ 913,373	$ 892,512
Other Intangible Assets, Ending balance	9,202,594	9,838,274
Net carrying amount	9,202,594	9,838,274
Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Net carrying amount	9,202,594	9,838,274
Gross Carrying Amount
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	24,291,316	22,776,020
Foreign currency exchange differences	700,873	1,515,296
Other Intangible Assets, Ending balance	24,992,189	24,291,316	22,776,020
Gross Carrying Amount \| KV1.3 Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	1,546,542	1,546,542
Other Intangible Assets, Ending balance	1,546,542	1,546,542	1,546,542
Gross Carrying Amount \| VDA Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	2,282,527	2,282,527
Other Intangible Assets, Ending balance	2,282,527	2,282,527	2,282,527
Gross Carrying Amount \| MultiCoreTechnology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	1,265,590	1,265,590
Other Intangible Assets, Ending balance	1,265,590	1,265,590	1,265,590
Gross Carrying Amount \| Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	19,196,657	17,681,361
Foreign currency exchange differences	700,873	1,515,296
Other Intangible Assets, Ending balance	19,897,530	19,196,657	17,681,361
Accumulated Amortisation
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(14,453,042)	(12,830,265)
Amortisation	(984,724)	(913,373)
Foreign currency exchange differences	(351,829)	(709,404)
Other Intangible Assets, Ending balance	(15,789,595)	(14,453,042)	(12,830,265)
Accumulated Amortisation \| KV1.3 Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(1,546,542)	(1,546,542)
Other Intangible Assets, Ending balance	(1,546,542)	(1,546,542)	(1,546,542)
Accumulated Amortisation \| VDA Compound
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(2,282,527)	(2,282,527)
Other Intangible Assets, Ending balance	(2,282,527)	(2,282,527)	(2,282,527)
Accumulated Amortisation \| MultiCoreTechnology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(1,265,590)	(1,265,590)
Other Intangible Assets, Ending balance	(1,265,590)	(1,265,590)	(1,265,590)
Accumulated Amortisation \| Cancer Stem Cell Technology
Disclosure of detailed information about intangible assets [line items]
Other Intangible Assets, Beginning balance	(9,358,383)	(7,735,606)
Amortisation	(984,724)	(913,373)
Foreign currency exchange differences	(351,829)	(709,404)
Other Intangible Assets, Ending balance	$ (10,694,936)	$ (9,358,383)	$ (7,735,606)

Goodwill - Additional Information (Details)	12 Months Ended
Goodwill - Additional Information (Details)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of reconciliation of changes in goodwill [abstract]
Description of basis on which unit's recoverable amount has been determined	The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 18.5% (2022: 17%).
Post-tax discount rate	18.50%	17.00%
Growth rates	0.00%

Issued Capital - Summary of Movement in Unlisted Share Warrants (Details) - Warrants		12 Months Ended
	Nov. 11, 2021 shares $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of warrants Opening balance \| shares		142,000,000	166,082,988	40,207,472
Number of warrants Granted during the financial year \| shares				150,000,000
Number of warrants Exercised during the financial year \| shares	(2,000,000)	0	(8,000,000)
Number of warrants Expired during the financial year \| shares			(16,082,988)	(24,124,484)
Number of warrants Closing balance \| shares		142,000,000	142,000,000	166,082,988
Weighted average exercise price Opening balance \| $ / shares		$ 0.06	$ 0.11	$ 0.59
Weighted average exercise price Granted during the financial year \| $ / shares				0.06
Weighted average exercise price Exercised during the financial year \| $ / shares	$ 0.06		0.06
Weighted average exercise price Expired during the financial year \| $ / shares			0.57	0.59
Weighted average exercise price Closing balance \| $ / shares		$ 0.06	$ 0.06	$ 0.11

Reserves

12 Months Ended

Jun. 30, 2023

Disclosure of reserves within equity [abstract]

Reserves

NOTE 21: RESERVES


	2023 A$		2022 A$
Foreign Currency Translation Reserve (a)		6,646,840		6,186,334
Share-based Payments Reserve (b)		7,858,906		6,337,264
Total Reserves		14,505,746		12,523,598

(a)

Foreign Currency Translation Reserve

Exchange differences arising on translation of the foreign controlled entities are taken to the foreign currency translation reserve, as described in Note 2(i). The reserve is recognized in profit or loss when the investment is disposed of.

(b)

Share-based Payments Reserve

The share-based payments reserve is used to recognize the fair value of options and warrants issued over the vesting period or the period of the Consultancy Agreement, as applicable. Further information about share-based payments is set out in Note 20.

Subsidiaries - Summary of Group Subsidiaries (Details)	12 Months Ended
Subsidiaries - Summary of Group Subsidiaries (Details)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of subsidiaries [line items]
Principal activity	Research and Development
Country of incorporation	Australia
Iliad Chemicals Pty Ltd
Disclosure of subsidiaries [line items]
Subsidiaries of Bionomics Limited	Iliad Chemicals Pty Ltd
Principal activity	Asset owner
Country of incorporation	Australia
Percentage owned	100.00%	100.00%
Bionomics Inc
Disclosure of subsidiaries [line items]
Subsidiaries of Bionomics Limited	Bionomics Inc
Principal activity	Asset owner
Country of incorporation	United States
Percentage owned	100.00%	100.00%

Financial Instruments - Categories of Financial Instruments (Details) - AUD ($)	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Disclosure of financial assets [abstract]
Cash and cash equivalents	$ 18,250,255		$ 33,564,857	$ 28,499,449	$ 4,577,747
Receivables	642,277		6,784,121
Other financial assets	119,000		119,000
Total financial assets	19,011,532		40,467,978
Financial Liabilities
Trade and other payables	3,500,487		2,786,280
Lease liability - rental property	533,583	$ 693,623	693,623	$ 867,841	$ 793,148
Contingent consideration at fair value	3,687,189		2,699,010
Total financial liabilities	$ 7,721,259		$ 6,178,913

Right-of-Use Assets

12 Months Ended

Jun. 30, 2023

Disclosure of quantitative information about right-of-use assets [line items]

Right-of-use Assets

NOTE 18: LEASE LIABILITIES


	2023 A$			2022 A$			2021 A$
Secured – at amortised costs

Loan Movement Schedule
Opening Balance – July 1		693,623			867,841			793,148
New lease for new property - being rented		-			-			854,500
Repayments		(160,040	)		(174,218	)		(779,807	)
Closing Balance – June 30		533,583			693,623			867,841

Disclosed in the financial statements as:


Current liabilities	171,841	160,040	174,218
Non-current liabilities	361,742	533,583	693,623
	533,583	693,623	867,841

Lease liabilities relate to building leases and are effectively secured by the buildings being leased (Note 14).

The total Group cash outflows for leases is set out below:


	2023 A$		2022 A$		2021 A$
Principal element of lease payments		160,040		174,218		779,807
Interest element of lease payments - continuing operations		21,278		26,872		26,934
Total cash outflows for leases		181,318		201,090		806,741

The Group's lease contracts include extension and termination options. These options are

negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group’s business needs.

Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term:


	Within five years A$		More than five years A$		Total A$
As at June 30, 2023
Extension options expected not to be exercised		-		1,183,105		1,183,105

As at June 30, 2022
Extension options expected not to be exercised		-		1,183,105		1,183,105

Right-of-use Assets

Disclosure of quantitative information about right-of-use assets [line items]

Right-of-use Assets

NOTE 14: RIGHT-OF-USE ASSETS


	2023 A$			2022 A$
Cost		854,500			854,500
Accumulated depreciation		(356,042	)		(185,142	)
		498,458			669,358

Opening balance July 1		669,358			862,716
Addition of new property being rented		-			-
Depreciation (Note 6)		(170,900	)		(193,358	)
Closing balance June 30		498,458			669,358

Refer to Note 18 for information on non-current assets pledged as security for lease liabilities by the Group.

Goodwill

12 Months Ended

Jun. 30, 2023

Intangible assets and goodwill [abstract]

Goodwill

NOTE 15: GOODWILL


	A$
Carrying amount at July 1, 2021		12,400,743
Additions		-
Foreign currency exchange differences		467,379
Carrying amount at June 30, 2022		12,868,122
Additions		-
Foreign currency exchange differences		216,178
Carrying amount at June 30, 2023		13,084,300

Impairment Tests

As identified in Note 4 the Group has only one CGU, drug development. Management tests annually whether goodwill has suffered any impairment, in accordance with the accounting policy stated in Note 2(n)(i) and (ii), and Note 2(l), respectively. For the purpose of impairment testing all goodwill is allocated to the drug development CGU.

The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 18.5% (2022: 17%). The Group is currently in its research phase and a 5 year forecast would not provide reasonable consideration of the time frame, revenue and costs projections. The cash flow projections are weighted based on the observable market comparables probability of realising projected milestone and royalty payments.

Management believes that the application of discounted cash flows of observable market comparables for one drug compound is reasonable to be applied to other compounds within the CGU at their respective development phases.

Management believes that any reasonably possible change in the key assumptions on which recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the CGU.

No growth rates or terminal values have been included in the forecast, as the full development life cycle has been taken into account with the cashflows.

Issued Capital - Summary of Share Options Outstanding (Details)	Jun. 30, 2023 shares $ / shares	Feb. 21, 2023 shares	Jul. 08, 2022 shares $ / shares	Jun. 30, 2022 shares	Dec. 22, 2021 shares $ / shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options \| shares	117,211,315	8,333,333	7,700,000	79,056,617	47,786,607	20,985,450	6,364,550
Tranche 6
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 20, 2015
Expiry date	Jul. 20, 2023
Exercise price	$ 0.3481		$ 0.0543		$ 0.2014
Number of options \| shares	10,000		481,251		2,986,663
Fair value at date of issue	$ 0.2513		$ 0.044		$ 0.082
Tranche 7
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 20, 2015
Expiry date	Jul. 20, 2023
Exercise price	$ 0.3481		$ 0.0543		$ 0.2014
Number of options \| shares	5,000		481,251		2,986,663
Fair value at date of issue	$ 0.2513		$ 0.045		$ 0.084
Tranche 8
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Sep. 05, 2017
Expiry date	Sep. 05, 2023
Exercise price	$ 0.4136		$ 0.0543		$ 0.2014
Number of options \| shares	10,000		481,251		2,986,663
Fair value at date of issue	$ 0.3062		$ 0.045		$ 0.085
Tranche 9
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Oct. 09, 2015
Expiry date	Oct. 09, 2023
Exercise price	$ 0.4311		$ 0.0543		$ 0.2014
Number of options \| shares	5,000		481,251		2,986,663
Fair value at date of issue	$ 0.3376		$ 0.046		$ 0.086
Tranche 10
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Oct. 10, 2013
Expiry date	Oct. 10, 2023
Exercise price	$ 0.575		$ 0.0543		$ 0.2014
Number of options \| shares	15,000		481,251		2,986,663
Fair value at date of issue	$ 0.5415		$ 0.046		$ 0.088
Tranche 11
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 04, 2016
Expiry date	Nov. 04, 2023
Exercise price	$ 0.2327		$ 0.0543		$ 0.2014
Number of options \| shares	4,000		481,251		2,986,663
Fair value at date of issue	$ 0.2448		$ 0.046		$ 0.089
Tranche 12
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2023
Exercise price	$ 0.2349		$ 0.0543		$ 0.2014
Number of options \| shares	200,000		481,251		2,986,663
Fair value at date of issue	$ 0.2621		$ 0.047		$ 0.09
Tranche 13
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2023
Exercise price	$ 0.2866		$ 0.0543		$ 0.2014
Number of options \| shares	200,000		481,239		2,986,663
Fair value at date of issue	$ 0.2504		$ 0.047		$ 0.091
Tranche 14
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2023
Exercise price	$ 0.3556				$ 0.2014
Number of options \| shares	5,000				2,986,663
Fair value at date of issue	$ 0.237				$ 0.092
Tranche 15
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 17, 2013
Expiry date	Dec. 17, 2023
Exercise price	$ 0.6611				$ 0.2014
Number of options \| shares	4,000				2,986,663
Fair value at date of issue	$ 0.4573				$ 0.093
Tranche 16
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 24, 2015
Expiry date	Dec. 24, 2023
Exercise price	$ 0.5125				$ 0.2014
Number of options \| shares	100,000				2,986,662
Fair value at date of issue	$ 0.1798				$ 0.094
Tranche 17
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 30, 2015
Expiry date	Dec. 30, 2023
Exercise price	$ 0.4838
Number of options \| shares	50,000
Fair value at date of issue	$ 0.1912
Tranche 18
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2024
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.089
Tranche 19
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Apr. 27, 2015
Expiry date	Apr. 27, 2024
Exercise price	$ 0.4765
Number of options \| shares	4,000
Fair value at date of issue	$ 0.2601
Tranche 20
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 06, 2016
Expiry date	May 06, 2024
Exercise price	$ 0.2936
Number of options \| shares	50,000
Fair value at date of issue	$ 0.2068
Tranche 21
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 25, 2015
Expiry date	May 25, 2024
Exercise price	$ 0.3982
Number of options \| shares	260,600
Fair value at date of issue	$ 0.278
Tranche 22
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2024
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.09
Tranche 23
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2024
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.091
Tranche 24
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 20, 2015
Expiry date	Jul. 20, 2024
Exercise price	$ 0.4077
Number of options \| shares	15,000
Fair value at date of issue	$ 0.264
Tranche 25
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Sep. 05, 2017
Expiry date	Sep. 05, 2024
Exercise price	$ 0.4136
Number of options \| shares	10,000
Fair value at date of issue	$ 0.3236
Tranche 26
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Oct. 09, 2015
Expiry date	Oct. 09, 2024
Exercise price	$ 0.4311
Number of options \| shares	5,000
Fair value at date of issue	$ 0.3521
Tranche 27
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 04, 2016
Expiry date	Nov. 04, 2024
Exercise price	$ 0.2327
Number of options \| shares	4,000
Fair value at date of issue	$ 0.2546
Tranche 28
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2024
Exercise price	$ 0.2349
Number of options \| shares	200,000
Fair value at date of issue	$ 0.2721
Tranche 29
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2024
Exercise price	$ 0.2866
Number of options \| shares	200,000
Fair value at date of issue	$ 0.2616
Tranche 30
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2024
Exercise price	$ 0.3556
Number of options \| shares	5,000
Fair value at date of issue	$ 0.2495
Tranche 31
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 24, 2015
Expiry date	Dec. 24, 2024
Exercise price	$ 0.5125
Number of options \| shares	100,000
Fair value at date of issue	$ 0.1925
Tranche 32
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 30, 2015
Expiry date	Dec. 30, 2024
Exercise price	$ 0.4838
Number of options \| shares	50,000
Fair value at date of issue	$ 0.2038
Tranche 33
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Apr. 27, 2015
Expiry date	Apr. 27, 2025
Exercise price	$ 0.4765
Number of options \| shares	4,000
Fair value at date of issue	$ 0.2722
Tranche 34
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 06, 2016
Expiry date	May 06, 2025
Exercise price	$ 0.2936
Number of options \| shares	50,000
Fair value at date of issue	$ 0.2164
Tranche 35
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 25, 2015
Expiry date	May 25, 2025
Exercise price	$ 0.3982
Number of options \| shares	255,600
Fair value at date of issue	$ 0.2893
Tranche 36
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 25, 2015
Expiry date	May 25, 2025
Exercise price	$ 0.3982
Number of options \| shares	5,000
Fair value at date of issue	$ 0.2893
Tranche 37
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 20, 2015
Expiry date	Jul. 20, 2025
Exercise price	$ 0.4077
Number of options \| shares	15,000
Fair value at date of issue	$ 0.2756
Tranche 38
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Aug. 28, 2020
Expiry date	Aug. 28, 2025
Exercise price	$ 0.0136
Number of options \| shares	6,000,000
Fair value at date of issue	$ 0.075
Tranche 39
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Aug. 28, 2020
Expiry date	Aug. 28, 2025
Exercise price	$ 0.0136
Number of options \| shares	6,000,000
Fair value at date of issue	$ 0.071
Tranche 40
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Aug. 28, 2020
Expiry date	Aug. 28, 2025
Exercise price	$ 0.0136
Number of options \| shares	500,000
Fair value at date of issue	$ 0.133
Tranche 41
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Aug. 28, 2020
Expiry date	Aug. 28, 2025
Exercise price	$ 0.0136
Number of options \| shares	500,000
Fair value at date of issue	$ 0.118
Tranche 42
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Sep. 05, 2017
Expiry date	Sep. 05, 2025
Exercise price	$ 0.0136
Number of options \| shares	10,000
Fair value at date of issue	$ 0.3388
Tranche 43
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Oct. 09, 2015
Expiry date	Oct. 09, 2025
Exercise price	$ 0.4311
Number of options \| shares	5,000
Fair value at date of issue	$ 0.3653
Tranche 44
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 04, 2016
Expiry date	Nov. 04, 2025
Exercise price	$ 0.2327
Number of options \| shares	4,000
Fair value at date of issue	$ 0.2633
Tranche 45
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2025
Exercise price	$ 0.2349
Number of options \| shares	200,000
Fair value at date of issue	$ 0.281
Tranche 46
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2025
Exercise price	$ 0.2866
Number of options \| shares	200,000
Fair value at date of issue	$ 0.2716
Tranche 47
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2025
Exercise price	$ 0.3556
Number of options \| shares	5,000
Fair value at date of issue	$ 0.2605
Tranche 48
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 24, 2015
Expiry date	Dec. 24, 2025
Exercise price	$ 0.5125
Number of options \| shares	100,000
Fair value at date of issue	$ 0.2039
Tranche 49
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 30, 2015
Expiry date	Dec. 30, 2025
Exercise price	$ 0.4838
Number of options \| shares	50,000
Fair value at date of issue	$ 0.2152
Tranche 50
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 06, 2016
Expiry date	May 06, 2026
Exercise price	$ 0.2936
Number of options \| shares	50,000
Fair value at date of issue	$ 0.2251
Tranche 51
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Sep. 05, 2017
Expiry date	Sep. 05, 2026
Exercise price	$ 0.4136
Number of options \| shares	10,000
Fair value at date of issue	$ 0.352
Tranche 52
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2026
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.074
Tranche 53
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 20, 2020
Expiry date	Oct. 20, 2026
Exercise price	$ 0.1519
Number of options \| shares	100,000
Fair value at date of issue	$ 0.089
Tranche 54
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 04, 2016
Expiry date	Nov. 04, 2026
Exercise price	$ 0.2327
Number of options \| shares	4,000
Fair value at date of issue	$ 0.271
Tranche 55
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2026
Exercise price	$ 0.2349
Number of options \| shares	200,000
Fair value at date of issue	$ 0.289
Tranche 56
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2026
Exercise price	$ 0.2866
Number of options \| shares	200,000
Fair value at date of issue	$ 0.2804
Tranche 57
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 28, 2016
Expiry date	Nov. 28, 2026
Exercise price	$ 0.3556
Number of options \| shares	5,000
Fair value at date of issue	$ 0.2703
Tranche 58
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2026
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.076
Tranche 59
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2027
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.078
Tranche 60
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2027
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.09
Tranche 61
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2027
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.079
Tranche 62
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2027
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.091
Tranche 63
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Sep. 05, 2017
Expiry date	Sep. 05, 2027
Exercise price	$ 0.4136
Number of options \| shares	10,000
Fair value at date of issue	$ 0.3636
Tranche 64
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2027
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.081
Tranche 65
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2027
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.092
Tranche 66
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 20, 2020
Expiry date	Oct. 20, 2027
Exercise price	$ 0.15191
Number of options \| shares	100,000
Fair value at date of issue	$ 0.095
Tranche 67
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2027
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.082
Tranche 68
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2027
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.094
Tranche 69
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Feb. 23, 2028
Exercise price	$ 0.052
Number of options \| shares	1,666,666
Fair value at date of issue	$ 0.014
Tranche 70
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2028
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.084
Tranche 71
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2028
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.095
Tranche 72
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2028
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.085
Tranche 73
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2028
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.096
Tranche 74
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jul. 08, 2028
Exercise price	$ 0.0543
Number of options \| shares	1,925,000
Fair value at date of issue	$ 0.041
Tranche 75
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2028
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.086
Tranche 76
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2028
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.097
Tranche 77
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Sep. 30, 2028
Exercise price	$ 0.052
Number of options \| shares	666,667
Fair value at date of issue	$ 0.015
Tranche 78
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 20, 2020
Expiry date	Oct. 20, 2028
Exercise price	$ 0.1519
Number of options \| shares	100,000
Fair value at date of issue	$ 0.099
Tranche 79
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Oct. 31, 2028
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.042
Tranche 80
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Dec. 16, 2028
Exercise price	$ 0.0321
Number of options \| shares	6,766,754
Fair value at date of issue	$ 0.017
Tranche 81
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2028
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.088
Tranche 82
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2028
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.098
Tranche 83
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jan. 31, 2029
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.043
Tranche 84
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Mar. 16, 2029
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.017
Tranche 85
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2029
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.098
Tranche 86
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Apr. 30, 2029
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.043
Tranche 87
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Jun. 16, 2029
Exercise price	$ 0.0321
Number of options \| shares	1,691,689
Fair value at date of issue	$ 0.018
Tranche 88
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2029
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.099
Tranche 89
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Jun. 30, 2029
Exercise price	$ 0.052
Number of options \| shares	5,000,000
Fair value at date of issue	$ 0.0144
Tranche 90
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jul. 31, 2029
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.044
Tranche 91
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Sep. 16, 2029
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.018
Tranche 92
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2029
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.1
Tranche 93
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 20, 2020
Expiry date	Oct. 20, 2029
Exercise price	$ 0.1519
Number of options \| shares	100,000
Fair value at date of issue	$ 0.103
Tranche 94
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Oct. 31, 2029
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.044
Tranche 95
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Dec. 16, 2029
Exercise price	$ 0.0321
Number of options \| shares	1,691,689
Fair value at date of issue	$ 0.018
Tranche 96
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2029
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.092
Tranche 97
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2029
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.101
Tranche 98
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jan. 31, 2030
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.045
Tranche 99
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Mar. 16, 2030
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.019
Tranche 100
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2030
Exercise price	$ 0.2014
Number of options \| shares	2,986,663
Fair value at date of issue	$ 0.093
Tranche 101
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Mar. 31, 2030
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.102
Tranche 102
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Apr. 30, 2030
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.045
Tranche 103
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Jun. 16, 2030
Exercise price	$ 0.0321
Number of options \| shares	1,691,689
Fair value at date of issue	$ 0.019
Tranche 104
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2030
Exercise price	$ 0.2014
Number of options \| shares	2,986,662
Fair value at date of issue	$ 0.094
Tranche 105
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Jun. 30, 2030
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.102
Tranche 106
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jul. 31, 2030
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.046
Tranche 107
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Sep. 16, 2030
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.019
Tranche 108
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Sep. 30, 2030
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.103
Tranche 109
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Nov. 20, 2020
Expiry date	Oct. 20, 2030
Exercise price	$ 0.1519
Number of options \| shares	100,000
Fair value at date of issue	$ 0.107
Tranche 110
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Oct. 31, 2030
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.046
Tranche 111
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Dec. 16, 2030
Exercise price	$ 0.0321
Number of options \| shares	1,691,689
Fair value at date of issue	$ 0.019
Tranche 112
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Dec. 02, 2021
Expiry date	Dec. 31, 2030
Exercise price	$ 0.0965
Number of options \| shares	839,385
Fair value at date of issue	$ 0.104
Tranche 113
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jan. 31, 2031
Exercise price	$ 0.054
Number of options \| shares	481,251
Fair value at date of issue	$ 0.046
Tranche 114
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Mar. 16, 2031
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.02
Tranche 115
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Apr. 30, 2031
Exercise price	$ 0.0543
Number of options \| shares	481,251
Fair value at date of issue	$ 0.047
Tranche 116
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Jun. 16, 2031
Exercise price	$ 0.0321
Number of options \| shares	1,691,689
Fair value at date of issue	$ 0.02
Tranche 117
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Jul. 08, 2022
Expiry date	Jul. 31, 2031
Exercise price	$ 0.0543
Number of options \| shares	481,239
Fair value at date of issue	$ 0.047
Tranche 118
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Sep. 16, 2031
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.02
Tranche 119
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	Feb. 21, 2023
Expiry date	Dec. 16, 2031
Exercise price	$ 0.0321
Number of options \| shares	1,691,688
Fair value at date of issue	$ 0.02

Reserves (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of reserves within equity [abstract]

Summary of Reserves


	2023 A$		2022 A$
Foreign Currency Translation Reserve (a)		6,646,840		6,186,334
Share-based Payments Reserve (b)		7,858,906		6,337,264
Total Reserves		14,505,746		12,523,598

(a)

Foreign Currency Translation Reserve

(b)

Share-based Payments Reserve

Segment Information

12 Months Ended

Jun. 30, 2023

Segment information [abstract]

Segment Information

NOTE 4: SEGMENT INFORMATION

The Group operates in one segment (CGU) being “drug development” in Australia. This is the basis on which its internal reports are reviewed and used by the Board of Directors (the “chief operating decision maker”) in monitoring, assessing performance and in determining the allocation of resources.

The results, assets and liabilities from this segment are equivalent to the consolidated financial statements.

Loss Per Share (Tables)

12 Months Ended

Jun. 30, 2023

Earnings per share [abstract]

Summary of Computation of Basic and Diluted Loss Per Share


	2023	2022	2021

Basic loss per share	(A$0.02) (2 cent)	(A$0.02) (2 cent)	(A$0.01) (1 cent)
Diluted loss per share	(A$0.02 (2 cent)	(A$0.02 (2 cent)	(A$0.01 (1 cent)

The basic and diluted loss per share amounts have been calculated using the ‘Loss after income tax’ figure in the consolidated statement of profit or and other comprehensive income.


	2023 A$			2022 A$			2021 A$
Loss Per Share (Basic and Diluted):
Loss after tax for the year		(31,846,957	)		(21,759,358	)		(8,697,037	)


	2023 number			2022 number			2011 number
Weighted Average Number of Ordinary Shares - Basic
Weighted average number of ordinary shares used in calculating basic loss per share:		1,468,735,424			1,353,350,744			779,941,036

Weighted Average Number of Ordinary Shares – Diluted
Weighted average number of ordinary shares used in calculating basic loss per share:		1,468,735,424			1,353,350,744			779,941,036
Shares deemed to be issued for no consideration in respect of employee options		46,690,480			31,065,272			20,056,450
Potential ordinary shares which are anti-dilutive and excluded		(46,690,480	)		(31,065,272	)		(20,056,450	)
Shares deemed to be issued for no consideration in respect of warrants		142,000,000			142,000,000			166,082,988
Potential ordinary shares which are anti-dilutive and excluded		(142,000,000	)		(142,000,000	)		(166,082,988	)
Weighted average number of ordinary shares used in the calculation of diluted loss per share		1,468,735,424			1,353,350,744			779,941,036

Summary of Number Of Potential Anti Dilutive Ordinary Shares Excluded From Computation Of Loss Per Share

The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share.


	2023 number		2022 number		2021 number
Employee options		46,690,480		31,065,272		20,056,450
Warrants		142,000,000		142,000,000		166,082,988

Trade and Other Receivables

12 Months Ended

Jun. 30, 2023

Trade and other receivables [abstract]

Trade and Other Receivables

NOTE 10: TRADE AND OTHER RECEIVABLES


	2023 A$		2022 A$
Current
Other receivables		886		42,483
Loss allowance		-		-
		886		42,483
GST receivables		13,832		21,877
		14,718		64,360

Other Assets - Summary of Detailed Information About Other Current Assets (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Miscellaneous current assets [abstract]
Prepayments	$ 1,202,826	$ 1,461,078
Accrued income	388	190
Other Assets, Net	$ 1,203,214	$ 1,461,268

Financial Instruments - Summary of Reconciliation of Level 3 Fair Value Measurements (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of fair value measurement of liabilities [line items]
Opening balance	$ 2,699,010	$ 1,762,656
Total (gain) or loss: - in profit or loss	988,179	936,354
Closing balance	3,687,189	2,699,010
Level 3
Disclosure of fair value measurement of liabilities [line items]
Opening balance	2,699,010	1,762,656
Total (gain) or loss: - in profit or loss	988,179	936,354
Closing balance	$ 3,687,189	$ 2,699,010

Revenue, Other Income and Other Gains and Losses - Summary Of Other Income From Continuing Operations (Parenthetical) (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Refundable tax offset rate	43.50%	43.50%	43.50%
Top of Range
Disclosure of disaggregation of revenue from contracts with customers [line items]
Annual revenue eligible for government grants	$ 20,000,000

Property, Plant And Equipment

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Property, Plant And Equipment

NOTE 13: PROPERTY, PLANT AND EQUIPMENT


	2023 A$		2022 A$
Cost at 1 July		72,035		106,753
Additions		-		1,544
Disposals		-		(36,262	)
Cost at 30 June		72,035		72,035


Accumulated depreciation at 1 July	(66,863	)	(98,526	)
Depreciation (Note 6)	(1,368	)	(2,681	)
Disposals	-		34,344
Accumulated depreciation at 30 June	(68,231	)	(66,863	)

Net Carrying Amounts at 30 June	3,804		5,172

Issued Capital - Summary of Movement in Unlisted Share Options (Details)		12 Months Ended
	Sep. 02, 2021 shares $ / shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Number of options Opening balance \| shares		79,056,617	20,985,450	6,364,550
Number of options Granted during the financial year \| shares		43,100,348	61,216,767	15,500,000
Number of options Forfeited during the financial year \| shares		(3,500,000)		(5,000)
Number of options Exercised during the financial year \| shares	(2,000,000)	0	(2,000,000)
Number of options Expired during the financial year \| shares		(1,445,650)	(1,145,600)	(874,100)
Number of options Closing balance \| shares		117,211,315	79,056,617	20,985,450
Weighted average exercise price Opening balance \| $ / shares		$ 0.16	$ 0.12	$ 0.4
Weighted average exercise price Granted during the financial year \| $ / shares		0.04	0.18	0.04
Weighted average exercise price Forfeited during the financial year \| $ / shares		0.05		0.41
Weighted average exercise price Exercised during the financial year \| $ / shares	$ 0.0136		0.0136
Weighted average exercise price Expired during the financial year \| $ / shares		0.39	0.42	0.45
Weighted average exercise price Closing balance \| $ / shares		$ 0.12	$ 0.16	$ 0.12

Key Management Personnel Compensation

12 Months Ended

Jun. 30, 2023

Key management personnel compensation [abstract]

Key Management Personnel Compensation

NOTE 23: KEY MANAGEMENT PERSONNEL COMPENSATION

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:


	2023 A$		2022 A$		2021 A$
Short-term employee compensation		3,717,144		2,535,550		2,269,030
Post-employment benefits		71,876		69,039		51,982
Other long-term benefits		33,133		22,241		9,480
Share-based payments		1,899,827		2,819,133		1,298,208
Total key management personnel compensation		5,721,980		5,445,963		3,628,700

Issued Capital (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of classes of share capital [line items]

Summary of Movements in Ordinary Shares

Movements in Ordinary Shares of the Company during the current period were as follows:


Date	Details	Number of shares		A$
Ordinary Shares
July 1, 2020	Opening balance		626,185,872		148,156,005
	Share issue - share placements (i)		185,757,511		21,229,874
	Share issue – rights (ii)		195,229,129		22,606,257
	Shares issued to employees		424,232		60,750
	Share issue costs		-		(423,492	)
	Warrants issued -underwriting fee (iii)		-		(1,439,247	)
June 30, 2021	Closing balance		1,007,596,744		190,190,147
	Shares issued on exercise of options (iv)		2,000,000		27,200
	Shares issued on exercise of warrants (iv)		8,000,000		480,000
	Transfer from share-based payments reserve as result of options and warrants being exercised		-		327,760
	Share issue in a US IPO and NASDAQ listing (v)		335,754,000		32,383,263
	Share issue costs		-		(5,712,611	)
June 30, 2022	Closing balance		1,353,350,744		217,695,759
	Share issue in a US F-1 (vi)		115,384,680		7,419,235
	Share issue costs		-		(1,702,332	)
June 30, 2023	Closing balance		1,468,735,424		223,412,662

(i)

During the year ended June 30, 2021, the following share placements occurred:

•

Issue of 54,333,000 shares at A$0.04 per share raising A$2,173,320. The share issue was approved by shareholders at a General Meeting held on August 26, 2020; and

•

Issue of 131,424,511 shares at A$0.145 per share raising A$19,056,554

(ii)

During the year ended June 30. 2021, the following rights issues occurred:

•

Issue of 54,304,446 at A$0.04 per share raising A$2,172,178; and

•

Issue of 140,924,683 shares at A$0.145 raising A$20,434,079

(iii)

(iv)

During the year ended June 30, 2022, the following shares were issued:

•

Issue of2,000,000 as a result of share options being exercised that had an exercise price of A$0.0136 per option; and

•

Issue of 8,000,000 shares as a result of warrants being exercised that had an exercise price of A$0.06 per warrant.

(v)

(vi)

During the year ended 30 June 2023, 115,384,680 shares were issued in a US IPO a F-1 share placement.

Summary of Movement in Unlisted Share Options

Movement in unlisted share options:


	2023				2022				2021
				Weighted				Weighted				Weighted
	Number			average	Number			average	Number			average
	of options			exercise	of options			exercise	of options			exercise
				price				price				price
Opening balance at beginning of financial year		79,056,617		A$0.16		20,985,450		A$0.12		6,364,550		A$0.40
Granted during the financial year		43,100,348		A$0.04		61,216,767		A$0.18		15,500,000		A$0.04
Forfeited during the financial year		(3,500,000	)	A$0.05		-		-		(5,000	)	A$0.41
Exercised during the financial year		-				(2,000,000	)	A$0.01		-		-
Expired during the financial year		(1,445,650	)	A$0.39		(1,145,600	)	A$0.42		(874,100	)	A$0.45
Closing balance at June 30		117,211,315		A$0.12		79,056,617		A$0.16		20,985,450		A$0.12

Summary of Share Options Issued to KMPs


	Dr Errol De Souza share options	Mr Jack Moschakis and Ms Liz Doolin share options
Share price at date of issue	A$0.11	A$0.15
Exercise price	A$0.04	A$0.04
Bionomics share volatility	105%	105%
Risk free interest rate	0.42%	0.43%


Share price at date of issue	A$0.13
Exercise price	A$0.1687
Bionomics share volatility	89%
Risk free interest rate	0.30%

Summary of Options Issued

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

8-Jul-22

8-Jul-23

8-Jul-28

A$0.0543

1,925,000

A$0.041

8-Jul-22

31-Oct-23

31-Oct-28

A$0.0543

481,251

A$0.042

8-Jul-22

31-Jan-24

31-Jan-29

A$0.0543

481,251

A$0.043

8-Jul-22

30-Apr-24

30-Apr-29

A$0.0543

481,251

A$0.043

8-Jul-22

31-Jul-24

31-Jul-29

A$0.0543

481,251

A$0.044

8-Jul-22

31-Oct-24

31-Oct-29

A$0.0543

481,251

A$0.044

8-Jul-22

31-Jan-25

31-Jan-30

A$0.0543

481,251

A$0.045

8-Jul-22

30-Apr-25

30-Apr-30

A$0.0543

481,251

A$0.045

8-Jul-22

31-Jul-25

31-Jul-30

A$0.0543

481,251

A$0.046

8-Jul-22

31-Oct-25

31-Oct-30

A$0.0543

481,251

A$0.046

8-Jul-22

31-Jan-26

31-Jan-31

A$0.0543

481,251

A$0.046

8-Jul-22

30-Apr-26

30-Apr-31

A$0.0543

481,251

A$0.047

8-Jul-22

31-Jul-26

31-Jul-31

A$0.0543

481,239

A$0.047

7,700,000

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

21-Feb-23

30-Jun-24

30-Jun-29

A$0.052

5,000,000

A$0.0053

21-Feb-23

23-Feb-23

23-Feb-28

A$0.052

1,666,666

A$0.014

21-Feb-23

30-Sep-23

30-Sep-28

A$0.052

1,666,667

A$0.015

8,333,333

Details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

21-Feb-23

16-Dec-23

16-Dec-28

A$0.0321

6,766,754

A$0.017

21-Feb-23

16-Mar-24

16-Mar-29

A$0.0321

1,691,688

A$0.017

21-Feb-23

16-Jun-24

16-Jun-29

A$0.0321

1,691,689

A$0.018

21-Feb-23

16-Sep-24

16-Sep-29

A$0.0321

1,691,688

A$0.018

21-Feb-23

16-Dec-24

16-Dec-29

A$0.0321

1,691,689

A$0.018

21-Feb-23

16-Mar-25

16-Mar-30

A$0.0321

1,691,688

A$0.019

21-Feb-23

16-Jun-25

16-Jun-30

A$0.0321

1,691,689

A$0.019

21-Feb-23

16-Sep-25

16-Sep-30

A$0.0321

1,691,688

A$0.019

21-Feb-23

16-Dec-25

16-Dec-30

A$0.0321

1,691,689

A$0.019

21-Feb-23

16-Mar-26

16-Mar-31

A$0.0321

1,691,688

A$0.02

21-Feb-23

16-Jun-26

16-Jun-31

A$0.0321

1,691,689

A$0.02

21-Feb-23

16-Sep-26

16-Sep-31

A$0.0321

1,691,688

A$0.02

21-Feb-23

16-Dec-26

16-Dec-31

A$0.0321

1,691,688

A$0.02

27,067,015

The options were issued on December 22, 2021, details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

2-Dec-21

30-Sep-21

30-Sep-26

A$0.2014

2,986,663

A$0.0740

2-Dec-21

31-Dec-21

31-Dec-26

A$0.2014

2,986,663

A$0.0760

2-Dec-21

31-Mar-22

31-Mar-27

A$0.2014

2,986,663

A$0.0780

2-Dec-21

30-Jun-22

30-Jun-27

A$0.2014

2,986,663

A$0.0790

2-Dec-21

30-Sep-22

30-Sep-27

A$0.2014

2,986,663

A$0.0810

2-Dec-21

31-Dec-22

31-Dec-27

A$0.2014

2,986,663

A$0.0820

2-Dec-21

31-Mar-23

31-Mar-28

A$0.2014

2,986,663

A$0.0840

2-Dec-21

30-Jun-23

30-Jun-28

A$0.2014

2,986,663

A$0.0850

2-Dec-21

30-Sep-23

30-Sep-28

A$0.2014

2,986,663

A$0.0860

2-Dec-21

31-Dec-23

31-Dec-28

A$0.2014

2,986,663

A$0.0880

2-Dec-21

31-Mar-24

31-Mar-24

A$0.2014

2,986,663

A$0.0890

2-Dec-21

30-Jun-24

30-Jun-24

A$0.2014

2,986,663

A$0.0900

2-Dec-21

30-Sep-24

30-Jun-24

A$0.2014

2,986,663

A$0.0910

2-Dec-21

31-Dec-24

31-Dec-29

A$0.2014

2,986,663

A$0.0920

2-Dec-21

31-Mar-25

31-Mar-30

A$0.2014

2,986,663

A$0.0930

2-Dec-21

30-Jun-25

30-Jun-30

A$0.2014

2,986,662

A$0.0940

47,786,607

The options were issued on 22 December 2021, details of the issue are set out below:

Exercise

Fair value at

Grant date

Vesting date

Expiry date

price

Number

date of issue

2-Dec-21

31-Mar-22

31-Mar-27

A$0.09645

839,385

A$0.0900

2-Dec-21

30-Jun-22

30-Jun-27

A$0.09645

839,385

A$0.0910

2-Dec-21

30-Sep-22

30-Sep-27

A$0.09645

839,385

A$0.0920

2-Dec-21

31-Dec-22

31-Dec-27

A$0.09645

839,385

A$0.0940

2-Dec-21

31-Mar-23

31-Mar-28

A$0.09645

839,385

A$0.0950

2-Dec-21

30-Jun-23

30-Jun-28

A$0.09645

839,385

A$0.0960

2-Dec-21

30-Sep-23

30-Sep-28

A$0.09645

839,385

A$0.0970

2-Dec-21

31-Dec-23

31-Dec-28

A$0.09645

839,385

A$0.0980

2-Dec-21

31-Mar-24

31-Mar-29

A$0.09645

839,385

A$0.0980

2-Dec-21

30-Jun-24

30-Jun-29

A$0.09645

839,385

A$0.0990

2-Dec-21

30-Sep-24

30-Sep-29

A$0.09645

839,385

A$0.1000

2-Dec-21

31-Dec-24

31-Dec-29

A$0.09645

839,385

A$0.1010

2-Dec-21

31-Mar-25

31-Mar-30

A$0.09645

839,385

A$0.1020

2-Dec-21

30-Jun-25

30-Jun-30

A$0.09645

839,385

A$0.1020

2-Dec-21

30-Sep-25

30-Sep-30

A$0.09645

839,385

A$0.1030

2-Dec-21

31-Dec-25

31-Dec-30

A$0.09645

839,385

A$0.1040

13,430,160


Grant date	Vesting date	Expiry date	Exercise price	Number	Fair value at date of issue
20-Nov-20	20-Oct-21	20-Oct-26	A$0.1687	100,000	A$0.089
20-Nov-20	20-Oct-22	20-Oct-27	A$0.1687	100,000	A$0.095
20-Nov-20	20-Oct-23	20-Oct-28	A$0.1687	100,000	A$0.099
20-Nov-20	20-Oct-24	20-Oct-29	A$0.1687	100,000	A$0.103
20-Nov-20	20-Oct-25	20 Oct-30	A$0.1687	100,000	A$0.107

Summary of Inputs Used

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.058
Exercise price	A$0.0543
Bionomics share volatility	80.13%
Risk free interest rate	3.196%


Share price at date of issue	A$0.028
Exercise price	A$0.0520
Bionomics share volatility	74,18%
Risk free interest rate	3.627%

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.028
Exercise price	A$0.0321
Bionomics share volatility	74.18%
Risk free interest rate	3.627%

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below:


Share price at date of issue	A$0.125
Exercise price	A$0.2014
Bionomics share volatility		85.53	%
Risk free interest rate		0.413	%

A Black-Scholes model was used to obtain the fair value of the above share options. Inputs used are summarised below


Share price at date of issue	A$0.125
Exercise price	A$0.0965
Bionomics share volatility		85.53	%
Risk free interest rate		0.413	%

Unlisted Share Options Issued


KMP	Number	Vesting conditions	Fair value at date of issue
Dr Errol De Souza	6,000,000	Company’s share price reaching $0.14 per share	A$0.075
Dr Errol De Souza	6,000,000	Company’s share price reaching $0.24 per share	A$0.071
Mr Jack Moschakis	1,000,000	Company’s share price reaching $0.14 per share	A$0.133
Mr Jack Moschakis	1,000,000	Company’s share price reaching $0.24 per share	A$0.118
Ms Liz Doolin	500,000	Company’s share price reaching $0.14 per share	A$0.133
Ms Liz Doolin	500,000	Company’s share price reaching $0.24 per share	A$0.118

Summery of Inputs Used to a Black-Scholes Model Used to Obtain Fair Value of Above Share Options


	Dr Errol De Souza share options	Mr Jack Moschakis and Ms Liz Doolin share options
Share price at date of issue	A$0.11	A$0.15
Exercise price	A$0.04	A$0.04
Bionomics share volatility	105%	105%
Risk free interest rate	0.42%	0.43%


Share price at date of issue	A$0.13
Exercise price	A$0.1687
Bionomics share volatility	89%
Risk free interest rate	0.30%

Summery of Share Options Outstanding

The table below lists share options outstanding at June 30, 2023:


Grant date	Expiry date	Exercise price	Number of options		Fair value
20-Jul-15	20-Jul-23	A$0.3481		10,000	A$0.2513
20-Jul-15	20-Jul-23	A$0.3481		5,000	A$0.2513
5-Sep-17	5-Sep-23	A$0.4136		10,000	A$0.3062
9-Oct-15	9-Oct-23	A$0.4311		5,000	A$0.3376
10-Oct-13	10-Oct-23	A$0.5750		15,000	A$0.5415
4-Nov-16	4-Nov-23	A$0.2327		4,000	A$0.2448
28-Nov-16	28-Nov-23	A$0.2349		200,000	A$0.2621
28-Nov-16	28-Nov-23	A$0.2866		200,000	A$0.2504
28-Nov-16	28-Nov-23	A$0.3556		5,000	A$0.2370
17-Dec-13	17-Dec-23	A$0.6611		4,000	A$0.4573
24-Dec-15	24-Dec-23	A$0.5125		100,000	A$0.1798
30-Dec-15	30-Dec-23	A$0.4838		50,000	A$0.1912
2-Dec-21	31-Mar-24	A$0.2014		2,986,663	A$0.0890
27-Apr-15	27-Apr-24	A$0.4765		4,000	A$0.2601
6-May-16	6-May-24	A$0.2936		50,000	A$0.2068
25-May-15	25-May-24	A$0.3982		260,600	A$0.2780
2-Dec-21	30-Jun-24	A$0.2014		2,986,663	A$0.0900
2-Dec-21	30-Jun-24	A$0.2014		2,986,663	A$0.0910
20-Jul-15	20-Jul-24	A$0.4077		15,000	A$0.2640
5-Sep-17	5-Sep-24	A$0.4136		10,000	A$0.3236
9-Oct-15	9-Oct-24	A$0.4311		5,000	A$0.3521
4-Nov-16	4-Nov-24	A$0.2327		4,000	A$0.2546
28-Nov-16	28-Nov-24	A$0.2349		200,000	A$0.2721
28-Nov-16	28-Nov-24	A$0.2866		200,000	A$0.2616
28-Nov-16	28-Nov-24	A$0.3556		5,000	A$0.2495
24-Dec-15	24-Dec-24	A$0.5125		100,000	A$0.1925
30-Dec-15	30-Dec-24	A$0.4838		50,000	A$0.2038
27-Apr-15	27-Apr-25	A$0.4765		4,000	A$0.2722
6-May-16	6-May-25	A$0.2936		50,000	A$0.2164
25-May-15	25-May-25	A$0.3982		255,600	A$0.2893
25-May-15	25-May-25	A$0.3982		5,000	A$0.2893
20-Jul-15	20-Jul-25	A$0.4077		15,000	A$0.2756
28-Aug-20	28-Aug-25	A$0.0136		6,000,000	A$0.0750
28-Aug-20	28-Aug-25	A$0.0136		6,000,000	A$0.0710
28-Aug-20	28-Aug-25	A$0.0136		500,000	A$0.1330
28-Aug-20	28-Aug-25	A$0.0136		500,000	A$0.1180
5-Sep-17	5-Sep-25	A$0.0136		10,000	A$0.3388
9-Oct-15	9-Oct-25	A$0.4311		5,000	A$0.3653
4-Nov-16	4-Nov-25	A$0.2327		4,000	A$0.2633
28-Nov-16	28-Nov-25	A$0.2349		200,000	A$0.2810


Grant date	Expiry date	Exercise price	Number of options		Fair value
28-Nov-16	28-Nov-25	A$0.2866		200,000	A$0.2716
28-Nov-16	28-Nov-25	A$0.3556		5,000	A$0.2605
24-Dec-15	24-Dec-25	A$0.5125		100,000	A$0.2039
30-Dec-15	30-Dec-25	A$0.4838		50,000	A$0.2152
6-May-16	6-May-26	A$0.2936		50,000	A$0.2251
5-Sep-17	5-Sep-26	A$0.4136		10,000	A$0.3520
2-Dec-21	30-Sep-26	A$0.2014		2,986,663	A$0.0740
20-Nov-20	20-Oct-26	A$0.1519		100,000	A$0.0890
4-Nov-16	4-Nov-26	A$0.2327		4,000	A$0.2710
28-Nov-16	28-Nov-26	A$0.2349		200,000	A$0.2890
28-Nov-16	28-Nov-26	A$0.2866		200,000	A$0.2804
28-Nov-16	28-Nov-26	A$0.3556		5,000	A$0.2703
2-Dec-21	31-Dec-26	A$0.2014		2,986,663	A$0.0760
2-Dec-21	31-Mar-27	A$0.2014		2,986,663	A$0.0780
2-Dec-21	31-Mar-27	A$0.0965		839,385	A$0.0900
2-Dec-21	30-Jun-27	A$0.2014		2,986,663	A$0.0790
2-Dec-21	30-Jun-27	A$0.0965		839,385	A$0.0910
5-Sep-17	5-Sep-27	A$0.4136		10,000	A$0.3636
2-Dec-21	30-Sep-27	A$0.2014		2,986,663	A$0.0810
2-Dec-21	30-Sep-27	A$0.0965		839,385	A$0.0920
20-Nov-20	20-Oct-27	A$0.15191		100,000	A$0.0950
2-Dec-21	31-Dec-27	A$0.2014		2,986,663	A$0.0820
2-Dec-21	31-Dec-27	A$0.0965		839,385	A$0.0940
21-Feb-23	23-Feb-28	A$0.0520		1,666,666	A$0.0140
2-Dec-21	31-Mar-28	A$0.2014		2,986,663	A$0.0840
2-Dec-21	31-Mar-28	A$0.0965		839,385	A$0.0950
2-Dec-21	30-Jun-28	A$0.2014		2,986,663	A$0.0850
2-Dec-21	30-Jun-28	A$0.0965		839,385	A$0.0960
8-Jul-22	8-Jul-28	A$0.0543		1,925,000	A$0.0410
2-Dec-21	30-Sep-28	A$0.2014		2,986,663	A$0.0860
2-Dec-21	30-Sep-28	A$0.0965		839,385	A$0.0970
21-Feb-23	30-Sep-28	A$0.0520		1,666,667	A$0.0150
20-Nov-20	20-Oct-28	A$0.1519		100,000	A$0.0990
8-Jul-22	31-Oct-28	A$0.0543		481,251	A$0.0420
21-Feb-23	16-Dec-28	A$0.0321		6,766,754	A$0.0170
2-Dec-21	31-Dec-28	A$0.2014		2,986,663	A$0.0880
2-Dec-21	31-Dec-28	A$0.0965		839,385	A$0.0980
8-Jul-22	31-Jan-29	A$0.0543		481,251	A$0.0430
21-Feb-23	16-Mar-29	A$0.0321		1,691,688	A$0.0170
2-Dec-21	31-Mar-29	A$0.0965		839,385	A$0.0980
8-Jul-22	30-Apr-29	A$0.0543		481,251	A$0.0430
21-Feb-23	16-Jun-29	A$0.0321		1,691,689	A$0.0180
2-Dec-21	30-Jun-29	A$0.0965		839,385	A$0.0990
21-Feb-23	30-Jun-29	A$0.0520		5,000,000	A$0.0144
8-Jul-22	31-Jul-29	A$0.0543		481,251	A$0.0440
21-Feb-23	16-Sep-29	A$0.0321		1,691,688	A$0.0180
2-Dec-21	30-Sep-29	A$0.0965		839,385	A$0.1000
20-Nov-20	20-Oct-29	A$0.1519		100,000	A$0.1030
8-Jul-22	31-Oct-29	A$0.0543		481,251	A$0.0440
21-Feb-23	16-Dec-29	A$0.0321		1,691,689	A$0.0180
2-Dec-21	31-Dec-29	A$0.2014		2,986,663	A$0.0920
2-Dec-21	31-Dec-29	A$0.0965		839,385	A$0.1010
8-Jul-22	31-Jan-30	A$0.0543		481,251	A$0.0450


Grant date	Expiry date	Exercise price	Number of options		Fair value
21-Feb-23	16-Mar-30	A$0.0321		1,691,688	A$0.0190
2-Dec-21	31-Mar-30	A$0.2014		2,986,663	A$0.0930
2-Dec-21	31-Mar-30	A$0.0965		839,385	A$0.1020
8-Jul-22	30-Apr-30	A$0.0543		481,251	A$0.0450
21-Feb-23	16-Jun-30	A$0.0321		1,691,689	A$0.0190
2-Dec-21	30-Jun-30	A$0.2014		2,986,662	A$0.0940
2-Dec-21	30-Jun-30	A$0.0965		839,385	A$0.1020
8-Jul-22	31-Jul-30	A$0.0543		481,251	A$0.0460
21-Feb-23	16-Sep-30	A$0.0321		1,691,688	A$0.0190
2-Dec-21	30-Sep-30	A$0.0965		839,385	A$0.1030
20-Nov-20	20-Oct-30	A$0.1519		100,000	A$0.1070
8-Jul-22	31-Oct-30	A$0.0543		481,251	A$0.0460
21-Feb-23	16-Dec-30	A$0.0321		1,691,689	A$0.0190
2-Dec-21	31-Dec-30	A$0.0965		839,385	A$0.1040
8-Jul-22	31-Jan-31	A$0.054		481,251	A$0.0460
21-Feb-23	16-Mar-31	A$0.0321		1,691,688	A$0.0200
8-Jul-22	30-Apr-31	A$0.0543		481,251	A$0.0470
21-Feb-23	16-Jun-31	A$0.0321		1,691,689	A$0.0200
8-Jul-22	31-Jul-31	A$0.0543		481,239	A$0.0470
21-Feb-23	16-Sep-31	A$0.0321		1,691,688	A$0.0200
21-Feb-23	16-Dec-31	A$0.0321		1,691,688	A$0.0200
				117,211,315

Summery of Movement in Unlisted Share Warrants

Movement in unlisted share warrants:


	2023			2022				2021
			Weighted				Weighted				Weighted
	Number		average	Number			average	Number			average
	of warrants		exercise	of warrants			exercise	of warrants			exercise
			price				price				price
Opening balance at beginning of financial year		142,000,000	A$0.06		166,082,988		A$0.11		40,207,472		A$0.59
Granted during the financial year	-		-	-			-		150,000,000		A$0.06
Exercised during the financial year	-		-		(8,000,000	)	A$0.06	-			-
Expired during the financial year	-		-		(16,082,988	)	A$0.57		(24,124,484	)	A$0.59
Closing balance at June 30		142,000,000	A$0.06		142,000,000		A$0.06		166,082,988		A$0.11

Summery of Lists of Warrants Outstanding

The table below lists warrants outstanding at June 30, 2023.


Grant Date	Expiry date	Exercise Price	No of options		Fair Value
26-Aug-20	26-Aug-23	A$0.06		142,000,000	A$0.01

Key Management Personnel

Disclosure of classes of share capital [line items]

Summary of Share Options Issued to KMPs

Details of share options that were issued to the KMPs are set out below:


KMP	Number
Mr Adrian Hinton	2,000,000
Mr Connor Bernstein	3,500,000
Ms Liz Doolin	2,000,000

Summery of Inputs Used to a Black-Scholes Model Used to Obtain Fair Value of Above Share Options

Details of share options that were issued to the KMPs are set out below:


KMP	Number
Mr Adrian Hinton	2,000,000
Mr Connor Bernstein	3,500,000
Ms Liz Doolin	2,000,000

Cash and Cash Equivalents

12 Months Ended

Jun. 30, 2023

Cash and cash equivalents [abstract]

Cash and Cash Equivalents

NOTE 8: CASH AND CASH EQUIVALENTS

Cash at the end of the financial year as shown in the statements of cash flows is reconciled to items in the Consolidated Statement of Financial Position as follows:


	2023 A$		2022 A$
Current
Cash at bank and on hand		18,250,255		33,564,857
		18,250,255		33,564,857

The weighted average interest rate on these deposits is 3.2% per annum (2022: 1.15% per annum).

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Continuing Operations
Revenue	$ 22,047	$ 263,634
Interest revenue	479,726	9,869	$ 5,756
Other income	627,558	5,798,362	1,302,587
Other (losses) and gains	(529,690)	(582,015)	4,272,931
Expenses
Research and development expenses	(19,613,270)	(15,998,999)	(5,762,303)
Administrative expenses	(8,636,180)	(7,398,476)	(4,372,823)
Occupancy expenses	(220,344)	(262,440)	(1,272,414)
Compliance expenses	(4,154,366)	(3,736,936)	(1,614,313)
Finance expenses	(29,230)	(44,165)	(1,443,885)
Loss before tax	(32,053,749)	(21,951,166)	(8,884,464)
Income tax benefit	206,792	191,808	187,427
Loss for the year	(31,846,957)	(21,759,358)	(8,697,037)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translating foreign operations	460,506	1,067,134	(1,169,171)
Total Comprehensive Loss for the Year	$ (31,386,451)	$ (20,692,224)	$ (9,866,208)
LOSS PER SHARE
Basic loss per share	$ (0.02)	$ (0.02)	$ (0.01)
Diluted loss per share	$ (0.02)	$ (0.02)	$ (0.01)

Discontinued Operations - Summary of Discontinued Operations (Statements of Financial Position) (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Current assets
Cash and cash equivalents	$ 18,250,255	$ 33,564,857	$ 28,499,449	$ 4,577,747
Trade and other receivables	14,718	64,360
Research and development incentives receivable	627,559	6,719,761
Other assets	1,203,214	1,461,268
Non-current assets
Property, plant and equipment	3,804	5,172
Right-to-use asset - rented property	498,458	669,358
Other intangible assets	9,202,594	9,838,274
Current liabilities
Trade and other payables	(3,500,487)	(2,786,280)
Lease liability - rented property	(171,841)	(160,040)	(174,218)
Provisions	(457,017)	(409,320)
Non-current liabilities
Lease liability - rented property	(361,742)	(533,583)	$ (693,623)
Deferred tax liabilities	(1,655,369)	(1,798,625)
Net assets disposed of	$ 43,003,902	$ 65,310,172

Lease Liabilities

12 Months Ended

Jun. 30, 2023

Lease liabilities [abstract]

Lease Liabilities

NOTE 18: LEASE LIABILITIES


	2023 A$			2022 A$			2021 A$
Secured – at amortised costs

Loan Movement Schedule
Opening Balance – July 1		693,623			867,841			793,148
New lease for new property - being rented		-			-			854,500
Repayments		(160,040	)		(174,218	)		(779,807	)
Closing Balance – June 30		533,583			693,623			867,841

Disclosed in the financial statements as:


Current liabilities	171,841	160,040	174,218
Non-current liabilities	361,742	533,583	693,623
	533,583	693,623	867,841

Lease liabilities relate to building leases and are effectively secured by the buildings being leased (Note 14).

The total Group cash outflows for leases is set out below:


	2023 A$		2022 A$		2021 A$
Principal element of lease payments		160,040		174,218		779,807
Interest element of lease payments - continuing operations		21,278		26,872		26,934
Total cash outflows for leases		181,318		201,090		806,741

The Group's lease contracts include extension and termination options. These options are

negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group’s business needs.

Set out below are the undiscounted potential future rental payments relating to periods following the exercise date of extension options that are not included in the lease term:


	Within five years A$		More than five years A$		Total A$
As at June 30, 2023
Extension options expected not to be exercised		-		1,183,105		1,183,105

As at June 30, 2022
Extension options expected not to be exercised		-		1,183,105		1,183,105

Contingent Liabilities

12 Months Ended

Jun. 30, 2023

Disclosure of contingent liabilities [abstract]

Contingent Liabilities

NOTE 30: CONTINGENT LIABILITIES

•

In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc., or Ironwood, pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.

•

The Group has provided a restricted cash deposit of A$119,000 (2022: A$119,000) as security for an unconditional irrevocable bank guarantee as a rent guarantee of A$119,000 (2022: A$119,000) to the landlord of the Company’s leased office premises.

•

The Group has contingent liability in relation to the employment agreement with Dr Spyros Papapetropoulos (see note 28 (c) to the Financial Statements for details (severance pay) of $787,500. (2022: contingent liability in relation to the agreement with Dr Errol De Souza and during the current year $683,701 was paid, (see note 28 (d) to the Financial Statements for details).

Other Financial Assets - Schedule of Other Financial Assets (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of financial assets [abstract]
Restricted deposits held as security and not available for use	$ 119,000	$ 119,000
Current assets	0	0
Non-current assets	119,000	119,000
Other financial assets, Total	$ 119,000	$ 119,000

Goodwill - Schedule of Changes in Goodwill (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of reconciliation of changes in goodwill [abstract]
Goodwill at beginning of period	$ 12,868,122	$ 12,400,743
Foreign currency exchange differences	216,178	467,379
Goodwill at end of period	$ 13,084,300	$ 12,868,122

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2023
Disclosure Of Summary Of Significant Accounting Policies [Abstract]
Basis of Consolidation	(a) Basis of Consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company: • has power over the investee; • is exposed, or has rights, to variable returns from its involvement with the investee, and • has the ability to use its power to affect its returns. Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.
Borrowings	(b) Borrowings Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.
Borrowing Costs	(c) Borrowing Costs All borrowing costs (other than transaction costs) are recognised in profit or loss in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.
Business Combinations	(d) Business Combinations Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value which is calculated as the sum of the acquisition-date fair values of assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred. At the acquisition date, the identifiable assets acquired, and the liabilities assumed are recognised at their fair value, except that: • Deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements, are recognised and measured in accordance with IAS 12 ‘Income Taxes’ and IAS 19 ‘Employee Benefits’, respectively; • Liabilities or equity instruments related to share-based payment arrangements of the acquiree, or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 ‘Share-based Payment’ at the acquisition date, and • Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 ‘Non-current Assets Held for Sale and Discontinued Operations’ are measured in accordance with that Standard. Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a gain on bargain purchase. Where the consideration transferred by the Group in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. The subsequent accounting for changes in the fair value of contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration is recognised at fair value, classified as a liability which is remeasured at subsequent reporting dates in accordance with IFRS 9 and IAS 137 ‘Provisions, Contingent Liabilities and Contingent Assets’ respectively, as appropriate, with the corresponding gain or loss being recognised in profit or loss. If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see above), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date.
Cash and Cash Equivalents	(e) Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the consolidated statement of financial position.
Earnings/(Loss) per Share	(f) Earnings/(Loss) per Share • Basic Earnings/(Loss) per Share Basic earnings/(loss) per share is calculated by dividing the profit/(loss) after income tax attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the year, adjusted for bonus elements in ordinary shares issued during the year. • Diluted Earnings/(Loss) per Share Diluted earnings/(loss) per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to options.
Employee Benefits	(g) Employee Benefits • Short-term and Long-term Employee Benefits A liability is recognised for benefits accruing to employees in respect of wages and salaries, annual leave and long service leave when it is probable that settlement will be required, and they are capable of being measured reliably. Liabilities recognised in respect of short-term employee benefits, are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Liabilities recognised in respect of long-term employee benefits are measured as the present value of the estimated future cash outflows to be made by the Group in respect of services provided by employees up to reporting date, discounted using rates applicable to high quality corporate bonds. • Superannuation Retirement benefits are contributions made to employee superannuation funds and are charged as expenses when incurred. These contributions are made to external superannuation funds and are not defined benefits programs. • Share-based Payments • Share-based compensation benefits have been provided to employees via the Bionomics Employee Equity Plan (“EEP”) that was approved by shareholders at the Annual General Meeting held on 2 December 2021, with the exception of share options issued to the Executive Chairman (Dr De Souza) and Chief Executive Officer (Dr Papapetropoulos) which were approved by shareholders at the General Meeting held on 21 February 2023. The fair value of shares issued to employees for no cash consideration under the EEP and share options issued to the Executive Chairman are recognized as an employee benefits expense with a corresponding increase in equity. The fair value is measured at grant date and recognized on a straight-line basis over the vesting period based on the Group’s estimate of equity instruments that will eventually vest or over the period of the Consultancy Agreement, as applicable. The disclosure in Note 20 relates to the EEP and the former Employee Share Option Plan (“ESOP”). The Bionomics EEP was approved by the Board and shareholders in 2017. Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Group for a period of not less than six months or a Director of the Group. Options are granted under the plan for no consideration and vest equally over five years, or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date. See Note 20 for details on how the fair value of options and warrants issued during the year are calculated.
Financial Assets	(h) Financial Assets All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognized financial assets are measured subsequently in their entirety at either amortized cost or fair value, depending on the classification of the financial assets. Classification of Financial Assets at amortized costs • The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flow, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payment of principal and interest on the principal amount outstanding. Debt instruments that meet the following conditions are measured subsequently at fair value through other comprehensive income (“FVTOCI”): • The financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets, and • The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. By default, all other financial assets are measured subsequently at fair value through profit or loss (“FVTPL”). Despite the foregoing, the Group may make the following irrevocable election/designation at initial recognition of a financial asset: • The Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income if certain criteria are met (see (ii) below); and • The Group may irrevocably designate a debt investment that meets the amortised cost or FVTOCI criteria as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch (see (ii) below). (i) Amortised Cost and Effective Interest Method The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocation interest income over the relevant period. For financial assets other than purchased or originated credit-impaired financial assets (i.e. assets that are credit-impaired on initial recognition), the effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) excluding expected credit losses, through the expected life of the debt instrument, or, where appropriate, a shorter period, to the gross carrying amount of the debt instrument on initial recognition. For purchased or originated credit-impaired financial assets, a credit-adjusted effective interest rate is calculated by discounting the estimated future cash flows, including expected credit losses, to the amortised cost of the debt instrument on initial recognition. The amortised cost of a financial asset is the amount at which the financial asset is measured at initial recognition minus the principal repayments, plus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, adjusted for any loss allowance. Interest income is recognised using the effective interest method for debt instruments measured subsequently at amortised cost and at FVTOCI. For financial assets other than purchased or originated credit-impaired financial assets, interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired, (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset. If, in subsequent reporting periods, the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset. For purchased or originated credit-impaired financial assets, the Group recognizes interest income by applying the credit-adjusted effective interest rate to the amortised cost of the financial asset from initial recognition. The calculation does not revert to the gross basis even if the credit risk of the financial asset subsequently improves so that the financial asset is no longer credit-impaired. Interest income is recognised in profit or loss and is included in the “other Scholes model was used to obtain income” line item. (ii) Financial Assets at FVTPL Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI are measured at FVTPL. Specifically: • Investments in equity instruments are classified as at FVTPL, unless the Group designates an equity investment that is neither held for trading nor a contingent consideration arising from a business combination as at FVTOCI on initial recognition. • Debt instruments that do not meet the amortised cost criteria or the FVTOCI criteria are classified as at FVTPL. In addition, debt instruments that meet either the amortised cost criteria or the FVTOCI criteria may be designated as at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency (so called ‘accounting mismatch’) that would arise from measuring assets or liabilities or recognizing the gains and losses on them on different bases. The Group has not designated any debt instructions as at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair values gains or losses recognised in profit or loss to the extent they are not part of a designated hedging relationship (see hedge accounting policy). The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset and is included in the ‘other gains and losses’ line item. (iii) Impairment of Financial Assets The Group recognizes a loss allowance for expected credit losses (“ECL”) on investments in debt instruments that are measured at amortised cost or a FVTOCI, lease receivables, trade receivables and contract assets, as well as on financial guaranteed contracts. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. The Group always recognizes lifetime ECL for trade receivables, contract assets and lease receivables. The expected credit losses on these financial assets are estimated using a provision matrix based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. For all other financial instruments, the Group recognizes lifetime ECL when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECL. Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.
Foreign Currencies	(i) Foreign Currencies The individual financial statements of each group entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each group entity are expressed in Australian dollars (“$”), which is the functional currency of the Company and the presentation currency for the consolidated financial statements. In preparing the financial statements of each individual group entity, transactions in currencies other than the entity’s functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences on monetary items are recognised in profit or loss in the period in which they arise except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the net investment in the foreign operation), which are recognised initially in other comprehensive income and reclassified from equity to profit or loss on repayment of the monetary items. For the purpose of presenting these consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated into Australian dollars using exchange rates prevailing at the end of the reporting period. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity. Goodwill and fair value adjustments to identifiable assets acquired and liabilities assumed through acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the rate of exchange prevailing at the end of each reporting period. Exchange differences arising are recognised in other comprehensive income and accumulated in equity.
Goods and Services Tax ("GST")	(j) Goods and Services Tax (“GST”) Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated statement of financial position. Cash flows are presented on a gross basis. The GST component of cash flow arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow.
Government Research and Development Incentives	(k) Government Research and Development Incentives Government grants, including Research and Development incentives, are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to cost reimbursements are recognised as other income in profit or loss in the period when the costs were incurred or when the incentive meets the recognition requirements (if later).
Impairment of Tangible and Intangible Assets Other than Goodwill and Indefinite Lived Intangibles	(l) Impairment of Tangible and Intangible Assets Other than Goodwill and Indefinite Lived Intangibles At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash generating unit (“CGU”) to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified. A CGU is the smallest identifiable group of assets that generates cash flow that is largely independent of cash flows from other assets or group of assets. The Company's CGU (drug development) is defined as a research program that has the potential to be commercialized at some point in the future. Achievement of certain milestones within the current central nervous system research program will determine when a new CGU comes into existence. Intangible assets with indefinite useful lives are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss. Where an impairment loss subsequently reverses, the carrying amount of the asset (or CGU) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.
Income Tax	(m) Income Tax Income tax expense represents the sum of the tax currently payable and deferred tax. Current Tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax as reported in the consolidated statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred Tax Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Deferred tax liabilities and assets are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and Deferred Tax for the Year Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case the current and deferred tax are also recognised in other comprehensive income or directly in equity, respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Tax Consolidation Legislation Bionomics and its wholly owned Australian controlled entities have implemented the tax consolidation legislation effective 31 December 2005. The head entity, Bionomics Limited, and the controlled entities in the tax consolidated group account for their own current and deferred tax amounts. These tax amounts are measured as if each entity in the tax consolidated group continues to be a stand-alone taxpayer in its own right. In addition to its own current and deferred tax amounts, Bionomics Limited also recognizes the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from controlled entities in the tax consolidated group. Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the Group. Any difference between the amounts assumed and amounts receivable or payable under the tax funding agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated entities.
Intangible Assets	(n) Intangible Assets (i) Intellectual Property Acquired intellectual property is recognised as an asset at cost and amortised over its useful life. There is currently no internally generated intellectual property that has been capitalised. Intellectual property with a finite life is amortised on a straight-line basis over that life. Intellectual property with an indefinite useful life is subjected to an annual impairment review. There is currently no intellectual property with an indefinite life. Current useful life of all existing intellectual property is in the range of 15 to 20 years. The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance date. (ii) Goodwill Goodwill arising on an acquisition of a business is carried at cost as established at the date of the acquisition of the business (see Note 2(d) above) less accumulated impairment losses, if any. For the purposes of impairment testing, goodwill is allocated to the Group's CGU that is expected to benefit from the synergies of the combination. A CGU to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the CGU may be impaired. If the recoverable amount of the CGU is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the CGU and then to the other assets of the CGU pro rata based on the carrying amount of each asset in the CGU. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods. On disposal of the relevant CGU, the attributable amount of goodwill is included in the determination of the profit or loss on disposal. (iii) Intangible Assets Acquired in a Business Combination Intangible assets acquired in a business combination and recognised separately from goodwill are initially recognised at their fair value at the acquisition date (which is regarded as their cost). Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.
Issued Capital	(o) Issued Capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, or for the acquisition of a business, are deducted directly from equity.
Leases	(p) Leases The Group assesses whether a contract is or contains a lease, at inception of the contract. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group as Lessee The Group assesses whether a contract is or contains a lease, at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee entity uses its incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise: • Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable; • Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date; • The amount expected to be payable by the lessee under residual value guarantees; • The exercise price of purchase options, if the lessee is reasonably certain to exercise the options, and • Payments of penalties for terminating the lease if the lease term reflects the exercise of an option to terminate the lease. The lease liability is presented as a separate line in the consolidated statement of financial position. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever: • The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate. • The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used). • A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification. The Group did not make any such adjustments during the periods presented. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. Current useful life of right-to-use assets is 5 years. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Group expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease. The right-of-use assets are presented as a separate line in the consolidated statement of financial position. The Group applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in Note 2(l) above. Group as Lessor Leases in which the Group does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Rental income arising is accounted for on a straight-line basis over the lease term and is included in revenue in the statement of profit or loss due to its operating nature. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.
Property, Plant and Equipment	(q) Property, Plant and Equipment Plant and equipment are stated at cost less accumulated depreciation or accumulated impairment losses, where applicable. Depreciation is recognized so as to write off the cost of assets less their residual values over their useful lives, using the diminishing value or straight-line methods, depending on the type of asset. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period. The depreciation rates for plant and equipment are 20 – 40%. An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss.
Research and Development	(r) Research and Development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized as an expense when it is incurred. Expenditures on development activities are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. Development costs have a finite life and are amortized on a systematic basis matched to the future economic benefits over the useful life of the project. At year end there are currently no capitalized development costs.
Revenue Recognition	(s) Revenue Recognition (i) License revenues in connection with licensing of the Group's intellectual property (including patents) to collaborators are recognized as a right to use the entity's intellectual property as it exists at the point in time at which the license is granted. This is because the contracts for the license of intellectual property are distinct and do not require, nor does the customer reasonably expect, that the Group will undertake further activities that significantly affect the intellectual property to which the collaborator has rights. (ii) Although the Group is entitled to sales-based royalties from any eventual sales of goods and services to third parties using the intellectual property transferred, these royalty arrangements do not of themselves indicate that the collaborator would reasonably expect the Group to undertake such activities, and no such activities are undertaken or contracted in practice. Accordingly, the promise to provide rights to the Group's intellectual property is accounted for as a performance obligation satisfied at a point in time. The following consideration is received in exchange for licenses of intellectual property: (a) Up-front payments - These are fixed amounts and are recognized at the point in time when the Group transfers the intellectual property to the collaborator. (b) Milestone payments - These are variable considerations that depends upon the collaborator reaching certain milestones in relation to the intellectual property licensed. Such amounts are only recognized when it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration (that is, the collaborator meeting the conditions to trigger payment) is subsequently resolved. (c) Sales-based royalties - These are variable consideration amounts promised in exchange for the license of intellectual property that occur late in the collaborator's development of the intellectual property and are recognized when the sales to third parties occur (as the performance obligation to transfer the intellectual property to the collaborator is already satisfied). (iii) Rental income is recognized on a straight-line basis over the term of the lease (refer to note 2(p) “Group as lessor” for further comments).

Property, Plant And Equipment - Schedule of Detailed Information About Property Plant And Equipment (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	$ 5,172
Depreciation	(1,368)	$ (2,681)	$ (45,553)
Property, plant and equipment at end of period	3,804	5,172
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	72,035	106,753
Additions		1,544
Disposals		(36,262)
Property, plant and equipment at end of period	72,035	72,035	106,753
Accumulated depreciation
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(66,863)	(98,526)
Depreciation	(1,368)	(2,681)
Disposals		34,344
Property, plant and equipment at end of period	$ (68,231)	$ (66,863)	$ (98,526)

Cash and Cash Equivalents (Tables)

12 Months Ended

Jun. 30, 2023

Cash and cash equivalents [abstract]

Disclosure of Detailed Information About Cash and Cash Equivalents

Cash at the end of the financial year as shown in the statements of cash flows is reconciled to items in the Consolidated Statement of Financial Position as follows:


	2023 A$		2022 A$
Current
Cash at bank and on hand		18,250,255		33,564,857
		18,250,255		33,564,857

Revenue, Other Income and Other Gains and Losses

12 Months Ended

Jun. 30, 2023

Disclosure Of Revenue Other Income And Other Gains And Losses [Abstract]

Revenue, Other Income and Other Gains and Losses

NOTE 5: REVENUE, OTHER INCOME AND OTHER GAINS AND LOSSES


	2023 A$		2022 A$		2021 A$
Revenue from Continuing Operations
Licenses		22,047		263,634		-
		22,047		263,634		-

Other Income from Continuing Operations
Rent		-		6,674		203,014
Government Research and Development Incentives (i)		627,558		5,791,688		928,073
Government assistance COVID-19 (Cash flow boost)		-		-		50,000
Government assistance COVID-19 (Jobkeeper)		-		-		121,500
		627,558		5,798,362		1,302,587

(i)


	2023 A$			2022 A$			2021 A$
Other gains and losses from Continuing Operations
Net (loss)/gain arising on changes in fair value of contingent consideration (Note 29)		(988,179	)		(936,354	)		3,212,503
Net realised and unrealised foreign currency gains		458,489			356,166			1,081,438
(Loss) on disposal of plant and equipment		-			(1,827	)		(21,010	)
		(529,690	)		(582,015	)		4,272,931

Other Financial Assets

12 Months Ended

Jun. 30, 2023

Disclosure Of Other Financial Assets [Abstract]

Other Financial Assets

NOTE 9: OTHER FINANCIAL ASSETS


	2023 A$		2022 A$
Restricted deposits held as security and not available for use		119,000		119,000

Disclosed in the financial statement as:


Current assets	-	-
Non-current assets	119,000	119,000
	119,000	119,000

The Group holds restricted term deposits of A$119,000 (2022: A$119,000), with a maturity date of June 3, 2024 (2022: June 3, 2022 respectively) as security for a bank guarantee (Note 30 (ii)) that is not available for use. The term deposits will be extended on maturity until the bank guarantee ceases to be required. The effective interest rate on these deposits is 4.20% (2022:1.95%).

Loss Per Share - Summary of Computation of Basic and Diluted Loss Per Share (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Earnings per share [line items]
Basic loss per share	$ (0.02)	$ (0.02)	$ (0.01)
Diluted loss per share	$ (0.02)	$ (0.02)	$ (0.01)
Loss Per Share (Basic and Diluted):
Loss after tax for the year from continuing and discontinuing operations	$ (31,846,957)	$ (21,759,358)	$ (8,697,037)
Loss after tax for the year	$ (31,846,957)	$ (21,759,358)	$ (8,697,037)
Weighted Average Number of Ordinary Shares - Basic and Diluted
Weighted average number of ordinary shares used in calculating basic loss per share:	1,468,735,424	1,353,350,744	779,941,036
Weighted average number of ordinary shares used in the calculation of diluted loss per share	1,468,735,424	1,353,350,744	779,941,036
Employee Options
Weighted Average Number of Ordinary Shares - Basic and Diluted
Shares deemed to be issued for no consideration in respect of employee options	46,690,480	31,065,272	20,056,450
Potential ordinary shares which are anti-dilutive and excluded	(46,690,480)	(31,065,272)	(20,056,450)
Warrants
Weighted Average Number of Ordinary Shares - Basic and Diluted
Shares deemed to be issued for no consideration in respect of warrants	142,000,000	142,000,000	166,082,988
Potential ordinary shares which are anti-dilutive and excluded	(142,000,000)	(142,000,000)	(166,082,988)

Reserves - Summary of Reserves (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of reserves within equity [abstract]
Foreign Currency Translation Reserve	$ 6,646,840	$ 6,186,334
Share-based Payments Reserve	7,858,906	6,337,264
Total Reserves	$ 14,505,746	$ 12,523,598

Contingent Consideration

12 Months Ended

Jun. 30, 2023

Contingent consideration [abstract]

Contingent Consideration

NOTE 29: CONTINGENT CONSIDERATION

During the year ended 30 June 2013, the Company acquired Eclipse Therapeutics, Inc (Eclipse) into its wholly owned subsidiary, Bionomics Inc. Part of the consideration are potential cash earn-outs to Eclipse security holders based on achieving late-stage development success or partnering outcomes of the Eclipse asset that was acquired. This liability is recorded at fair value; see Note 22(j), for information about the calculation of the fair value. Due to changes in the projected inputs, being the timing and quantum of expected cash outflow, which are in USD dollars, the liability increased by A$988,179 at 30 June 2023 (increased by A$936,354 at 30 June 2022). Inputs used are based on the anticipated amounts and timing of potential milestone and royalty payments from licensing agreement with Carina Biotech Pty Ltd (Carina). International financial reporting standards required that in a “business combination” (the Company acquiring Eclipse) any contingent consideration liability at acquisition date needs to be recorded at the fair value and subsequent changes in the fair value is recognised in profit or loss, but any contingent assets at acquisition date are not allowed to be recorded. The Company has a contingent asset (the expected payments to be received from Carina) at 30 June 2023 which is greater than the contingent consideration liability.


	2023 A$		2022 A$
Opening balance		2,699,010		1,762,656
Change in fair value		988,179		936,354
Closing balance		3,687,189		2,699,010

Lease Liabilities - Schedule of Lease Liabilities Secured at Amortised Costs (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jul. 01, 2022
Lease liabilities [abstract]
Opening Balance - July 1	$ 693,623	$ 867,841	$ 793,148
New lease for new property - being rented			854,500
Repayments	(160,040)	(174,218)	(779,807)
Closing Balance - June 30	533,583	693,623	867,841
Current liabilities	171,841	160,040	174,218
Non-current liabilities	361,742	533,583	693,623
Total lease liabilities	$ 533,583	$ 693,623	$ 867,841	$ 693,623

Issued Capital - Summary of Movements in Ordinary Shares (Details)		12 Months Ended
	Sep. 02, 2021 shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 AUD ($) shares	Jun. 30, 2021 AUD ($) shares
Disclosure of classes of share capital [line items]
Share issue - rights			$ 480,000	$ 22,606,257
Shares issued to employees				$ 60,750
Shares issued on exercise of options, shares \| shares	2,000,000	0	2,000,000
Shares issued on exercise of warrants, shares \| shares			8,000,000
Share issue in a US F-1, shares \| shares		115,384,680
Ordinary Shares
Disclosure of classes of share capital [line items]
Opening balance, shares \| shares		1,353,350,744	1,007,596,744	626,185,872
Opening balance		$ 217,695,759	$ 190,190,147	$ 148,156,005
Share issue - share placement, shares \| shares				185,757,511
Share issue - share placement				$ 21,229,874
Share issue - rights, shares \| shares				195,229,129
Share issue - rights				$ 22,606,257
Shares issued to employees, shares \| shares				424,232
Shares issued to employees				$ 60,750
Shares issued on exercise of options, shares \| shares			2,000,000
Shares issued on exercise of options			$ 27,200
Shares issued on exercise of warrants, shares \| shares			8,000,000
Shares issued on exercise of warrants			$ 480,000
Transfer from share-based payments reserve as result of options and warrants being exercised			$ 327,760
Share issue in a US IPO and NASDAQ listing, shares \| shares			335,754,000
Share issue in a US IPO and NASDAQ listing			$ 32,383,263
Share issue in a US F-1, shares \| shares		115,384,680
Share issue in a US F-1		$ 7,419,235
Share issue costs		$ (1,702,332)	$ (5,712,611)	(423,492)
Warrants issued - underwriting fee				$ (1,439,247)
Closing balance, shares \| shares		1,468,735,424	1,353,350,744	1,007,596,744
Closing balance		$ 223,412,662	$ 217,695,759	$ 190,190,147

Issued Capital - Unlisted Share Options Issued (Details) - $ / shares		12 Months Ended
	Aug. 28, 2020	Jun. 30, 2023
Disclosure of classes of share capital [line items]
Vesting period		five years
Dr Errol De Souza \| Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	6,000,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.075
Dr Errol De Souza \| Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	6,000,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.071
Mr Jack Moschakis \| Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	1,000,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.133
Mr Jack Moschakis \| Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	1,000,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.118
Ms Liz Doolin \| Share Price Reaching Dollar 0.14 Per Share
Disclosure of classes of share capital [line items]
Share options issued	500,000
Vesting period	Company’s share price reaching $0.14 per share
Fair value at date of issue	$ 0.133
Ms Liz Doolin \| Share Price Reaching Dollar 0.24 Per Share
Disclosure of classes of share capital [line items]
Share options issued	500,000
Vesting period	Company’s share price reaching $0.24 per share
Fair value at date of issue	$ 0.118

Issued Capital - Details of Share Options That Were Issued to KMPs (Details) - Share Options - Key Management Personnel	Jul. 15, 2022 shares
Mr Adrian Hinton
Disclosure of classes of share capital [line items]
Share options issued	2,000,000
Mr Connor Bernstein
Disclosure of classes of share capital [line items]
Share options issued	3,500,000
Ms Liz Doolin
Disclosure of classes of share capital [line items]
Share options issued	2,000,000

Remuneration of Auditors (Tables)

12 Months Ended

Jun. 30, 2023

Auditor's remuneration [abstract]

Schedule of Auditors Remuneration Explanatory


	2023 A$		2022 A$		2021 A$
Audit or Review of Financial Reports
- Group		357,500		969,726		86,500
Agreed -upon-procedures
- Shares issued under the F-1		118,000		-		-
- Shelf (F-3) & ATM SEC filing		25,000		-		-
		500,500		969,726		86,500

Commitments For Expenditure

12 Months Ended

Jun. 30, 2023

Commitments For Expenditure [Abstract]

Commitments For Expenditure

NOTE 24: COMMITMENTS FOR EXPENDITURE

Operating Leases

Operating leases related to photocopier with lease term of 3 years (2022: 4 years). The following table gives information about this lease commitment, which are not included in the lease liability due to the application of the practical expedients to exclude low value leases from lease liabilities.


	2023 A$		2022 A$
Non-cancellable Operating Lease Commitments
Within one year		5,469		5,064
Later than one year but not greater than five		10,103		13,504
Later than five years		-		-
Minimum lease payments		15,572		18,568

Lease Liabilities - Schedule of Undiscounted Potential Future Rental Payments (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Disclosure of maturity analysis of operating lease payments [line items]
Extension options expected not to be exercised	$ 1,183,105	$ 1,183,105
More than five years
Disclosure of maturity analysis of operating lease payments [line items]
Extension options expected not to be exercised	$ 1,183,105	$ 1,183,105

Contingent Consideration - Disclosure of Contingent Consideration (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Contingent consideration [abstract]
Opening balance	$ 2,699,010	$ 1,762,656
Change in fair value	988,179	936,354
Closing balance	$ 3,687,189	$ 2,699,010

Summary of Significant Accounting Policies - Additional Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of voluntary change in accounting policy [line items]
Cash consideration under the EEP	$ 5,866,810	$ 5,997,505	$ 4,034,965
Vesting period	five years
Useful life of right-to-use assets	5 years
Bottom of Range \| Plant and Equipment
Disclosure of voluntary change in accounting policy [line items]
Depreciation rates for plant and equipment	20.00%
Top of Range \| Plant and Equipment
Disclosure of voluntary change in accounting policy [line items]
Depreciation rates for plant and equipment	40.00%
Intellectual Property \| Bottom of Range
Disclosure of voluntary change in accounting policy [line items]
Intangible assets, useful life	15 years
Intellectual Property \| Top of Range
Disclosure of voluntary change in accounting policy [line items]
Intangible assets, useful life	20 years
Executive Chairman
Disclosure of voluntary change in accounting policy [line items]
Cash consideration under the EEP	$ 0

Financial Instruments

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about financial instruments [abstract]

Financial Instruments

NOTE 22: FINANCIAL INSTRUMENTS

(a)

Capital Risk Management

The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns whilst maximizing the return to stakeholders through the optimisation of the debt and equity balance.

During April 2021, the Group repaid in full its bank loan and equipment mortgage. The capital structure of the Group now consists of lease liabilities for rental property (Note 18) cash and cash equivalents (Note 8) and equity attributable to equity holders of the parent, comprising issued capital (Note 20), reserves (Note 21) and retained earnings.

The Group’s policy is to fund the research and development activities and operations through the issue of equity and the commercialisation of intellectual property assets. Project specific borrowings are utilized where appropriate and also minor borrowings for operational assets, as required.

(b)

Categories of Financial Instruments


	2023 A$		2022 A$
Financial Assets
Cash and cash equivalents		18,250,255		33,564,857
Receivables		642,277		6,784,121
Other financial assets		119,000		119,000
		19,011,532		40,467,978

Financial Liabilities
Trade and other payables		3,500,487		2,786,280
Lease liability – rental property		533,583		693,623
Contingent consideration at fair value		3,687,189		2,699,010
		7,721,259		6,178,913

(c)

Financial Risk Management Objectives

The Board, through the Audit and Risk Management (“ARM”) Committee, is responsible for ensuring there are adequate policies in relation to risk management, compliance and internal control systems.

In summary, Group policies are designed to ensure significant strategic, operational, legal, reputational and financial risks are identified, assessed, and effectively monitored and managed in a manner sufficient for a company of Bionomics’ size and stage of development to enable achievement of the Group’s business strategy and objectives.

The Group’s risk management policies are managed by the key management personnel and are reviewed by the ARM Committee according to a timetable of assessment and review proposed by that committee and approved by the Board.

(d)

Market Risk

The Group’s activities expose it primarily to the financial risks of changes in foreign currency exchange rates (see (e) below) and interest rates (see (f) below).

The Group may use derivative financial instruments to manage its exposure to foreign currency risk, if and when appropriate.

The Group has not entered into any interest rate derivatives.

The Group measures market risk exposures using sensitivity analysis. There has been no material change to the Group’s exposure to market risks or the manner in which these risks are managed and measured.

There were no derivative financial instruments outstanding as at June 30, 2023 (2022: nil).

(e)

Foreign Currency Risk Management

The Group undertakes certain transactions denominated in foreign currencies; consequently, exposures to exchange rate fluctuations arise. Exchange rate exposures are managed in accordance with established policies. The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars is as follows:


	2023 A$			2022
Denominated in USD
Monetary items
Cash and cash equivalents		2,552,731			17,786,031
Trade and other payables		(2,451,693	)		(1,298,425	)
Contingent consideration liability		(3,687,189	)		(2,699,010	)
Total monetary items		(3,586,151	)		13,788,596
Non-monetary items
Goodwill		6,137,205			5,921,027
Other intangible assets		9,202,594			9,838,274
Deferred tax liability		(1,655,369	)		(1,798,625	)
Total non-monetary items		13,684,430			13,960,676

Total denominated in USD		10,098,279			27,749,272

Foreign Currency Sensitivity Analysis

The following table details the Group’s sensitivity to a 10% increase and decrease in the Australian dollar against the US dollar. 10% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in foreign currency rates. The sensitivity analysis below includes only outstanding foreign currency denominated monetary items and adjusts their translation at the year-end for a 10% change in foreign currency rates. A positive number below indicates an increase in profit or equity where the Australian dollar strengthens 10% against the relevant currency.

For a 10% weakening of the Australian dollar against the relevant currency, there would be a comparable impact on the profit or equity with the balances being the opposite.


	2023 A$			2022 A$			2021 A$
10% increase
Profit or loss (i)		(579,305	)		1,796,641			(222,678	)
Equity (ii)		91097			18,815			3,135
10% decrease
Profit or loss (i)		579,305			(1,796,641	)		222,678
Equity (ii)		(91,097	)		(18,815	)		(3,135	)

(i)

This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period.

(ii)

This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period in the subsidiaries which is denominated in USD and reflected in the foreign currency translation reserve.

The Group’s sensitivity to foreign currency has decreased as at June 30, 2023 mainly due to an increase in cash and cash equivalents that are denominated in USD as a result of the US IPO.

The sensitivity analysis may not represent the quantum of foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year. Requirements change during the financial year depending on research and development.

Forward Foreign Exchange Contracts

It is the policy of the Group to enter into forward foreign currency contracts to cover specific foreign currency payments and receipts when appropriate (such as when there is a legal commitment to pay or receive foreign currency or the Executive Chairman or Chief Executive Officer has a high degree of confidence (>90%) that a foreign currency exposure will arise).

Under the Group’s Treasury Policy, the Chief Financial Officer will manage the foreign exchange transaction risk adopting the following guidelines:

•

Generally, hedge foreign exchange exposure identified above by entering into a forward currency contract.

•

The duration of any forward currency contract(s) will approximate the period in which the net currency exposure arises.

•

Recognizing the uncertainty that exists in projecting forward foreign currency flows, a maximum net foreign currency exposure position may be held at any point in time.

Due to the long-term nature of the net investment in the USD denominated wholly owned subsidiaries, the investments will not be hedged into Australian dollars, with the result that the Australian dollar value of the investments will fluctuate with the market rate through the foreign currency translation reserve.

There were no forward foreign currency contracts outstanding as at June 30, 2023 (2022: nil).

(f)

Interest Rate Risk Management

The Group has no borrowings, other than lease liability (rental property) which is at fixed interest rate. The Group does not use interest rate swap contracts or forward interest rate contracts.

The Group is exposed to interest rate risk only in relation to the cash and cash equivalent balances.

Interest Rate Sensitivity Analysis

The Group has no borrowings, other than lease liability (rental property) which is at a fixed interest rate.

(g)

Credit Risk Management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults.

The credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies.

The carrying amount of financial assets recorded in the financial statements, net of any allowances for losses, represents the Group’s maximum exposure to credit risk.

(h)

Liquidity Risk Management

Ultimate responsibility for liquidity risk management rests with the Board, which has approved an appropriate liquidity risk management framework for management of the Group’s short-, medium- and long-term funding. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching maturity profiles of financial assets and liabilities.

(i)

Liquidity and Interest Rate Risk

The following tables detail the Group’s remaining contractual maturity for its financial liabilities with agreed repayment terms. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay.

To the extent that interest flows are at a variable rate, the undiscounted amount is derived from interest rate applicable at the end of the reporting period. The tables include both interest and principal cash flows.


2023	Weighted average effective interest rate %	Less than 1 month A$		1 – 3 months A$		3 – 12 months A$		1 to 5 years A$		5 + years A$		Total A$
Trade and other payables	-		3,500,487		-		-		-		-		3,500,487
Lease liability – rental property (fixed interest rate)	3.56		15,564		46,691		125,018		375,989		-		563,262
			3,516,051		46,691		125,018		375,989		-		4,063,749


2022	Weighted average effective interest rate %	Less than 1 month A$		1 – 3 months A$		3 – 12 months A$		1 to 5 years A$		5 + years A$		Total A$
Trade and other payables	-		2,786,280		-		-		-		-		2,786,280
Lease liability – rental property (fixed interest rate)	3.56		15,069		45,206		121,043		563,262		-		744,580
			2,801,349		45,206		121,043		563,262		-		3,530,860

(j)

Fair Value of Financial Instruments

The Group has no financial assets that are measured at fair value and the only financial liability that is measured at fair value at the end of each reporting period is contingent consideration (Note 30). The value of financial assets and other financial liabilities approximate their fair value. The following table gives information about how the fair value of the financial liability is determined.

Financial Liabilities

Fair value as at 30 June
2023
A$

Fair value as at 30 June
2022
A$

Fair value
hierarchy

Valuation
technique

Significant
unobservable
inputs

Relationship
of unobservable
inputs to
fair value

Contingent consideration in a business combination (Note 29)

3,687,189

2,699,010

Level 3

Discounted cash flow

Discount rate of 25% (pre-tax) and probability adjusted revenue projections.

The higher the discount rate, the lower the value.  The higher the possible revenue the higher value.

Reconciliation of Level 3 fair value measurements


	2023		2022
	Contingent consideration in a business combination A$		Contingent consideration in a business combination A$
Opening balance Total (gain) or loss:		2,699,010		1,762,656
- in profit or loss		988,179		936,354
Closing balance		3,687,189		2,699,010

Discontinued Operations - Summary of Discontinued Operations (Statements of Profit or Loss) (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of analysis of single amount of discontinued operations [line items]
Revenue	$ 22,047	$ 263,634
Other income	627,558	5,798,362	$ 1,302,587
Loss before tax	(32,053,749)	(21,951,166)	(8,884,464)
Loss for the year	$ (31,846,957)	$ (21,759,358)	$ (8,697,037)

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 17
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2023-03-23

+ Details

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2023-03-23

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard
-URIDate 2023-03-23

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard
-URIDate 2023-03-23

+ Details

Income Taxes Relating to Continuing Operations - Summary of Reconciliation to Accounting Loss (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Loss from continuing operations	$ (32,053,749)	$ (21,951,166)	$ (8,884,464)
Tax at the Australian tax rate of 25% (2021 25% & 2020: 30%)	(8,013,437)	(5,487,792)	(2,665,339)
Tax effect of non-deductible / non-assessable amounts
Exempt income from government assistance	(156,890)	(1,447,922)	(293,422)
Entertainment expenses	1,448	1,231	727
Net gain arising on changes in fair value of contingent consideration	247,045	234,089	(963,751)
Share-based payments	476,138	707,422	392,505
Research and development expenditure	360,666	3,328,556	640,050
Amortisation of share issue costs	(285,631)	(285,631)
Temporary differences not recorded as an asset	(787,392)	(58,374)	(632,779)
Tax losses not recorded	7,872,870	2,779,547	3,253,265
Effect of different tax rates in other jurisdictions	78,391	37,066	81,317
Total income tax benefit	$ (206,792)	$ (191,808)	$ (187,427)

Expenses Relating to Continuing Operations

12 Months Ended

Jun. 30, 2023

Expenses by nature [abstract]

Expenses Relating to Continuing Operations

NOTE 6: EXPENSES RELATING TO CONTINUING OPERATIONS


	2023 A$		2022 A$		2021 A$
Loss before income tax benefit includes the following specific expenses:

Finance expenses
- Interest expense on lease liabilities		21,278		26,872		26,934
- Bank fees		7,952		17,293		17,527
- Amortisation of transaction costs (Note18)						252,019
- Accrual of final payment (Note18)						528,819
- Interest expense on bank loan and other loans						618,586
		29,230		44,165		1,443,885

Employment benefit expenses of:
- Wages and salaries		3,785,547		2,901,689		2,577,954
- Superannuation		176,710		266,127		148,662
- Share-based payments		1,904,553		2,829,689		1,308,349
		5,866,810		5,997,505		4,034,965

Depreciation and Amortisation of non-current assets
- Plant and equipment (Note 13)		1,368		2,681		45,553
- Right-of-use assets (rental property) (Note 14)		170,900		193,358		762,813
- Intellectual property (Note 16)		984,724		913,373		892,512
		1,156,992		1,109,412		1,700,878
Rental expense on operating leases (low value assets)
- Minimum lease payments		5,729		5,260		7,277

Other Financial Assets (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of financial assets [abstract]

Schedule of Other Financial Assets


	2023 A$		2022 A$
Restricted deposits held as security and not available for use		119,000		119,000

Disclosed in the financial statement as:


Current assets	-	-
Non-current assets	119,000	119,000
	119,000	119,000

Financial Instruments (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about financial instruments [abstract]

Categories of Financial Instruments

(b)

Categories of Financial Instruments


	2023 A$		2022 A$
Financial Assets
Cash and cash equivalents		18,250,255		33,564,857
Receivables		642,277		6,784,121
Other financial assets		119,000		119,000
		19,011,532		40,467,978

Financial Liabilities
Trade and other payables		3,500,487		2,786,280
Lease liability – rental property		533,583		693,623
Contingent consideration at fair value		3,687,189		2,699,010
		7,721,259		6,178,913

Disclosure of Foreign Currency Risk Management

The Group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars is as follows:


	2023 A$			2022
Denominated in USD
Monetary items
Cash and cash equivalents		2,552,731			17,786,031
Trade and other payables		(2,451,693	)		(1,298,425	)
Contingent consideration liability		(3,687,189	)		(2,699,010	)
Total monetary items		(3,586,151	)		13,788,596
Non-monetary items
Goodwill		6,137,205			5,921,027
Other intangible assets		9,202,594			9,838,274
Deferred tax liability		(1,655,369	)		(1,798,625	)
Total non-monetary items		13,684,430			13,960,676

Total denominated in USD		10,098,279			27,749,272

Summary of Foreign Currency Sensitivity Analysis

For a 10% weakening of the Australian dollar against the relevant currency, there would be a comparable impact on the profit or equity with the balances being the opposite.


	2023 A$			2022 A$			2021 A$
10% increase
Profit or loss (i)		(579,305	)		1,796,641			(222,678	)
Equity (ii)		91097			18,815			3,135
10% decrease
Profit or loss (i)		579,305			(1,796,641	)		222,678
Equity (ii)		(91,097	)		(18,815	)		(3,135	)

(i)

This is attributable to the exposure to outstanding USD net monetary assets at the end of the reporting period.

(ii)

Summary of Remaining Contractual Maturity for Financial Liabilities


2023	Weighted average effective interest rate %	Less than 1 month A$		1 – 3 months A$		3 – 12 months A$		1 to 5 years A$		5 + years A$		Total A$
Trade and other payables	-		3,500,487		-		-		-		-		3,500,487
Lease liability – rental property (fixed interest rate)	3.56		15,564		46,691		125,018		375,989		-		563,262
			3,516,051		46,691		125,018		375,989		-		4,063,749


2022	Weighted average effective interest rate %	Less than 1 month A$		1 – 3 months A$		3 – 12 months A$		1 to 5 years A$		5 + years A$		Total A$
Trade and other payables	-		2,786,280		-		-		-		-		2,786,280
Lease liability – rental property (fixed interest rate)	3.56		15,069		45,206		121,043		563,262		-		744,580
			2,801,349		45,206		121,043		563,262		-		3,530,860

Summary of Fair Value of Financial Instruments

The following table gives information about how the fair value of the financial liability is determined.

Financial Liabilities

Fair value as at 30 June
2023
A$

Fair value as at 30 June
2022
A$

Fair value
hierarchy

Valuation
technique

Significant
unobservable
inputs

Relationship
of unobservable
inputs to
fair value

Contingent consideration in a business combination (Note 29)

3,687,189

2,699,010

Level 3

Discounted cash flow

Discount rate of 25% (pre-tax) and probability adjusted revenue projections.

The higher the discount rate, the lower the value.  The higher the possible revenue the higher value.

Summary of Reconciliation of Level 3 Fair Value Measurements

Reconciliation of Level 3 fair value measurements


	2023		2022
	Contingent consideration in a business combination A$		Contingent consideration in a business combination A$
Opening balance Total (gain) or loss:		2,699,010		1,762,656
- in profit or loss		988,179		936,354
Closing balance		3,687,189		2,699,010

Consolidated Statement of Financial Position - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 18,250,255	$ 33,564,857
Trade and other receivables	14,718	64,360
Research and development incentives receivable	627,559	6,719,761
Other assets	1,203,214	1,461,268
TOTAL CURRENT ASSETS	20,095,746	41,810,246
NON-CURRENT ASSETS
Property, plant and equipment	3,804	5,172
Right-to-use asset - rented property	498,458	669,358
Goodwill	13,084,300	12,868,122
Other intangible assets	9,202,594	9,838,274
Other financial assets	119,000	119,000
TOTAL NON-CURRENT ASSETS	22,908,156	23,499,926
TOTAL ASSETS	43,003,902	65,310,172
CURRENT LIABILITIES
Trade and other payables	3,500,487	2,786,280
Lease liability - rented property	171,841	160,040
Provisions	457,017	409,320
TOTAL CURRENT LIABILITIES	4,129,345	3,355,640
NON-CURRENT LIABILITIES
Lease liability - rented property	361,742	533,583
Provisions	22,398	10,460
Deferred tax liability	1,655,369	1,798,625
Contingent consideration	3,687,189	2,699,010
TOTAL NON-CURRENT LIABILITIES	5,726,698	5,041,678
TOTAL LIABILITIES	9,856,043	8,397,318
NET ASSETS	33,147,859	56,912,854
EQUITY
Issued capital	223,412,662	217,695,759
Reserves	14,505,746	12,523,598
Accumulated losses	(204,770,549)	(173,306,503)
TOTAL EQUITY	$ 33,147,859	$ 56,912,854

Events Occurring After Reporting Date (Additional Information) (Details)		12 Months Ended
	Oct. 18, 2023 USD ($) shares	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issuing shares		$ 7,419,235	$ 32,890,463	$ 43,836,131
ATM Program
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from issuing shares	$ 6,715,878
Net proceeds after deducting commission and issuance fee	$ 6,409,359
ATM Program \| ADSs
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued \| shares	2,100,866
ATM Program \| Ordinary Shares
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued \| shares	378,155,880

Subsidiaries (Tables)

12 Months Ended

Jun. 30, 2023

Disclosure of subsidiaries [abstract]

Summary of Group Subsidiaries

Details of the Group’s subsidiaries at the end of the reporting period are as follows:


			Percentage owned
Entity	Principal activity	Country of incorporation	2023 %	2022 %
Head Entity
Bionomics Limited	Research and Development	Australia

Subsidiaries of Bionomics Limited
Iliad Chemicals Pty Ltd	Asset owner	Australia	100	100
Bionomics Inc	Asset owner	United States	100	100

Commitments For Expenditure (Tables)

12 Months Ended

Jun. 30, 2023

Commitments For Expenditure [Abstract]

Summary of Non cancellable Operating Lease Commitments

The following table gives information about this lease commitment, which are not included in the lease liability due to the application of the practical expedients to exclude low value leases from lease liabilities.


	2023 A$		2022 A$
Non-cancellable Operating Lease Commitments
Within one year		5,469		5,064
Later than one year but not greater than five		10,103		13,504
Later than five years		-		-
Minimum lease payments		15,572		18,568

Financial Instruments - Summary of Fair Value of Financial Instruments (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about financial instruments [line items]
Contingent consideration in a business combination	$ 3,687,189	$ 2,699,010	$ 1,762,656
Level 3
Disclosure of detailed information about financial instruments [line items]
Contingent consideration in a business combination	$ 3,687,189	$ 2,699,010	$ 1,762,656
Description of valuation technique	Discounted cash flow
Description of significant unobservable inputs	Discount rate of 25% (pre-tax) and probability adjusted revenue projections.
Description of relationship of unobservable inputs to fair value	The higher the discount rate, the lower the value. The higher the possible revenue the higher value.

Other Intangible Assets

12 Months Ended

Jun. 30, 2023

Disclosure of detailed information about intangible assets [abstract]

Other Intangible Assets

NOTE 16: OTHER INTANGIBLE ASSETS

Intellectual Property

The acquired intellectual property relates to KV1.3 compound, VDA compound, MultiCore technology and cancer stem cell technology, and is carried at its cost as at its date of acquisition, less accumulated amortisation and impairment charges. There is currently no internally generated intellectual property capitalised.


	KV1.3 compound			VDA compound			MultiCore technology			Cancer stem cell technology			Total
	A$			A$			A$			A$			A$
Gross carrying amount at July 1, 2021		1,546,542			2,282,527			1,265,590			17,681,361			22,776,020
Additions		-			-			-			-			-
Foreign currency exchange differences		-			-			-			1,515,296			1,515,296
Gross carrying amount at June 30, 2022		1,546,542			2,282,527			1,265,590			19,196,657			24,291,316
Additions		-			-			-			-			-
Foreign currency exchange differences		-			-			-			700,873			700,873.00
Gross carrying amount at June 30, 2023		1,546,542			2,282,527			1,265,590			19,897,530			24,992,189

Accumulated amortisation amount at July 1, 2021		(1,546,542	)		(2,282,527	)		(1,265,590	)		(7,735,606	)		(12,830,265	)
Amortisation (Note 6)		-			-			-			(913,373	)		(913,373	)
Foreign currency exchange differences		-			-			-			(709,404	)		(709,404	)
Accumulated amortisation amount at June 30, 2022		(1,546,542	)		(2,282,527	)		(1,265,590	)		(9,358,383	)		(14,453,042	)
Amortisation (Note 6)		-			-			-			(984,724	)		(984,724	)
Foreign currency exchange differences		-			-			-			(351,829	)		(351,829	)
Accumulated amortisation amount at June 30, 2023		(1,546,542	)		(2,282,527	)		(1,265,590	)		(10,694,936	)		(15,789,595	)

Net carrying amount June 30, 2022		-			-			-			9,838,274			9,838,274
Net carrying amount June 30, 2023		-			-			-			9,202,594			9,202,594

Related Party Transactions - Additional Information (Details)		12 Months Ended
	Jan. 05, 2023 USD ($)	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 AUD ($) $ / shares shares	Aug. 26, 2020 $ / shares
Dr Spyros Papapetropoulos
Disclosure of transactions between related parties [line items]
New chief executive officer remuneration per year	$ 525,000
Amount reimbursement for the cost of procuring health benefits per month	2,500
Signing on bonus	$ 50,000
Explanation of the employment contract		On 5 January 2023, Dr Spyros Papapetropoulos commenced employment as President and Chief Executive Officer, details of the employment contract are set out below:•Fixed Remuneration of $525,000 per year base salary, plus reimbursement for the cost of procuring health benefits in the United States for an amount equal to $2,500 per month;•Signing on bonus of $50,000;•A short-term incentive/bonus potential of 50% of base salary, upon meeting the applicable performance criteria established by the Remuneration Committee of the Board, against agreed financial, strategic and operational targets;•Severance pay of 1 times base salary plus a 1 time target bonus potential to be paid in equal instalments over the following 12-month period; and•any outstanding equity compensation awards will fully and immediately vest.
Dr Errol De Souza
Disclosure of transactions between related parties [line items]
Agreed transitional amount payable		$ 351,376
Bonus payable			$ 332,325
Mr Connors
Disclosure of transactions between related parties [line items]
Number of shares issued \| shares		3,500,000	3,500,000	0
Loans to Directors and Other Key Management Personnel
Disclosure of transactions between related parties [line items]
Loans to director or other key management personnel		$ 0		$ 0
Apeiron
Disclosure of transactions between related parties [line items]
Number of shares issued \| shares		0	0	14,574,780
Fair value at date of issue \| $ / shares					$ 0.06
Presight
Disclosure of transactions between related parties [line items]
Number of shares issued \| shares				109,311,660
Fair value at date of issue \| $ / shares				$ 0.09645
BVF Partners
Disclosure of transactions between related parties [line items]
Number of shares issued \| shares				7,287,480
Fair value at date of issue \| $ / shares				$ 0.09645

Provisions - Summary of Detailed Information About Provisions (Details) - AUD ($)	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Provision Abstract
Current Employee benefits	$ 457,017	$ 409,320
Non-Current Employee benefits	$ 22,398	$ 10,460

Segment Information - Additional Information (Details)	12 Months Ended
Segment Information - Additional Information (Details)	Jun. 30, 2022 Segment
Segment information [abstract]
Number of operating segment	1

Revenue, Other Income and Other Gains and Losses - Summary of Other gains and losses from Continuing Operations (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net (loss)/gain arising on changes in fair value of contingent consideration (Note 29)	$ (988,179)	$ (936,354)	$ 3,212,503
Net realised and unrealised foreign currency gains	458,489	356,166	1,081,438
(Loss) on disposal of plant and equipment		(1,827)	(21,010)
Other gains and losses from Continuing Operations	$ (529,690)	$ (582,015)	$ 4,272,931

Issued Capital - Summary of Lists of Warrants Outstanding (Details)	12 Months Ended
	Jun. 30, 2023 shares $ / shares	Feb. 21, 2023 shares	Jul. 08, 2022 shares	Jun. 30, 2022 shares	Dec. 22, 2021 shares	Jun. 30, 2021 shares	Jun. 30, 2020 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options \| shares	117,211,315	8,333,333	7,700,000	79,056,617	47,786,607	20,985,450	6,364,550
Warrants
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	26-Aug-20
Expiry date	Aug. 26, 2023
Exercise price \| $ / shares	$ 0.06
Number of options \| shares	142,000,000
Fair value at date of issue \| $ / shares	$ 0.01

Issued Capital - Summary of Inputs Used to a Black-Scholes Model Used to Obtain Fair Value of Above Share Options (Details)			12 Months Ended
	Sep. 02, 2021 $ / shares	Nov. 20, 2020 $ / shares	Jun. 30, 2023 $ / shares
Disclosure of classes of share capital [line items]
Share price at date of issue	$ 0.19
Black Scholes Model
Disclosure of classes of share capital [line items]
Share price at date of issue \| (per share)		$ 0.13	$ 0.14
Exercise price		$ 0.1687
Bionomics share volatility		89.00%
Risk free interest rate		0.30%

Subsidiaries

12 Months Ended

Jun. 30, 2023

Disclosure of subsidiaries [abstract]

Subsidiaries

NOTE 12: SUBSIDIARIES

Details of the Group’s subsidiaries at the end of the reporting period are as follows:


			Percentage owned
Entity	Principal activity	Country of incorporation	2023 %	2022 %
Head Entity
Bionomics Limited	Research and Development	Australia

Subsidiaries of Bionomics Limited
Iliad Chemicals Pty Ltd	Asset owner	Australia	100	100
Bionomics Inc	Asset owner	United States	100	100